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In a proportion of sudden cardiac deaths (SCD), no structural pathology can be identified 
and a diagnosis of sudden arrhythmic death syndrome (SADS) is advocated. Recognition 
of SADS is important since a significant proportion is attributed to inherited cardiac 
conditions, and evaluation of relatives may identify individuals at risk. 
 
Aims 
The aims of the thesis are: To investigate the magnitude of SADS in young (≤35 years) 
and athletic individuals; To investigate the impact of expert cardiac pathology; To evaluate 
a large cohort of SADS families to ascertain: 1.The diagnostic yield of familial evaluation, 
2.Short-term outcomes, 3.The implications of autopsy findings of uncertain significance, 
4.The impact of higher intercostal leads, 5.The limitations of current risk stratification 
protocols in Brugada syndrome (BrS). 
 
Methods and Results 
Appraisal of the Office of National Statistics data revealed an incidence of young SADS of 
0.24/100,000/year. Histopathological evaluation of hearts of athletic individuals who 
experienced SCD (n=118), identified a morphologically normal heart in 23% of cases. A 
study of 158 SCD cases where a pathological evaluation was performed by both the 
referring and an expert cardiac pathologist identified a disparity in the diagnosis in 41% of 
cases. 
 
Evaluation of 83 families of victims of SADS demonstrated a diagnostic yield of 48%, with 
BrS being the predominant familial diagnosis. A quarter of the relatives (65 of 271 
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evaluated) were diagnosed with an inherited condition. During 25.5±16.8 months of follow-
up, 1 patient died, despite being cleared after comprehensive clinical evaluation. A review 
of 50 SADS victims with a familial diagnosis of BrS identified high-risk features in only 
20%, highlighting the limitations of current risk stratification protocols. Utilising higher 
intercostal V1 and V2 leads during Ajmaline testing doubled the diagnostic yield of BrS. 
Finally, familial evaluation following SCD with autopsy findings of uncertain significance 
identified a similar proportion of primary arrhythmogenic syndromes to “true” SADS. 
 
Conclusions 
After a suspected SADS death expert cardiac pathology evaluation is necessary to ensure 
accurate diagnosis. First-degree relatives should be referred for comprehensive cardiac 
screening in an expert setting. Higher intercostal leads should be used when BrS is 
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INTRODUCTION TO THE THESIS 
 
Sudden cardiac death (SCD) accounts for 50% of cardiovascular mortality with an 
estimated annual toll between 100,000 and 120,000 deaths in the United Kingdom (UK).1,2 
The majority of SCDs are secondary to atherosclerotic coronary artery disease and affect 
the older segment (>35 years) of the population.3 Occasionally, a young (≤35 years), 
apparently healthy person falls victim. The majority of SCDs in the young are secondary to 
previously quiescent, inherited cardiac diseases, galvanizing discussions relating to 
primary and secondary prevention strategies to avert such catastrophes. In a significant 
proportion of sudden deaths no obvious cause is identified and the death is attributed to 
“natural causes”.4,5 Failure to identify a cause of death may be attributed to inherent 
limitations of the autopsies, as autopsies performed at the request of the coroner, are 
predominantly geared to rule out foul play. It is well established however, that in a 
proportion of cases no cause is identified despite detailed histopathological examination 
and toxicology screen by a cardiac pathologist.6 In such cases the death is presumed to 
be secondary to primary arrhythmia and is classified as sudden arrhythmic death 
syndrome (SADS).7 
 
A number of primary prevention strategies have been proposed to avert SCD in the young 
ranging from targeted evaluation of high-risk individuals, such as people with symptoms 
suggestive of cardiac disease or family history of inherited cardiac conditions or SCD, to 
widespread screening of all young individuals and in particular young athletes, irrespective 
of background risk. The use of automated external defibrillators (AED) in public venues 
has been recommended for secondary prevention. As part of the National service 
framework for coronary heart disease, the department of health published in 2005 the 
chapter 8 for arrhythmias and SCD, endorsing targeted screening. The authors recognised 
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that when sudden unexplained cardiac death occurs, close relatives are at potential risk of 
having a fatal cardiac condition and that a coroner’s post-mortem is vital to determine the 
cause of death and provide the opportunity to assess the potential risk to the family. They 
advocated, and proposed as markers of good practice, that an expert post mortem is 
carried out and evaluation of relatives takes place in a dedicated clinic, with staff who are 
trained in the diagnosis, management and support for these families.8 
 
The implementation of preventative strategies is hindered by the considerable lack of 
evidence in the field of SCD, particularly in young individuals. The epidemiology of SCD, 
and SADS, is not well established in the young due to the absence of systematic 
registries. Moreover, there is no evidence to support the added value of cardiac pathology 
for the post-mortem evaluation of victims of SCD compared to the routine coroner’s 
autopsies. Finally, there are limited studies assessing the impact of targeted familial 
evaluation in an expert setting, and questions relating to the best investigative protocol 
remain unanswered. 
 
The aim of the current thesis was to offer a comprehensive review of SADS, incorporating 
epidemiological data, with the group’s experience from a specialist cardiac pathology unit 
and a specialist inherited cardiac diseases clinic. Given the complexity of the project, the 
large volume of data required, and the relatively low frequency of conditions predisposing 
to SADS, collaboration with leading institutions and individuals with established expertise 
in relevant areas was essential. To ensure the success of the project the author reinforced 
collaborative links between Prof Sharma’s inherited cardiac diseases clinic in Lewisham 
and Dr E.R Behr at St George’s hospital, Prof M.N Sheppard at Royal Brompton hospital, 




The primary aim was to assess the diagnostic yield of comprehensive clinical evaluation in 
an expert setting of a large cohort of SADS families. Additional aims were to ascertain the 
effect of familial evaluation to short-term outcomes and investigate the impact of utilizing 
higher intercostal leads in the diagnosis of Brugada syndrome (BrS), a fairly novel primary 
arrhythmogenic syndrome implicated in SADS. Adopting a holistic approach, the author 
also aimed to investigate the magnitude of SADS in young and athletic individuals and 
explore the impact of cardiac pathology. Based on the author’s experience during the 
project, two further, novel research questions were developed; 1. What is the significance 
and implications of autopsy findings that suggest cardiac structural abnormalities but are 
not diagnostic of conditions implicated in SCD (uncertain significance)? and 2. How 
effective would current risk stratification protocols in Brugada syndrome (BrS) have been 
in identifying the SADS probands that initiated familial evaluation in our clinic? 
 
To investigate the magnitude of SADS in the young, in chapter 1 the authors critically 
appraised data from the ONS for causes of death in the 1-34 years age group in England 
and Wales. To investigate the impact of SADS in athletic individuals in chapter 2 the 
authors retrospectively analysed 118 hearts of people who participated in regular sport 
activities, referred to the Centre for Cardiac Pathology in the National Lung and Heart 
Institute. In chapter 3, we evaluated a sample of 158 consecutive cases of SCD, where 
both the referring pathologist and the cardiac pathologist examined the heart and provided 
a cause of death, in order to assess diagnostic discrepancies between general and 
specialist pathologist and potential implications. In chapter 4, the authors evaluated a large 
cohort of SADS families to ascertain the diagnostic yield of familial evaluation and short-
term outcomes. In chapter 5 we were able to ascertain the implications of autopsy findings 
of uncertain significance by correlating post-mortem with clinical data. Finally, by utilizing 
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data from the cohorts in chapters 4 and 5, the author investigated the impact of higher 
intercostal leads (chapter 6) and the limitations of current risk stratification protocols in 
Brugada syndrome (BrS) (chapter 7). 
 
Chapter 1: The epidemiology of sudden cardiac death and sudden 
arrhythmic death syndrome in the young 




The epidemiology of SCD in the young (≤35 years) is not well established. Studies in 
young athletic and non-athletic individuals have reported a wide range of incidence of SCD 
ranging from 0.5 per 100,000 per year to 11 per 100,000 per year (Table 1).9,10 Most 
studies report a male predominance with a male to female ratio of 3:1 in the general 
population and 9:1 in young athletes.11 Inherited cardiomyopathies are the commonest 
cause of SCD in athletes, whereas coronary artery pathology including coronary artery 
anomalies and atherosclerotic disease predominate in the non-athletic population.10,12-14 
 
1.1.1 The Olmsted County study 
 
One of the most robust studies investigating sudden death in young individuals is the 
Olmsted County study.12 The investigators collected prospective data on all sudden, 
unexpected, non-traumatic deaths of residents aged 20–40 years over a 30-year period. 
Data collection included death certificates, complete community outpatient and inpatient 
medical records, coroner’s reports, and autopsy reports. Most importantly, all individuals 
included in the study had undergone post-mortem evaluation, including histological 
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evaluation and toxicology screen, at a single centre and in particular in the Pathology 
Department of the Mayo Clinic. The incidence of sudden death was estimated based on 
population census data. 
 
Table 1: Summary of studies reporting the incidence of SCD and SADS in 
























Retrospective 1998-2008 18-35 3.5 
(1.2) 
Sweden16 General Retrospective 1992-1999 15-35 0.93 
(0.20) 
Denmark17 General Retrospective 2000-2006 1-35 2.8 
(0.81) 























Retrospective 1985-1997 15-17 0.46 
(0) 
USA19 High school 
& college 
athletes 
Prospective 1983-1993 13-24 0.75 
(0.04) 
USA20 High school 
athletes 




Retrospective 2004-2008 17-23 2.3 
(----) 








Based on the identification of 54 deaths between 1960 and 1989 the incidence of sudden, 
unexpected, non-traumatic death was estimated to be 6.2 per 100,000 per year. The 
majority of deaths (57%) were attributed to cardiac causes, with an estimated incidence of 
SCD of 3.6 per 100,000 per year. The predominant cause of SCD (18 of 31 cases; 58%) 
was coronary artery disease defined as post-mortem evidence of severe chronic 
obstructive atherosclerosis, acute plaque rupture, acute thrombotic occlusion and acute 
myocardial ischaemia. Other cardiac pathology included presumed primary arrhythmia 
(n=6) and myocarditis (n=4). On initial inspection the study appears to suggest that 
cardiomyopathy and in particular hypertrophic cardiomyopathy (HCM) accounted for only 2 
deaths. Detailed review of the deceaseds’ characteristics, however, reveals that in 9 cases 
the histological findings were consistent with a diagnosis of arrhythmogenic right 
ventricular cardiomyopathy (ARVC), defined by the authors as interstitial fatty infiltration 
extending through 75% of the RV myocardial thickness. Of the 9 deaths, 3 were attributed 
to seizures, 2 to coronary artery disease, 2 to unknown cause, 1 to arrhythmia and in 1 
case there was evidence of associated aortic dissection. Of importance, 7 deaths were 
ascribed an unknown cause of death and in 5 of these cases the post-mortem was 
reported as normal. Adding individuals with possible ARVC, in the absence of histological 
evidence of other cardiac pathology (n=6) and those with a normal post-mortem, which 
could represent SADS deaths (n=5), would bring the incidence of SCD to 4.8 per 100,000 
per year and SADS to 0.6 per 100,000 per year. 
 
1.1.2 Studies in military personnel 
 
The military personnel provide a unique opportunity to examine the incidence and causes 
of SCD. Unlike studies in the general population, the exact number of persons under 
examination is usually clearly identifiable, health care provision is captured and 
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documented and there is centralization of autopsy reporting. Active surveillance in health 
and in death, with routine performance of an autopsy, allows for reduction of case referral 
bias, as might be seen in high-profile cases with disproportionate media attention.10,15,23,24 
On the other hand however, by virtue of a military population, there is risk of ascertainment 
bias. Moreover, results from the military population do not necessarily extrapolate to the 
general population, given that they represent a fitter, almost athletic population as a result 
of mandated weight control and physical fitness standards.  
 
A 25-year review of autopsies in United States (US) military recruits aged 18–35 revealed 
a high rate of non-traumatic sudden deaths of 13 per 100,000 recruit-years.10 The authors 
utilized census data relating to recruit numbers and data held from the Department of 
Defense Recruit Mortality Registry. They retrospectively analysed all recruit deaths 
between 1977 and 2001. The authors identified 277 deaths among 6.3 million recruits. Of 
those, 152 were non-traumatic and in the great majority (n=148; 97%) an autopsy report 
was available. One hundred and twenty-six deaths were judged to represent a sudden 
death defined as an event resulting in death or terminal life support within 1 hour of the 
inciting event and were included in the study. Half of the deaths (n=64; 51%) were defined 
as cardiac in origin based on the pathological findings and the clinical circumstances. As in 
the Olmsted County study, the most prevalent pathology was related to coronary artery 
disease (n=39; 61% of cardiac deaths) but on this occasion coronary artery anomalies 
rather than coronary artery atherosclerosis was the predominant finding.24 Myocarditis 
(n=13) and cardiomyopathies (HCM: n=8; ARVC: n=1) accounted for most of the 
remaining cardiac deaths. Most importantly, however, 44 of the 126 sudden deaths (35%) 
were labeled as idiopathic based on the absence of pre-existing disease and a normal 
post-mortem examination. Such deaths are likely to represent deaths secondary to an 
arrhythmic event and would be classified as SADS deaths by contemporary criteria, 
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representing an incidence of 4.6 per 100,000 recruit-years. Should we add the potential 
SADS deaths to the cardiac deaths reported by the authors, the estimated rate of SCD 
would increase to 11.2 per 100,000 recruit-years, which is the highest rate reported in the 
literature. 
 
In the limitations of the study the authors highlight that the reported incidence may 
represent an underestimate since all recruits undergo pre-enlistment screening with history 
and cardiovascular examination, which may have identified individuals with cardiac 
disease and prevented a number of sudden deaths. Other limitations of the study relate to 
the fact that post-mortem evaluations were performed by a number of pathologists in 
military and general hospitals with no consistent diagnostic criteria and, therefore, the 
accuracy of the autopsy conclusions may have been compromised. Finally, almost one-
third (27%) of victims classified as idiopathic sudden death were associated with sickle-cell 
trait, which according to recent publications may in its own right predispose to sudden 
death.25,26 
 
In a study published in 2011 by the same group, the authors reviewed all deaths that 
occurred in uniformed personnel, including recruits as in the previous study, while on 
active duty. All death records were reviewed by at least 3 authors, on this occasion, and a 
final determination was made as to clinical cause of death. Of 14,771 deaths between 
1998 and 2008, 902 deaths were thought to represent non-traumatic, sudden deaths of 
potentially cardiac aetiology for which complete data, including an autopsy report were 
available. Of the 902 deaths, 298 deaths affected young individuals defined as <35 years, 
accounting for an incidence of SCD in the young close to 3.5 per 100,000 person-years, 
which is considerably lower than the reported incidence in military recruits. Unfortunately, 
the authors did not provide an explanation for this discrepancy. Although the consistency 
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of the population may have accounted to some extent for the difference, it is unlikely that it 
justified such a disparity. Military personnel who are under regular medical surveillance 
and are subjected to regular fitness tests over a number of years may be less likely to 
exhibit significant cardiovascular disorders, compared to newly recruited individuals who 
are more representative of the general population. Coronary artery pathology was the 
predominant cause of structural heart disease (n=88; 30%), followed by cardiomyopathy 
(n=67; 22%) and myocarditis (n=17; 6%). In this cohort however, the most common cause 
of potential SCD in the young was SADS, with 123 (41%) of victims classified as sudden 
unexplained death based on the absence of any significant ante-mortem history and a 
normal post-mortem examination. Based on the census data the estimated incidence of 
SADS was 1.2 per 100,000 per year in individuals less than 35 years old and 2.0 per 
100,000 per year in older recruits. 
 
1.1.3 Retrospective general population reviews 
 
Winsten et al. investigated the incidence of SCD in young individuals between the ages of 
15 and 35 years in Sweden.16 The authors reviewed a National forensic medicine 
database for deaths between January 1992 and December 1999. Most unexpected, 
sudden deaths in Sweden undergo a post-mortem, which according to the authors are 
conducted by a small number of pathologists, adhering to established protocols. One 
hundred and eighty-one deaths were identified, corresponding to an overall incidence of 
SCD of 0.93 per 100,000 per year. Cardiomyopathies were the most common reported 
pathology, accounting for 29% of all cases (DCM 12%, HCM 10%, ARVC 7%). A 
structurally normal heart, corresponding to SADS deaths, was present in 21% of cases. 
Coronary atherosclerosis was considered the principal cause of death in 18% of the cases 
but the authors failed to provide details relating to the severity of the coronary artery 
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lesions and as to whether evidence of acute or previous myocardial infarct were present. 
The authors identified a gender predilection with a male to female ratio of almost 3:1. The 
reported incidence of SCD is likely to represent an underestimate given that comparison 
with the Swedish Death Registry, a central database where all deaths are recorded 
irrespective of forensic post-mortem examination, revealed that 20% of potential SCDs 
had not been included in the forensic database. 
 
More recently, nationwide death certificate and autopsy reports based reviews performed 
in Ireland and Denmark reported an incidence of SCD of 2.9 per 100,000 person-years 
and 2.8 per 100,000 person-years, respectively.17,18 Both studies were published after the 
commencement of the current thesis and after the publication of our Office of National 
Statistics data and utilized similar methodology. In the Irish study the investigators 
reviewed all deaths in individuals aged between 15 and 35 years. Utilizing death 
certificates, the authors identified 292 cases that could possibly represent SCD. Of those 
116 cases (40%) were included in the study analysis based on the presence of an 
adequate post-mortem, which in the authors’ opinion confirmed cardiac pathology. The 
predominant cause of death was SADS (27%), based on a normal post-mortem. This 
represented an incidence of SADS of 0.76 per 100,000 per year, although the exclusion of 
the paediatric population may have resulted in an underestimate. Other prevalent causes 
included coronary artery disease with evidence of acute or prior myocardial infarction 
(21%) and cardiomyopathies (19%). Of importance, this study differentiates between HCM 
and left ventricular hypertrophy (LVH) based on the presence of myocardial disarray, with 
LVH accounting for 10% of SCDs. 
 
In the Danish study the authors reviewed death certificates of individuals aged 1-35 years. 
Of the 470 classified as SCDs, 314 (67%) had undergone a post-mortem. In the autopsied 
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cases, the most prevalent finding was that of a normal heart (43%), implying a SADS 
death. Based on census data the incidence of SADS was estimated at 0.81 per 100,000 
per year. Ischaemic heart disease accounted for 13% of deaths. A definitive diagnosis of 
cardiomyopathy was present in 22 (7%) of autopsied cases with ARVC being the most 
common one. In a further 34 cases, the post-mortem reported a hypertrophied heart or 
myocardial fibrosis. Sudden cardiac death exhibited a gender predilection with a male to 
female ratio of 2:1. There was also an age predilection; for every decade, the risk of SCD 
roughly doubled in relation to the previous decade and the risk of dying of SCD was >10 
times higher for persons aged 30–35 years than for persons aged 1–10 years. 
 
1.1.4 The epidemiology of sudden arrhythmic death syndrome in the United Kingdom 
 
In the UK the magnitude of SADS in the general population has been studied specifically 
or as part of the wider spectrum of sudden death in three prospective coroners’ studies. 
The Wandsworth study, published back in 1988, reported on post-mortem findings of 
Caucasian individuals aged between 18 and 69 years who experienced a sudden death of 
“natural” causes.4 The authors prospectively monitored all non-traumatic deaths over a 3-
year period. All individuals underwent extensive post-mortem examination and toxicology 
screen, according to well-defined protocols. The authors outlined clear diagnostic criteria 
for cardiac pathology, including strict criteria for the diagnosis of ischaemic heart disease.  
Of the 322 deaths included in the study, 224 (70%) deaths were thought to be secondary 
to SCD. Ischaemic heart disease accounted for the majority of sudden cardiac deaths 
(84%) while in a small but significant proportion of potential sudden cardiac deaths (4.9%) 
no cause was identified despite detailed histopathological examination. Based on census 
data, these figures equated to a SADS incidence of 1.83 per 100,000 per year.4 
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The first national survey of SCD and SADS in the UK was published in 2003.3 The authors 
performed a prospective survey using a stratified random sample of 83 coroners of the 
132 coroner’s jurisdictions in England. The total period of surveillance was about 2 years. 
Subjects included in the study were apparently healthy, Caucasian individuals, aged 16-64 
years, who died suddenly. Information collected by the investigators included pre-morbid 
history, circumstances of death and the results of the local post-mortem examination. A 
transverse myocardial slice (1 cm thickness) through both ventricles at mid-septal level 
and blood sample was sent to the investigators. In those cases in whom macroscopic 
inspection of the transverse myocardial slice revealed no evidence of infarction or 
ischaemia and in whom neither significant coronary disease nor any other identifiable 
cause of death was found at post mortem, the whole heart was sent to the investigators for 
examination. Of the 692 cases of SCD identified, in 528 cases the authors had the 
opportunity to evaluate a complete set of data. The study’s expert cardiac pathologist 
examined 517 myocardial slices and 47 whole heart specimens. Out of the 564 cases 
where tissue samples were reviewed by the expert cardiac pathologist, 4.1% had a 
morphologically normal heart, with negative toxicology. Based on the estimated age-
specific population census data the incidence of SADS was estimated at 0.5 per 100,000 
per year.3 
 
The same group performed a further national prospective study surveying 117 coroner’s 
jurisdictions in England over a 20-month period. They attempted to identify all SADS 
deaths in Caucasian individuals aged 4-64 years. During the same period the authors 
reviewed the Office of National Statistics (ONS) mortality figures for certified causes of 
death in 4-64-year-olds in England. The investigators identified deaths ascribed to the 
International Classification of Diseases-ninth edition (ICD-9) code 798.1 (sudden death 
cause unknown-instantaneous death) which is considered to most accurately represent a 
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SADS death, as well as other ICD-9 codes that were likely to represent SADS deaths. The 
study reported an estimated SADS mortality of 0.16 per 100,000 per year based on the 
coroner survey compared to 0.10 per 100,000 per year estimated by the 798.1 ICD-9 code 
of the ONS data. This considerable underestimate was a result of misclassification of 
SADS deaths identified by the coroner’s survey under other ICD-9 codes including 
myocardial infarction, cardiomyopathy, epilepsy, drowning and other ill-defined causes.7 
Inclusion of other ICD-9 codes for ill-defined and unknown causes of mortality to which 
SADS cases could be inaccurately attributed, increased the potential annual death rate for 
SADS as high as 1.38 per 100,000 per annum. 
 
Based on the estimated incidence of potential SADS from the ONS data, the authors 
noted an age predilection. The incidence of SADS was lower in the very young (0.14 per 
100,000 per year for individuals aged 4-15 years) and gradually increased and peaked at 
2.36 per 100,000 per year in individuals aged 45-54 yeas. Additionally, although there was 
no significant gender predilection in the very young (4-15 years), the incidence of SADS 
gradually increased in males with advancing age, with a peak male to female ratio of 3.2 to 




The incidence of SADS in young individuals has not been studied and in the absence of a 
systematic national registry documenting sudden cardiac deaths in the young, the true 
impact of such fatalities in the UK is speculative. Unsurprisingly, the sudden death of a 
young individual commonly galvanises emotionally charged debates between the lay and 
medical communities relating to the demand for preventative measures, underscoring the 
need to establish the magnitude and pathogenesis of sudden cardiac deaths in the 
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young.11,27 Such information is fundamental to facilitate any debate about local provisions 
for a potential cardiovascular screening programmes and subsequent exercise 
recommendations.28-30 To address the scientific gap relating to the magnitude of SADS in 
young individuals in the UK the authors examined and critically appraised the Office of 
National Statistics data for causes of death in the 1-34 years age group in England and 
Wales for four consecutive years, (2002-2005). We estimated the incidence of SCD and 
SADS, examined gender and age distribution and attempted to assess the impact of 
potential misclassifications of causes of death.31 
 
1.3 Personal contribution 
 
The author collected, reviewed and analysed all ONS data relevant to the project and 




The ONS is the government agency responsible for compiling, analysing, and 
disseminating many of the National statistics including periodic census of the population 
and health statistics. The data used in the mortality statistics are derived from information 
obtained by the doctor certifying the death, the coroner, and details supplied by the 
informant to the Registrar. The deaths in males and females are reported by the ONS in 5-
yearly age groups. The causes of death are registered according to the International 
Classification of Diseases-10 (ICD-10).32 
 
This study was based purely on available data from the ONS and the author did not 
directly review death certificates or post-mortem reports. The investigators analysed the 
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ONS mortality data stating the cause of death for England and Wales for four consecutive 
years 2002–2005, inclusive. Five of the ICD-10 chapters were included in the analysis 
(Table 2). Within these chapters, two of the senior investigators (Dr Elijah R. Behr. and 
Prof M.N. Sheppard) scrutinized the ICD-10 classification codes to identify codes that may 
represent cardiac deaths. Data were then summed from the existing age subgroups to 
include deaths of individuals from the age of 1 year to the age of 34 years, inclusive. 
 
Table 2: List of the 5 chapters of the World Health Organisation International 
Classification of Diseases – 10 included in the analysis 
Chapter VI Diseases of the nervous system 
Chapter IX Diseases of the circulatory system 
Chapter X Diseases of the respiratory system 
Chapter XVIII Symptoms, signs and abnormal clinical and 
laboratory findings, not elsewhere classified 
Chapter XX External causes of morbidity and mortality 
 
The selected ICD-10 codes were subsequently divided into four classes as deemed 
relevant by the investigators (Table 3): Class A1: definite cardiac deaths with no structural 
heart disease identified at post-mortem representing SADS; Class A2: definite cardiac 
deaths with structural heart disease identified at post-mortem comprising sudden and non-
sudden deaths with likely causation by structural heart disease; Class A3: definite cardiac 
deaths with indeterminate cause comprising sudden and non-sudden deaths where the 
presence or absence of underlying heart disease was either not recorded or ill defined; 
and Class B: possible cardiac deaths since a proportion of these deaths may represent 
misclassifications of cardiac deaths and in particular SADS as epilepsy or drowning. 
Where there was disagreement relating to the class of an ICD-10 code, a third senior 
author (S.S.) was consulted. Although the great majority of deaths referred to “natural 
causes” (non-accidental, non-malicious), a small proportion of the total cohort is likely to 
represent accidental deaths since ICD-10 codes W65–W74 from Chapter XX representing 
accidental drowning and submersion were included in Class B.  
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Incidence rates were calculated based on the ONS census data of the resident population 
for individuals aged 1–35 years in England and Wales. Data were further analysed 
according to age subgroup and gender in order to identify potential trends or gender 
differences. 
 
Table 3: Examples of the most frequent ICD-10 codes included in each Class 
(presented in order of frequency) 
Class ICD-10 code 
Class A1 
(definite cardiac deaths with 
NO structural disease) 
R96:    Other sudden death, cause unknown 
I49.9:   Cardiac arrhythmia, unspecified 
I46.1:   Sudden cardiac death, so described 
I45.6:   Pre-excitation syndrome (WPW) 
Class A2 
(definite cardiac deaths with 
structural disease) 
I21.9:   Acute myocardial infarction, unspecified 
I25.1:   Atherosclerotic heart disease 
I42.0:   Dilated cardiomyopathy 
I42.9:   Cardiomyopathy, unspecified 
Class A3 
(definite cardiac deaths with 
indeterminate cause) 
I50.9:   Heart failure, unspecified 
I51.9:   Heart disease, unspecified 
I50.1:   Left ventricular failure 
I50.0:   Congestive heart failure 
Class B 
(possible cardiac deaths) 
G40.9: Epilepsy, unspecified 
G41.9  Status epilepticus, unspecified 
W69    Drowning and submersion while in natural water 
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Data interpretation and analyses were performed using SPSS software, version 14 (SPSS 
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Inc., Chicago, IL, USA). Data are expressed in means and standard deviations. Annual 
mortality incidence per 100,000 was calculated as the mean of the 4 years using the 
following type: (100 000 x number of deaths)/population size. Chi-square or Fisher’s exact 




The number of deaths in the 1–34 years age group is reported in table 4 according to 
class (A1, A2, A3, B) and year of death. Analysis of the ONS data revealed an average of 
419±16.5 definite cardiac deaths per annum (Class A1 + A2 + A3) equating to 8 young 
cardiac deaths per week in England and Wales. On the basis of the average estimated 
size of the resident population of this age of 23,564,050, these data indicate an incidence 
of young cardiac death of 1.8±0.1 per 100 000 per year. There were also an average of 
433±6.2 deaths per year, also corresponding to about 8 deaths per week, in Class B which 
comprised primarily deaths from drowning, epileptic seizures, and other ill-defined causes 
of mortality (Figure 1). There was no significant variation in the number of the resident 
population or the number of deaths per year. 
 
Table 4: Number of deaths according to class per year 








2002 2003 2004 2005    
A1 60 50 57 61 228 57.0 (5.0) 0.2 (0.0) 
A2 363 358 324 324 1369 342.3 (21.2) 1.5 (0.1) 
A3 19 20 21 20 80 20.0 (0.8) 0.2 (0.0) 
A1+A2+A3 442 428 402 405 1677 419.3 (19.1) 1.8 (0.1) 
B 438 424 434 436 1732 433.0 (6.2) 1.8 (0.0) 
Total 
(A1+A2+A3 +B) 




Figure 1: Causes of death in the young expressed as percentage of the total number 
of deaths in Class B (possible cardiac deaths). 
SIDS: sudden infant death syndrome. 
 
The most prevalent cardiovascular pathology identified in ONS was ischaemic heart 
disease comprising one-third (33.5%) of the definite cardiac deaths (A1 + A2 + A3). 
Although the majority of ischaemic deaths (56%) were attributed to acute myocardial 
infarction (ICD-10 code: I21.9), in a significant proportion (32%), the presence of 
atherosclerotic heart disease alone (ICD-10 code: I25.1) was documented as the principal 
cause of death, comprising 19% and 11% of the definite cardiac deaths, respectively 
(Figure 2). Cardiomyopathies were the second commonest cause of cardiac death 
corresponding to 27% of definite cardiac deaths, with dilated and hypertrophic 
cardiomyopathies accounting for 12% and 5% of the deaths, respectively. Sudden 
arrhythmic death syndrome accounted for 14% of definite cardiac deaths followed by 
32 




Figure 2: Causes of cardiac death in the young expressed as percentage of the total 
number of definite cardiac deaths (A1 + A2 + A3).  
DCM: Dilated cardiomyopathy; HCM: Hypertrophic cardiomyopathy; HD: Heart disease; 
CM: Cardiomyopathy; SADS: Sudden arrhythmic death syndrome. 
 
1.5.1 Causes of death by gender and age 
 
Definite cardiac deaths (Class A1 + A2 + A3) were more prevalent among males with a 
male to female ratio of 2.4 : 1. The only pathology associated with a statistically significant 
difference between the male and female gender was ischaemic or potentially ischaemic 
causes which accounted for 22% of all deaths in males but only 13% in females (p<0.001). 
The same gender difference was also observed for possible cardiac deaths (Class B) with 
a male to female ratio of 2.0 : 1. Deaths attributed to epilepsy accounted for 22% of all 
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deaths in males but 31% in females (p<0.001), whereas drowning-related deaths were 
more prevalent among males (9% vs. 4%, p<0.001) (Figure 3). 
 
 
Figure 3: Proportional (%) distribution of underlying cause of death by gender.  
IHD: Ischaemic heart disease; SADS: Sudden arrhythmic death syndrome. 
 
There was a rising incidence of definite cardiac deaths with advancing age, with 
individuals ≥30 years old having a 10-fold risk compared with children aged <10 years. 
The only underlying causes of definite cardiac death exhibiting a significant age trend were 
ischaemia and cardiomyopathies. Ischaemic deaths exhibited an increasing trend with 
advancing age, accounting for almost one-third (31%) of all deaths in the 30–34 years age 
group but only 1% in children aged <10 years (p<0.001). In contrast, cardiomyopathy-
related deaths peaked during adolescence, accounting for a greater proportion of deaths 
at the 10–19 years age group (18%) and accounting for only 11% of deaths in the 30–34 
years age group (p=0.001) (Figure 4). Deaths secondary to SADS did not exhibit any 





Figure 4: Proportional (%) distribution of underlying cause of death by age.  
IHD: Ischaemic heart disease; SADS: Sudden arrhythmic death syndrome 
 
A similar trend to definite cardiac deaths (A1-3) was observed with possible cardiac deaths 
in Class B, with individuals 30–34 years old having a five-fold risk compared with children 
aged <10 years old. Underlying causes exhibiting a statistically significant age trend 
included deaths attributed to epilepsy and drowning. Epilepsy-related deaths peaked in the 
second and third decades of life, accounting for almost one-third of deaths in the 10–19 
and 20–29 years age groups (p<0.001). Drowning exhibited a reverse trend with age, 
accounting for 21% of deaths in children aged <10 years but only 3% in individuals ≥30 









1.6.1 The magnitude of sudden cardiac death in the young 
 
According to the ONS data, the incidence of cardiac death in the young in England and 
Wales is 1.8 per 100,000 per year, which corresponds to eight young lives per week. 
Considering the devastating impact of sudden death in the young and the potential 
number of life years lost our findings suggest that the number of deaths identified is 
sufficiently high to command attention even without the inclusion of potential 
misclassifications (Class B). If consideration is given to the possibility that at least 20% of 
deaths attributed to epilepsy or drowning may actually be caused by a primary myocardial 
electrical disorder, then the estimate of sudden and cardiac death in the young in England 
and Wales is at least 10 per week. 
 
The incidence of SCD based on the ONS data is almost double the incidence reported by 
Italian and Swedish studies, which, however, are likely to have provided an underestimate 
in the context of cardiac screening and under-reporting, respectively.16,29 On the contrary, 
our figure is half that documented in a retrospective study of sudden death in young 
individuals in the USA where the authors reported an incidence of 3.6 per 100,000 per 
year,10,12 and almost a sixth of the incidence reported in young US military recruits.10,15 Both 
studies are likely to have produced more accurate estimates compared to our study given 
their more robust methodology; in both studies the authors reviewed post-mortem reports 
and death certificates which were based on autopsy evaluation of all subjects. Our 
estimate is also lower compared to nationwide studies performed subsequently to our 
study in Ireland and Denmark, where the incidence of SCD was reported as 2.8 per 
100,000 person-years.17,18 Our lower estimate compared to the US and Irish studies may 
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be partly explained by the different age groups, since these studies did not include very 
young individuals (<15 years) in whom the incidence of SCD may be up to 10-fold lower 
based on our results. Therefore, it is likely that our figure derived from the ONS data is a 
significant underestimate of the true incidence of cardiac death in the young, given the 
nature of our study and the absence of systematic screening in the UK. 
 
1.6.2 The magnitude of sudden arrhythmic death syndrome in the young 
 
The incidence of Class A1 deaths that best correlate with SADS was 0.24 per 100 000 per 
year, with no significant gender or age predilection. This figure is lower compared to the 
majority of published studies in Europe and the US, where the incidence of SADS ranges 
from 0.6 to 1.2 per 100,000 per year.10,12,15,17,18 On the other hand, this figure is significantly 
higher than the previous incidence of 0.10 per 100 000 per year obtained from the UK 
ONS statistics for 1997–1999 that used the ICD-9 classification.7 As evident however from 
a prospective national coroner survey, calculations based on ONS data are likely to 
underestimate the true incidence of SADS.7 The most plausible explanation for this 
discrepancy is that the ONS mortality statistics are derived largely from documentation on 
death certificates, which may under-report the true incidence of cardiac arrhythmias. 
Malignant cardiac arrhythmias secondary to ion channelopathies such as Brugada 
syndrome and long-QT syndrome may manifest as epileptiform seizures and collapse 
secondary to brain anoxia or drowning resulting in misclassification of genuine cases of 
SADS as epilepsy33,34 or unexplained drowning.35,36 The latter is particularly relevant since 
there is a well-established association between the most common subtype of long-QT 
syndrome, LQT1, and sudden death in swimmers.37,38 Support to this notion is provided by 
our findings in the main SADS study (chapter 4), where 4 out of the 8 SADS victims who 
had been referred for specialist evaluation because of symptoms prior to their death, had 
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experienced at least one episode of generalised seizures (Table 11). All four victims had 
been referred to a neurologist and had undergone head imaging (CT and/or MRI) and an 
electroencepalogram, which in all cases were normal. In two of the victims no formal 
diagnosis was reached due to a single episode of seizures in the first case and nocturnal 
episodes, alone, in the second case. The other two victims had received diagnosis and 
treatment for epilepsy. Familial evaluation identified the Brugada phenotype in three 
families and LQT in one. 
 
Further support that the incidence of SADS is likely to be underestimated by the ONS data 
is provided by the thesis studies examining the discrepancy of the interpretation of 
histopathological findings between general and specialist cardiac pathologist (chapter 3) 
and the familial evaluation of victims of SCD with autopsy findings of uncertain significance 
(chapter 5). Both studies indicate that the significance of post-mortem findings such as 
limited coronary atherosclerosis, left ventricular hypertrophy in the absence of myocardial 
disarray, myocardial fatty infiltration, mitral valve prolapse and myocarditis,39 may be 
overestimated. Such findings may falsely be attributed as the primary cause of death, 
misclassifying SADS deaths under other causes of SCD. Most importantly however, 
overestimation of the significance of such findings may misguide familial evaluation 
targeting structural disorders rather than primary arrhythmogenic syndromes, with 
potentially devastating consequences. 
 
1.6.3 Effect of gender and age 
 
Consistent with prior literature reports, ischaemic or potentially ischaemic causes 
contributed a greater proportion of deaths in males and with increasing age, in particular 
after the age of 30 years. Conversely, potentially inherited cardiomyopathies such as 
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hypertrophic and dilated cardiomyopathies did not exhibit any gender predilection but 
there was a significant age trend, contributing a greater proportion of deaths in the 10 - 19 
age group with a gradual decrease thereafter. 
 
Epilepsy appeared to exhibit a female predilection, accounting for a greater proportion of 
deaths during adolescence. These results should however be viewed with caution given 
the limited data available and the multiple factors which may influence epilepsy-related 
mortality, as established by a prior large, prospective study in the UK.40 Finally, in accord 
with previous reports, drowning-associated deaths were more prevalent among males and 
children aged <10 years, with a reverse trend with increasing age.41 
 
1.6.4 Limitations  
 
This epidemiological study exhibits some important limitations that warrant mention. The 
cause of death was ascertained from the ONS data and the authors did not examine death 
certificates or post-mortem reports on an individual basis in order to identify potential 
misclassifications. Although the ONS data do not provide information regarding the 
number of deceased individuals who underwent a post-mortem examination, it would be 
reasonable to assume that the majority of the victims were subjected to a post-mortem 
examination given their youth and the UK medico-legal implications. 
 
The investigator concedes that this study relied solely on information provided to the ONS 
from documentation on death certificates and post-mortem reports which may not always 
accurately reflect the true cause of death given the ambiguities related to the diagnosis of 
conditions associated with sudden cardiac death in the young. This may explain the 
absence of conditions such as arrhythmogenic right ventricular cardiomyopathy (ARVC) as 
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a distinct entity, whereas minor manifestation of certain common disorders such as 
atherosclerosis may have been falsely attributed as the cause of death. In addition, ARVC 
does not have its own ICD-10 code and is classified currently as I42.8 - other 
cardiomyopathies. The purpose of this study, however, was to provide an estimate of the 
incidence of cardiac death and underlying cardiac causes in the young in order to highlight 
the need to establish the scale and nature of the problem.  
 
Chapter 2: The epidemiology of sudden cardiac death and sudden 
arrhythmic death syndrome in athletes 




Most studies investigating the incidence of SCD in young athletes, defined as ≤35 years 
old, come from the US. One of the first studies conducted by Maron et al. utilized a unique 
insurance program for catastrophic injury or death, mandatory for all student athletes 
engaged in school sports in Minnesota.9 As such the precise number of participants and 
deaths due to cardiovascular disease could be ascertained. The authors retrospectively 
reviewed the Minnesota State High School League records for the 12-year period, 
1985/1986 to 1996/1997 inclusive, for grades 10 to 12. During that period the authors 
identified only 3 deaths, all classified as of cardiovascular aetiology after autopsy: 1 
coronary artery anomaly, 1 myocarditis, 1 aortic valve stenosis with bicuspid aortic valve. 
Based on the athlete population the authors calculated the incidence of SCD as 0.46 per 
100,000 per year; 95% CI: 0.09 to 1.34. All 3 deaths occurred in male athletes and the 




Further studies in American high school and college athletes were performed by van 
Camp et al.19 and more recently by Drezner et al.20 and Harmon et al.21 All three studies 
utilized existing athlete registries in order to estimate the total number of collegiate 
athletes competing over the respective study period (i.e. denominator). Depending on the 
study, the investigators relied on a number of different sources of reporting deaths in 
athletes including registries, sporting organizations, parent organizations as well as media 
reports. As such all studies are vulnerable to different selection biases relating to the 
number of deaths, which are likely to have underestimated the true incidence of SCD. The 
study by van Camp et al. reported an incidence of SCD of 0.75 per 100,000 per year for 
male athletes and 0.13 per 100,000 per year for female athletes. The study by Drezner et 
al was designed to assess the effectiveness of emergency response planning for sudden 
cardiac arrest rather than the incidence of SCD in high school athletes. Based on their 
findings however, the study reported an incidence of sudden cardiac arrest in high school 
student athletes of 4.4 per 100,000 per year. Although this estimate may have been 
influenced by responder bias, it is consistent with recent findings from a prospective, 
population-based study of paediatric out-of-hospital cardiac arrest in which the incidence 
of cardiac arrest caused by cardiovascular disease in adolescents 14 to 24 years was 3.75 
per 100 000 person-years.42 Finally, the study by Harmon et al. reported an incidence of 
SCD of 2.3 per 100,000 per year, highlighting a considerable gender (male versus female 
athletes - 2.3 to 1), ethnicity (black athletes versus white athletes - 3.3 to 1) and sport 
(basketball versus cross-country - 3.7 to 1) predilection. 
 
In a second study by Maron et al.14 the authors attempted to calculate the incidence of 
SCD in US competitive athletes, based on the data from a US National registry of sudden 
death in athletes and the estimated number of participants in all competitive sports ≤39 
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years old in the US during the same time period. The authors identified 1866 deaths over 
a 27-year period of which 1049 were classified as cardiovascular. The authors were able 
to confirm the cause of death by reviewing the autopsy report in only 690 (66%) cases of 
potentially cardiovascular deaths. Cardiomyopathies accounted for the majority of deaths 
(51%), followed by coronary artery pathology and predominantly coronary artery 
anomalies (21%) and myocarditis (6%). In contrast to the general population studies 
deaths attributed to SADS accounted for less than 4%. The incidence of sudden deaths in 
these athletes was reported as 0.61 per 100 000 person-years. Although the attempt to 
database SCDs in young athletes is admirable, the methodology employed to collect the 
data, such as internet searches and media accounts, makes the results prone to 
numerous selection biases, which are likely to lead to inaccurate conclusions. Essentially, 
there is no reliable numerator or denominator, subjects were subjected to different post-
mortem investigations and there is also an issue of reliability of post-mortem results since 
they were performed by numerous pathologists across the US. 
 
The only large European study addressing systematically the incidence of SCD in young 
athletes is the one by Corrado et al.22 The study is unique in that a well-defined population 
of athletes and non-athletes in the Veneto region of Italy was prospectively studied for 25 
years. Most importantly however, and in contrast to all other studies, because of the highly 
organized referral network, all deaths in young (12-35 years) individuals considered to be 
of cardiac cause were referred for post-mortem evaluation to a single centre and 
underwent detailed histopathological evaluation of the heart by a small number of expert 
cardiac pathologists. Moreover, the unique pre-participation screening program which is 
enforced by law in Italy ensures that athletes participating in formal competition are 
subjected to annual medical reviews. Based on the results of this study the incidence of 
SCD in young athletes was estimated at 4.19 per 100,000 per year prior to the initiation of 
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the pre-participation screening program. The incidence of SCD in young non-athletes was 
around 1.0 per 100,000 per year with no significant fluctuations over the 25-year period. In 
the Veneto cohort, rhythm and conduction abnormalities, which could be considered to 




The incidence of SADS in athletic populations in the UK has not been studied and in a 
similar manner to young individuals, in the absence of a systematic national registry 
documenting sudden cardiac deaths in athletes, the true impact of such fatalities remains 
speculative. A considerable proportion of SCDs in athletes are secondary to previously 
quiescent cardiac diseases, galvanizing discussions relating to primary and secondary 
prevention strategies to avert such catastrophes, particularly when one considers that 
athletes are perceived as the healthiest segment of society. Establishing the magnitude 
and pathogenesis of sudden cardiac death in young athletes is fundamental to facilitate 
any debate about local provisions for a potential cardiovascular screening programme.28-30 
Finally, establishing the impact of SADS may also inform the debate as to the most 
appropriate screening protocol since the 12-lead ECG is the principal diagnostic tool for 
identifying all primary arrhythmogenic syndromes. 
 
To address the scientific gap relating to the magnitude of SADS in athletic individuals in 
the UK we conducted a study in collaboration with the Cardiac Risk in the Young (CRY) 
centre for cardiac pathology at Royal Brompton Hospital. The authors performed a 
retrospective analysis of 118 hearts referred to the cardiac pathology centre, of people 
who participated in regular sport activities and experienced sudden death, between 1996 
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and 2008. The contribution of individual underlying cardiac pathologies and in particular 
the finding of a normal heart (SADS) was reported.43 
 
2.3 Personal contribution 
 
The author reviewed data relevant to the project and assisted with analysis of data and 
drafting of the published manuscript. The author was not involved with the post-mortem 
evaluation or toxicology screen of any of the subjects or the initial raw data collection that 





Between January 1996 and July 2008, 118 cases of sudden death in people participating 
in regular sport activities, defined as ≥ 2 hours per week, were referred to the Cardiac Risk 
in the Young (CRY) Centre for Cardiac Pathology at the Royal Brompton Hospital for 
further evaluation, by coroners and pathologists throughout the UK. Subjects were divided 
into two groups based upon their age at death: (a) ≤35 years and (b) >35 years. Data on 
age, sex, circumstances of death, sporting discipline, antecedent cardiac symptoms, past 
medical history and a family history of cardiac disease (when available) of the deceased 







2.4.1 Post-mortem evaluation 
 
The hearts were referred to the Cardiac Risk in the Young (CRY) Centre for Cardiac 
Pathology at the Royal Brompton Hospital with the consent of the coroner and the family 
of the deceased. A specific protocol was established for handling all SCD referrals, 
summarised in Figure 5. 
 
Figure 5: Flow chart depicting the cardiac referral procedure at the Cardiac Risk in 





Pathological analysis of all hearts was performed by a single cardiac pathologist (MNS) 
with the consent of the coroner and family of the deceased. The heart weight was 
recorded and measurements of the left and right ventricular wall thickness and internal 
cavity dimensions were made at mid-ventricular level excluding papillary muscle and fat. 
The extramural coronary arteries were studied macroscopically in the intact heart by 
making multiple cross sections of the vessels (3–5mm apart). Multiple (10 to 20) tissue 
sections were routinely taken according to agreed national and international criteria44 and 
included: the right ventricular outflow tract; a right lateral cut containing right atrium, 
posterior leaflet of the tricuspid valve and lateral right ventricle; a left lateral cut containing 
left atrium, mitral valve and lateral left ventricle; circumferential right and left ventricle 
samples; the anterior and posterior septum; the three major coronary arteries; the 
ascending aorta; and the conduction system. Extra tissue sections were taken to confirm 
pathology when this was detected macroscopically or microscopically. Sections were fixed 
in formalin, embedded in paraffin and stained with haematoxylin and eosin stain or elastic 
Van Gieson to highlight myocardial fibrosis. Table 5 summarises the macroscopic and 
histological criteria for specific cardiac diseases, as defined by MNS, based on established 
literature. Results were reported in four broad categories: (a) cardiomyopathies; (b) 
coronary artery pathology; (c) morphologically normal heart and (d) other cardiac 
pathology, including myocardial inflammation and valvular heart disease. 
 
All patients included in the studies underwent a toxicology screen as part of the coroner’s 




Table 5: Macroscopic and microscopic definitions of cardiac pathology 
Disorder Macroscopic appearance Microscopic appearance 
Cardiomyopathy 
HCM Left ventricular wall thickness ≥15 
mm and or heart weight ≥500g in 
males or ≥400g in females. 
Myocyte hypertrophy, 
significant disarray (≥2 LV 




disease if clinical history 
of hypertension) 
Left ventricular wall thickness ≥15 
mm and or heart weight ≥500g in 
males or ≥400g in females. 
Myocyte hypertrophy with or 
without fibrosis. No myocyte 
disarray.* 
ARVC Right ventricular dilatation and 
thinning with fatty replacement and 
fibrosis. Epicardial fat and fibrosis 
in the outer left ventricle. 
Fibro-fatty replacement, 
mainly epicardial extending to 
replace the full thickness of 
the right ventricular wall. Left 
ventricular involvement occurs 
with subepicardial fibrous 
tissue and fat. 
Obesity cardiomyopathy Left ventricular wall thickness 
>15mm and/or heart weight ≥500g 
in males or ≥400g in females with a 
BMI ≥30Kg/m2 
Myocyte hypertrophy, nuclear 
enlargement, with or without 
fibrosis. 
No myocyte disarray.* 
DCM Enlarged heart with heart weight 
≥500g in males or ≥400g in 
females. Dilated ventricular 
chamber (>40mm), 
circumferentially thin walled 
(<10mm) with mid-myocardial 
fibrosis. 
Replacement and interstitial 
fibrosis throughout the left 
ventricle. Degenerative 
changes in the myocytes. 
Myocyte size varies from 
atrophied to hypertrophied. 
Idiopathic fibrosis Normal left ventricular thickness 
≤15 mm 
Focal and diffuse interstitial 
and/or replacement fibrosis in 
the ventricular wall 
Coronary artery pathology 
Atherosclerosis  Atherosclerosis with narrowing 
>75% 
Rupture/thrombosis of 
coronary artery and/or 




Anomalous origin of the coronary 
artery, coronary artery atresia, 
stenosis  
Fibrosis/acute/chronic 
infarction in the left ventricle 
Coronary artery spasm Circumferential subendocardial 
haemorrhagic infarction with normal 
coronaries 
Acute infarction in the LV 
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Table 5: Macroscopic and microscopic definitions of cardiac pathology 
Coronary dissection Tear in the coronary artery media Infarction in the territory of the 
artery 
Coronary artery bridging Coronary artery bridging was 
considered pathologically 
significant when the left anterior 
descending coronary artery had a 
long (15-30mm) and deep (≥3mm) 
intra-myocardial course.  
Ischaemic damage in the 
antero-septal left ventricle. 
Morphologically normal heart 
Normal heart Normal Normal 
Other cardiac pathology 
Myocarditis Normal or dilated ventricle Inflammatory infiltrate of the 
myocardium with necrosis 
and/or degeneration of 
adjacent myocytes, in the 
absence of coronary artery 
disease. 
>14 leucocytes/mm2 with the 
presence of T- lymphocytes 
>7 cells/mm2. 
Mitral valve rupture Mitral valve papillary muscle or 
chordae tendineae rupture with  
marked ballooning of both leaflets 
above the atrioventricular junction 
Myxoid change in the valve 
with associated fibrosis. 
Floppy mitral valve Mitral valve thickened with prolapse 
of both cusps into the left atrium. 
Myxoid change in the valve 
Aortic dissection or 
rupture 
Tear in the proximal aorta above 
the aortic ro haemopericardium. 
Focal to widespread cystic 
medial change in the aorta. 
Bicuspid valve Two leaflets associated with 
nodular calcification with significant 
aortic orifice stenosis. 
Left ventricular hypertrophy 
with or without fibrosis 
Sickle cell crisis Normal Sickle cell in intramural 
coronary vessels with micro-
infarcts in the myocardium 
 
* isolated myocyte disarray confined to the anteroseptal and posteroseptal junctions  
  should be considered normal 
ARVC: Arrhythmogenic right ventricular cardiomyopathy; DCM: Dilated cardiomyopathy; 




Trust gebnerated approval was obtained from the Brompton, Harefield and National Heart 




Data interpretation and analyses were performed using Stata version 10.1 (Statacorp, 
Texas USA). Means and standard deviations (SD) were calculated for continuous 
variables. Group differences are examined using t-test where appropriate. A value p<0.05 






Of the 118 cases of SCD, the majority were amateur sports participants (n=107, 91%) and 
included seven subjects who had participated in 2–23 marathons. The remaining 11 cases 
were seven athletes at a professional or semi-professional level (soccer n=6, cycling n=1) 
and four who participated in intensive physical training in the armed forces. 
 
The subjects were predominantly male (n=113; 96%). One hundred and thirteen athletes 
(96%) were white and five were black (African/Caribbean in origin). The mean (SD) age of 
SCD in this series was 27.9±12.5 years (range 7–59). Seventy-five per cent of all deaths 
were in subjects aged ≤35 years and almost one-third were in child or adolescent athletes 
(<18 years). The greatest number of deaths (n=20) occurred in the 16–20 year age group 
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(Figure 6). With the exception of one case, all female athletes who died were in the 
younger age group. 
 
 
Figure 6: Bar chart showing the number of sudden deaths in athletes in relation to 
age in 118 deaths in sportsmen referred to a tertiary centre in the UK over a 12-year 
period. 
 
The vast majority of SCDs (81%) occurred during (66%) or immediately after (15%) 
exercise. In relation to sporting discipline, most deaths occurred in soccer, followed by 











Table 6: Demographic characteristics of the athletic cohort 
Characteristics Values 
Number of subjects 118 
Male 113 (96%) 
Age (years), mean±SD, {range} 27.9±12.5, {7–59} 
Number of subjects ⩽35 years 89 (75%) 
Sport discipline  
    Soccer 44 (37%) 
    Running 24 (20%) 
    Rugby 11 (9%) 
    Cycling 8 (7%) 
    Swimming 5 (4%) 
    Weight lifting 3 (3%) 
    Golf 3 (3%) 
    Other (⩽2 subjects/discipline) 20 (17%) 
 
2.5.2 Antecedent symptoms, past medical history and family history of cardiac Disease 
 
Of the 118 cases, 21 (18%) had experienced one or more antecedent cardiovascular 
symptoms which could be attributed to underlying cardiac disease (Table 7). In 20 subjects 
(17%) there was a family history of premature cardiovascular disease (≤50 years old), with 
IHD in the majority of cases (69%). In 8 (7%) cases there was a family history of 
premature SCD in a first-degree relative. Twenty-five (21%) of the subjects had relevant 
previous medical history; 7 had a history of confirmed cardiac disease, 9 were clinically 
suspected to have underlying cardiac pathology, 5 had risk factors for coronary artery 
disease and 4 had had at least one epileptic seizure (Table 7). Ten athletes (8%) had a 
previous diagnosis of asthma. As far as the authors can ascertain, none of the subjects 
had been subject to pre-participation cardiovascular evaluation to identify disorders 





Table 7: Antecedent symptoms, family history and relevant cardiac history of the 
118 subjects * 
Patient information Number of cases n=118 





Family history premature SCD (≤50 years old)         20 (17%) 15 (17%) 5 (17%) 
Symptoms *         21 (18%) 16 (18%) 5 (17%) 
Syncope/dizziness         10   (9%)   9 (10%) 1   (3%) 
Shortness of breath           7   (6%)   5   (6%) 2   (7%) 
Palpitations           6   (5%)   6   (7%) 0 
Chest pain           4   (3%)   3   (3%) 1   (3%) 
Relevant past medical history         25 (21%) 16 (18%) 9 (31%) 
Clinical suspicion of heart disease ♯         12 (10%)   9 (10%) 3 (10%) 
Seizures           4   (3%)   4   (5%) 0 
Diabetes           3   (3%)   1   (1%) 2   (7%) 
Hypercholesterolaemia           4   (3%)   0 4 (14%) 
Congenital heart disease           3   (3%)   3   (3%) 0 
Previous cardiac arrest           2   (2%)   1   (1%) 1   (3%) 
Atrial fibrillation           1   (1%)   0 1   (3%) 
Viral myocarditis           1   (1%)   1   (1%) 0 
 
* symptoms/findings do not add up since some subjects had more than one 
symptom/finding. 
♯ abnormal ECG; n=4, abnormal echo; n=2, heart murmur; n=3, possible arrhythmia; n=3.  
 
2.5.3 Causes of sudden cardiac death 
 
Abnormal cardiac pathology (macroscopic and/or microscopic) was identified in 91 (77%) 








Figure 7: Pie chart showing the causes of sudden cardiac death in 118 sports 
deaths referred to a tertiary cardiac centre in the UK over 12 years. 
ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, hypertrophic 
cardiomyopathy; LVH, left ventricular hypertrophy. Percentages do not add up to 100% 
because of rounding. 
 
Toxicology screen  
 
All but two subjects had a normal toxicology screen. Both were body builders and had 







Deaths attributed to a primary myocardial disorder (cardiomyopathy) were identified in 73 
(62%) of all athletes. Left ventricular hypertrophy (LVH) was the most commonly identified 
abnormality on macroscopic examination and was detected in 49 (42%) athletes raising 
the possibility of HCM. However, only 13/49 (27%) athletes with LVH exhibited associated 
myocyte disarray, the historically regarded histological hallmark of HCM. The remaining 
cases of LVH (n=36; 31%) were associated with histological evidence of either isolated 
myocyte hypertrophy (n=27) or myocyte hypertrophy and fibrosis (n=9). The authors 
classified these cases under the term ‘‘idiopathic LVH’’. One case of HCM and another of 
idiopathic LVH were associated with the presence of anabolic steroid traces on toxicology 
screen. 
 
Athletes with HCM were predominantly in the younger age group (≤35 years) with a mean 
age of 24.6±7.1 years (range 11–43) and all but one case were male. Similarly, 71% of all 
victims with idiopathic LVH were in the younger age group with a mean age of 32.7±12.6 
years (range 9–59) and all were male. Of the five Afro-Caribbean subjects, four had 
evidence of idiopathic LVH. 
 
Arrhythmogenic right ventricular cardiomyopathy was the second most common diagnosis 
and was identified in 16 (14%) members of our cohort. There was evidence of biventricular 
involvement in 50% of cases. In contrast with cases of idiopathic LVH and HCM, deaths 
were equally distributed between the older and younger age group with a mean age of 
35.9±12.2 years (range 16–57). 
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Idiopathic fibrosis without LVH occurred in seven cases with all but one in the younger age 
group with a mean age 28.4±8.5 years (range 17–43). Finally, one case exhibited features 
of both ARVC and HCM. There was insufficient tissue sampling to provide a definite 
diagnosis and the case was classified as an undetermined cardiomyopathy. 
 
Table 8: Cause of sudden cardiac death according to histopathological findings 
Diagnoses ⩽35 >35 Total 
Cardiomyopathy 49 24 73 
Idiopathic left ventricular hypertrophy 19 8 27 
Idiopathic left ventricular hypertrophy with fibrosis 3 6 9 
Arrhythmogenic right ventricular cardiomyopathy 9 7 16 
Hypertrophic cardiomyopathy 11 2 13 
Idiopathic fibrosis 6 1 7 
Undetermined cardiomyopathy 1 0 1 
Morphologically normal heart 26 1 27 
Coronary artery pathology 7 4 11 
Anomalous coronary artery 6 0 6 
Atherosclerosis 0 3 3 
Coronary “spasm” 1 0 1 
Coronary dissection 0 1 1 
Other cardiac pathology 7 0 7 
Myocarditis 3 0 3 
Floppy mitral valve 2 0 2 
Complex congenital heart disease 1 0 1 
Sickle cell crisis 1 0 1 
 
Coronary artery pathology  
 
Coronary artery pathology was identified in 11 (9%) subjects. The main pathology was a 
congenital anomaly of the coronary arteries which was seen in six subjects all of whom 
were male and ≤35 years old (mean age 15.8±6.2 years; range 7–25). Both coronary 
arteries arose from the same coronary ostium in four cases; two cases had the left 
coronary artery arising from the right sinus and two cases had the right coronary artery 
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arising from the left sinus. Of the remaining two cases, one had atresia and hypoplasia of 
the left coronary artery and the other stenosis of the ostium and a shelf-like slit of the left 
coronary artery. Coronary atherosclerosis was the cause of death in only three athletes 
who were all aged >35 years (mean age 49.7±4.0 years; range 45–52). A single case of 
coronary artery spasm was detected in a 17-year-old man, as well as one case of 
spontaneous dissection of the left anterior descending artery in a 38-year-old man. 
 
Other cardiac pathology 
 
Lymphocyte myocarditis was the predominant finding in three cases. Two subjects had 
valvular disease which included floppy mitral valve and associated myocardial fibrosis. 
There was a single subject with corrected, complex congenital heart disease of 
univentricular circulation and Fontan circulation who exhibited biventricular hypertrophy 
with no other associated anomalies. Finally, one subject had evidence of an acute sickle 
cell crisis with sickling within the coronary arteries and associated acute ischaemia. 
 
Morphologically normal heart  
 
In almost a quarter of our cohort (23%) the post mortem disclosed no cardiac abnormality 
which could account for the cause of death, despite detailed macroscopic and microscopic 
examination. The majority of these cases (96%) were in the younger age group. The mean 
age of victims with a morphologically normal heart was 18±6.1 years (range 8–42) which 
was significantly lower than that of those dying with identifiable cardiac pathology 






Of the five female athletes in the series, two had a morphologically normal heart, one had 




The cardiovascular benefits of regular physical activity are well established45 and only a 
small proportion of athletes with unsuspected cardiac pathology are at increased risk of 
exercise-related SCD.9,11,13,14,22,46 The majority of data examining the aetiology of deaths in 
athletes originates from the USA (690 cases of primary cardiovascular death),14 although a 
number of smaller studies exist in European countries, including France (80 cases)47 Spain 
(61 cases),48 Italy (55 cases),22 and Ireland (51 cases).49 Data in the UK are scarce and 
limited to a small group of older sport participants. This study of 118 SCDs in athletic 
individuals is the largest reported series in the UK. 
 
2.6.1 Sport and gender predilection  
 
Consistent with large American14 and Italian series22,50 of SCD in athletes, just over 80% of 
deaths occurred during or immediately after exercise, indicating that the interplay of 
physical, metabolic and endocrine stresses of exercise on the heart is an important trigger 
for fatal ventricular arrhythmias. Soccer and running were the sports most commonly 
associated with SCD and this is in agreement with most other studies.9,13,14,22,30,46,50 This 
sport bias most certainly represents the high participation rates in these sporting 
disciplines in most Western European countries. In concurrence with previous studies, the 
great majority (96%) of SCD subjects in our cohort were male.9,14,22,46-52 Based on our ONS 
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data male gender appears to confer some degree of increased risk (2.5 to 1) of SCD 
outside the context of sports. However, within the context of this study, male 
predominance (23 to 1) may be largely attributed to the lower participation rate of women 
in sport generally and specifically in sports popular with male subjects, such as soccer, 
which is the predominant sport in our study. 
 
2.6.2 Morphologically normal heart 
 
Despite detailed macroscopic and histological examination by an expert cardiac 
pathologist, in a quarter of the cohort (23%) no structural cardiac abnormality was 
identified, implying a SADS death. Previous studies have reported significantly lower rates, 
as low as 1%,14,46,51 with only a Spanish series reporting a figure comparable to our study 
(16.3%).48 Although selection bias has certainly contributed to the high prevalence of SCD 
with a morphologically normal heart, this study highlights the importance of establishing 
such a diagnosis since primary arrhythmogenic syndromes can be identified in relatives 
and appropriate treatment instigated to avoid further tragedies.53 Of interest, three children 
(aged 7–15 years) with morphologically normal hearts died during swimming. This sport 
has been particularly associated with deaths in LQTS54,55 and CPVT.36 
 
2.6.3 Cardiomyopathy  
 
Consistent with previous studies in the USA9,14 and Italy,22,50 our results indicate that 
cardiomyopathies are the most prevalent underlying pathology in SCD related to athletic 
activity. In this series, however, LVH without myocyte disarray, was the predominant 
finding (31%), compared with HCM and ARVC in the USA and Italy, respectively. 
Idiopathic LVH is becoming increasingly recognised and although it has been reported in 
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previous studies, this is the first series in which it predominates. Its exact significance at 
this stage is unclear and was the subject of investigation in our study of post-mortem 
findings of uncertain significance (study V). In the context of athletic individuals it may 
represent an acquired pathological variant of the physiological LVH exhibited as part of the 
‘‘athlete’s heart’’ in certain genetically predisposed backgrounds.56 The finding of idiopathic 
LVH in four out of five Afro-Caribbean cases of SCD may be relevant in this regard since a 
recent study by our group in highly trained black athletes showed that 3% exhibit 
substantial LVH (>15 mm) and it is plausible that in such athletes, marked LVH 
predisposes to exercise-related fatal ventricular arrhythmias.57 LVH has also been 
associated with the use of anabolic steroids.58 In our study traces of anabolic steroids were 
identified at post mortem in two body builders; one was diagnosed with idiopathic LVH and 
the other with HCM.  
 
Idiopathic myocardial fibrosis with or without LVH, featured in 14% of this cohort in 
contrast to significantly lower rates in previous studies (2%–3%).47-49 The aetiology and 
importance of cardiac fibrosis also remains unclear; however, transient myocardial 
damage has been detected in athletes in the post-race setting and has been associated 
with transient diastolic and systolic dysfunction.59 Possibly, in some athletes prolonged 
arduous physical activity may result in myocardial necrosis and subsequent fibrosis. This 
pathology may represent an acquired, exercise-related cardiomyopathy and/or genetic 
predisposition leading to a fatal arrhythmia. This concern was raised in a recent case 
report from our group of a marathon runner who died during a race with marked LVH and 
myocardial fibrosis.60 It is also possible that at least some of these cases may be due to 
the recently recognised familial arrhythmogenic left ventricular cardiomyopathy.61 
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ARVC was the second most common cardiomyopathy and accounted for 14% of all 
sudden deaths in our series. Our figures were significantly higher than those reported in 
the US series9,14 and not dissimilar from the reports from the Veneto region of Italy22,50,51,62 
and other European countries.16,47,48,63,64 These observations suggest that there may be a 
higher genetic cluster of ARVC in Europe or, owing to the Venetian experience, a greater 
awareness of this disorder amongst pathologists in Europe. Moreover, recent studies have 
demonstrated that intense endurance exercise causes acute dysfunction of the RV.65 
Although short-term recovery appears complete, chronic structural changes and reduced 
RV function are evident in some of the most practiced athletes, leading to the hypothesis 
that an ARVC-like phenotype may be acquired through intense exercise.66 
 
Of note, we did not observe deaths from dilated cardiomyopathy in our cohort, which 
contrasts with series from other countries where the range was 2–11%.46-48,51 
 
Coronary artery pathology 
 
Coronary artery pathology was less prevalent in this study than in the US and Italian 
experience. Sudden cardiac death secondary to anomalous coronary arteries was 
confined to the younger age group (median age of 17 years) in this series, a trend 
supported by previous reports.9,14,22,47,48,50 Atherosclerotic coronary artery disease was seen 
in a much smaller number of individuals and was confined to the older (>35 years) age 






2.6.4 Clinical implications related to pre-participation screening 
 
The absence of antecedent cardiac symptoms and/or a family history of cardiac disease 
and/or SCD in almost 80% of cases confirm prior observations that most cardiovascular 
disorders responsible for SCD in the athlete are clinically silent and unlikely to be 
discovered from spontaneous symptoms. Cardiovascular screening with ECG testing has 
been associated with a significantly higher diagnostic yield than reliance on history alone, 
although concerns remain relating to the high false positive yield and the need for 
unnecessary investigations and potential false disqualification from sport.11,27,68-70 This study 
indicates that based on the high prevalence of cardiomyopathies and the relatively low 
occurrence of coronary artery pathology in our subjects, pre-participation cardiovascular 
screening using a 12-lead ECG may have raised suspicion of an underlying cardiac 
abnormality in a significant proportion of SCD victims. This argument is further reinforced 
by the high prevalence of SCDs in people with a morphologically normal heart, of which a 
significant proportion may be attributed to inherited ion channelopathies, which might be 
potentially detected by the 12-lead ECG. 
 
We concede that almost one-third of the cases in this series exhibited idiopathic LVH and 
it may be argued that these cases may not have been identified with ECG. It is unclear at 
this stage whether idiopathic LVH represents a spectrum of the HCM phenotype, an 
exaggeration of the physiological response56 resulting in pathological LVH or whether it is 
indeed an innocent bystander (genuine physiological LVH) in a person who may have 
succumbed to a fatal ventricular disorder owing to an undetectable ion channel disorder or 
congenital accessory pathway. However, it is well established that over 90% of people 
with HCM have an abnormal ECG,71 and athletic individuals with LVH on 
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echocardiography are more likely to exhibit repolarisation anomalies, and in particular T-
wave inversions, in their ECG.72  
 
The predominance of deaths due to idiopathic LVH and idiopathic myocardial fibrosis does 
raise the possibility that some deaths in sport may be secondary to acquired myocardial 
disorders resulting from the long-term effects of intensive exercise, warranting several 
cardiac assessments throughout the athlete’s career. 
 
The Italian screening programme in athletes has been successful in identifying and 
preventing deaths predominantly from the cardiomyopathies through subsequent 
disqualification of the affected subject from sporting activities of moderate to high intensity 
to minimise the risk of SCD. In this regard it is prudent to highlight that in this study almost 
one-fifth of all SCDs in athletes occurred at rest, suggesting that the identification of 
cardiovascular diseases and subsequent disqualification from sport will not necessarily 




We concede that conclusions drawn from this study do not necessarily apply to the whole 
of the UK because of a significant selection bias. The CRY Centre for Cardiac Pathology 
at the Royal Brompton Hospital is an internationally recognised cardiac pathology centre in 
the UK, where the hearts of many young athletes are commonly referred, especially when 
the findings are ambiguous and no clear cause of death can be established by the local 
pathologist. It is therefore highly probable that cardiac anomalies such as coronary artery 
atherosclerosis, which can be easily identified, and cardiomyopathies such as HCM, which 
have been well characterised, are under-represented in this cohort. Similarly the 
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prevalence of less well-defined entities such as idiopathic left ventricular hypertrophy and 
a morphologically normal heart are likely to represent an overestimate. 
 
Diagnostic criteria reported in table 5 are based on National and International 
recommendations but also on the experience of our cardiac pathologist (MNS).44,73 As a 
result certain definitions, such as the differentiation of HCM from idiopathic LVH, may be 
considered arbitrary rather than evidence based. In addition, the post-mortem diagnosis of 
a potential cause of SCD in all athletic individuals was based on the analysis and 
interpretation of the autopsy findings by a single pathologist (MNS), albeit an 
acknowledged international expert. As such we were unable to provide inter-observer 
variability. Having an additional pathologist to corroborate the cardiac pathological 
interpretation would be desirable, but single centres cannot justify more than one cardiac 
pathologist. There are also few cardiac pathology specialists in the UK, posing a limitation 
on double reporting. 
 
Chapter 3: Post-mortem evaluation of victims of sudden cardiac death - 
Impact of cardiac pathology 




Post-mortem examination is a critical first diagnostic step required to guide clinical 
evaluation of surviving relatives of victims of SCD. In the UK the pathologist’s report is 
commonly the sole determinant as to whether relatives are referred for familial evaluation 
for potentially inherited cardiac conditions and more specifically whether subsequent 
investigations are directed towards structural disorders or primary arrhythmogenic 
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syndromes. Best practice guidelines set by the Royal College of Pathologists and the 
Association for European Cardiovascular Pathology recommend referral of the whole heart 
to specialist centres with high volume of cardiac autopsies and established expertise.44,73 
According to both governing bodies all potential sudden cardiac deaths should be 
subjected to a comprehensive macroscopic and histological evaluation as well as 
toxicology screen. The pathologist should address the following subjects; 1. whether the 
death is attributable to a cardiac disease or to other causes of sudden death; 2. the nature 
of the cardiac disease, and whether the mechanism was arrhythmic or mechanical; 3. 
whether the cardiac condition causing sudden death may be inherited, requiring screening 
and counselling of the next of kin; 4. the possibility of toxic or illicit drug abuse and other 
unnatural deaths. 
 
Despite the guidelines however, there is widespread variation in Europe as to the rate of 
autopsies for SCD even within the same country.74 An observational study by Winkel et al. 
surveyed the rate of autopsies performed in different counties in Denmark after a sudden 
death in individuals aged between 1-35 years. The authors identified a significant 
difference in the rate of autopsies performed ranging from 60% to 88%. Autopsies were 
more often conducted in urban areas compared to rural areas and in East Denmark 
compared to West Denmark. The authors concluded that despite operating under the 
same set of laws, there were significant regional differences in forensic investigations of 
young persons suffering a sudden unexpected death and called for a revision of the way 
these deaths are handled. 
 
In the UK all sudden unexpected deaths, particularly in young individuals, have an autopsy 
carried out by a coroner’s pathologist. Most British pathologists, however, have limited 
experience with conditions predisposing to young SCD, with few resources and time 
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constraints. Moreover, the introduction of the Human Tissue Act in 2004 has limited 
preservation of tissue at autopsy.75,76 All these factors translate to either the absence or 
limited histopathological examination in cases of SCD, which remains unsatisfactory and 
may lead to erroneous diagnoses.3,7,77-79 In 2006 the National Confidential Enquiry into 
Patient Outcome and Death (NCEPOD) audit of coronial autopsy reports in England, 
Wales and Northern Ireland was critical of autopsy practice.80 The audit reported that a 
high proportion of coronial autopsies did not comply with the guidance issued by the Royal 
College of Pathologists. A further on-line survey of pathologists in the UK aimed to provide 
an overview of current autopsy practice.77 Of the 1213 pathologists invited, only 406 
completed the survey. Results confirmed considerable pressures of time and resources 
and limitations on examination and sampling. The survey concluded that the 
circumstances under which coronial autopsies are conducted in many parts of the UK 
make it difficult or impossible to comply with the Royal College of Pathology guidelines, 
which set higher standards than what can be achieved in routine practice. 
 
A recent study published by Wilms et al.78 evaluated the reporting of autopsies performed 
in the investigation of sudden unexplained death in the young in New Zealand. Similarly to 
the UK, New Zealand has established guidelines, introduced in May 2008, that closely 
reflect those of the Royal College of Pathologists. The study was based on the fact that all 
cases of sudden and unexpected deaths in 0–40 year olds are referred to the cardiac 
inherited disease group, which the authors reviewed. Two periods were reviewed 
corresponding to a period before and after the new guidelines on autopsy practice, in 
order to assess the impact of such guidelines. Data were examined in four sections: 1. 
details of presentation and previous history; 2. data gathered at the time of the post-
mortem; 3. results of histological tests and toxicology; and 4. analysis of the coronary 
arteries. One hundred and ten deaths were included in the study. Relating to the post-
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mortem evaluation of the victims, over 95% listed heart weight, valvular examinations, 
pulmonary and some myocardial histology. Less than 50%, however, commented on 
septal, left ventricular and right ventricular wall thickness. Less than 50% mentioned the 
site of histology samples, or gave specific description of left ventricular or right ventricular 
histology or conduction system. Toxicology was not mentioned in a third of cases. 
Histology of coronary arteries was described in less than a fifth of victims (18%). After the 
publication of the guidelines some improvement of reporting was noted, with a higher 
reporting rates of the number and location of histology samples (from 0 to 47%) and higher 
reporting rates of coronary artery histology (from 6% to 50%). The authors concluded that 
most autopsy reports fall short of best practice guidelines and need to be more consistent 




To investigate concerns over autopsies performed by general pathologists and the 
potential for erroneous diagnosis by comparing diagnostic discrepancies between general 
pathologists and a specialist cardiac pathologist. 
 
3.3 Personal contribution 
 
The author reviewed data relevant to the project and assisted with analysis of data and 
drafting of the published manuscript. The author was not involved with the post-mortem 
evaluation or toxicology screen of any of the subjects or the initial raw data collection that 






The charity Cardiac Risk in the Young (CRY) launched the Centre for Cardiac Pathology in 
the National Lung and Heart Institute (Imperial College) in March 2007 to address the 
need for detailed, high-quality histopathological evaluation of cases of SCD from 
potentially inherited conditions, by a cardiac pathologist, at no cost to the family, coroner 
or health service. The authors prospectively reviewed a sample of 200 consecutive cases 
of SCD referred to the CRY centre of cardiac pathology between March 2007 and 
December 2009. Inclusion criteria were as follows: 1. referral by a coronial pathologist of a 
witnessed instantaneous death or a suspected sudden death, 2. the individual was seen 
alive and well up to 24 hours prior to death, 3. non-cardiac causes excluded at initial 
autopsy, 4. Negative toxicology screen, 5. the referring pathologist had performed 
pathological evaluation of the heart and provided a potential cardiac cause accounting for 
the sudden death. All ages were included. One hundred and fifty eight cases fulfilled all 
criteria and were included in the study. The 158 autopsies of SCD victims were performed 
by local pathologists in 45 different counties within the UK. Data on age, sex, 
location/circumstances of death of the deceased were obtained from the referring 
pathologist or coroner. 
 
The methodology relating to specimen referral process (figure 5) and pathological analysis 




Trust generated approval was obtained from the Brompton, Harefield and National Heart 





Data interpretation and analyses were performed using Stata version 10.1 (Statacorp, 
Texas USA). Means and standard deviations (SD) or median and interquartile range (IQR) 
were calculated for continuous variables. Group differences are examined using t-test and 
Mann–Whitney U test for parameters with normal and non-normal distributions, 
respectively. Chi-square or Fisher’s exact test was used to test group differences of 
proportions. A value p<0.05 was considered statistically significant throughout. 
 
The kappa (κ) coefficient was used as a measure of agreement between the referring and 
our expert cardiac pathologist. The strength of the agreement was designed as poor (κ < 
0), slight (κ = 0-0.20), fair (κ = 0.21-0.40), moderate (κ = 0.41-0.60), substantial (κ = 0.61- 




The cohort (n=158) was predominantly male (n=66%). The mean age was 32 years, age 
range <1-98 years and 58% were ≤35 years. The majority of deaths occurred at home 
(n=90, 57%) and most died at rest or during sleep (n=54). Sudden cardiac death occurred 
during or immediately after exertion in 14% of the total cohort, most of whom were young 






3.5.1 Causes of sudden cardiac death 
 
A morphologically normal heart, consistent with a SADS death was the predominant 
finding of our cardiac pathologist accounting for just over 50% of the cases. In over one 
third (37%) of the cohort a cardiomyopathy was identified. The most common 
cardiomyopathies included: idiopathic LVH of whom 42% were associated with fibrosis, 
HCM, ARVC, and obesity cardiomyopathy. Obesity cardiomyopathy affected 
predominantly those aged over 35 years. However, a third (10/29) were young with the 
youngest victim aged 9 years with a BMI of 33.1 kg/m2. Myocardial inflammation was 
noted in 5 patients. The inflammatory types were: lymphocytic (n=2), toxic (n=1), 
eosinophilic and lymphocytic (n=1), granulomatous cardiac sarcoid (n=1) and eosinophillic 
(n=1). Valvular pathology comprised predominantly of mitral valve prolapse (n=3) which 
was associated with left ventricular fibrosis in 2 cases, followed by bicuspid aortic valve 
(n=2). Other pathology included congenital cardiac disease, coronary artery pathology, 
hypertensive heart disease, aortic dissection and cardiac tumours (Table 9). 
 
3.5.2 Specialist cardiac pathology analysis compared to coronial pathology 
 
In 94 of the 158 cases (60%) the provisional diagnosis made by the referring pathologist 
matched the diagnosis of our cardiac pathologist (Table 9). The κ coefficient as a statistical 
measure of concordance was moderately significant at 0.48. Consensus was greatest in 
the diagnosis of DCM, where all 6 cases assigned as DCM by the referring pathologist 
were confirmed by our cardiac pathologist. 
 
Referring pathologists were more inclined to diagnose pathology rather than designate the 
heart as morphologically normal, with only 50 out of 80 normal hearts being described as 
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such. Of the 30 normal hearts diagnosed with pathology by the referring pathologist, 20 
were thought to have signs of cardiomyopathy, the majority being ARVC. Of the 21 cases 
assigned a diagnosis of ARVC by the referring pathologist, 13 were reassigned to a 
morphologically normal heart after evaluation by our pathologist. The main observation 
mis-attributed to ARVC was isolated fatty infiltration of the right ventricle (n=10), which is 
considered a normal finding in the absence of myocardial fibrosis. Myocarditis was also 
over-reported by the referring pathologist, with 4 out of the 9 cases reassigned to a 
morphologically normal heart by our cardiac pathologist. In the majority of cases 
inflammation was focal with no necrosis and/or degeneration of adjacent myocytes. In 2 
out of 5 cases of valvular disease over-interpretation of floppy mitral was noted especially 
in older patients where slight ballooning of the mitral leaflet edges is a normal finding. Both 
cases were reassigned as normal heart. Finally, coronary artery atheroma was considered 
a significant cause of death in 3 cases included under the heading of other pathology by 
the referring pathologist but was determined to be non-significant by our expert cardiac 
pathologist, highlighting the issue of over-interpretation of the significance of coronary 
atheroma in the collapsed coronary arteries at autopsy. 
 
Similarly, HCM was over-diagnosed in 10 cases. The referring pathologists had either 
assigned a diagnosis of HCM in cases of isolated LVH or over-interpreted the extent of 
myocyte disarray due to sampling of the anteroseptal and posteroseptal walls. Isolated 
myocyte disarray confined to the anteroseptal and posteroseptal junctions should be 
considered a normal finding. Five of the 17 cases diagnosed as HCM by the referring 





Table 9: Comparison of pathological diagnosis in 158 cases of sudden cardiac death 
where both the referring pathologists (vertical columns) and the expert cardiac 
pathologist (horizontal columns) performed a post-mortem cardiac evaluation. The 
shaded boxes indicate those cases where there was agreement. 

















ARVC 2 2 1 0 0 0 0 0 0 0 5 
HCM 0 7 1 0 0 0 0 0 1 2 11 
LVH 1 5 9 0 0 0 0 0 1 0 16 
DCM 0 0 0 6 0 0 0 0 0 2 8 
CM NOS 0 0 0 0 4 0 0 0 0 0 4 
Other CM 3 1 1 0 0 6 1 0 2 1 15 
Inflammation 0 0 1 0 0 0 4 0 0 0 5 
Valvular disease 0 0 0 0 0 0 0 3 1 1 5 
Normal 13 1 2 0 1 3 4 2 50 4 80 
Other pathology 2 1 0 0 0 1 0 0 2 3 9 
Total 21 17 15 6 5 10 9 5 57 13 158 
 
ARVC: Arrhythmogenic right ventricular cardiomyopathy; CM: cardiomyopathy; DCM: 
Dilated cardiomyopathy; HCM: Hypertrophic cardiomyopathy; LVH: Left ventricular 




This study reported the results of a unique specialist cardiac pathology service dedicated 
to the pathological investigation of SCD. To the best of our knowledge this is the first study 
to compare the results of autopsies as reported by a general pathologist and an expert 
cardiac pathologist. Our study demonstrates considerable differences in the interpretation 
of histopathological findings. Coronial general pathologists had the tendency to over 
diagnose pathology. Of the 74 individuals whose death was attributed to underlying 
cardiomyopathy by the general pathologist, 20 (24%) cases were reassigned to a 
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diagnosis of a normal heart by the specialist cardiac pathologist. The majority of those 
cases (n=13 out of 20) were due to over diagnosis of fatty infiltration and mild right 
ventricular dilatation for ARVC. The same was true for the presence of myocardial 
inflammation and valvular disease since almost 50% of the cases (4 out of 9 cases of 
inflammation; 2 out of 5 cases of valvular disease) were considered to represent normal 
findings by the cardiac pathologist (Table 9). 
 
3.6.1 Clinical implications 
 
Accurate interpretation of the pathological findings is of utmost importance in order to 
determine whether the death could be attributed to a potentially inherited cardiac 
condition. Based on available evidence81,82 the Department of Health has produced 
guidelines8 recommending the referral of all first-degree relatives of victims of SCD due to 
a potentially inherited cardiac pathology to specialist clinics, in an attempt to identify 
carriers of quiescent disease and prevent further tragedies. The pathologists report is likely 
to determine whether surviving relatives will be referred for comprehensive evaluation in a 
specialist cardiogenetics clinic and guide such a screening process towards structural 
disorders or primary arrhythmogenic syndromes. 
 
Based on the results of the study, 6 families may have not been referred for further 
evaluation based on a diagnosis of myocarditis (n=4) and valvular pathology (n=2) from 
the general pathologist. Both myocardial inflammation and valve disease have been 
correlated with SCD14 and in most cases are considered acquired or congenital disorders 
that are unlikely to affect other family members. On the contrary, however, reassigning the 
diagnosis to a normal heart by our expert cardiac pathologist, would by definition imply a 
SADS death with a recommendation for comprehensive evaluation of all first-degree 
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relatives of the deceased for primary arrhythmogenic syndromes. Moreover, an erroneous 
diagnosis of cardiomyopathy by the general pathologist in 20 cases may have misled 
clinicians and led to missed diagnostic opportunities. This is particularly the case in well-
established cardiomyopathies such as HCM and DCM, where a normal 12-lead ECG and 
transthoracic echocardiogram may suffice as first line screening, negating the need for 
further evaluation for possible arrhythmogenic syndromes. 
 
3.6.2 The importance of a cardiac pathology service 
 
Concerns over autopsies undertaken on behalf of UK coroners have been reported. In a 
quarter of investigated cases the cardiac autopsy was not of sufficient standard.79 In 
recent times pathologists have received limited exposure to autopsy work due to the 
decline in the hospital autopsy and may be unfamiliar with the spectrum of normal 
variations such as those associated with gender and age where fatty infiltration of the right 
ventricle and slight ballooning of the mitral valve can be misinterpreted as pathological. 
The diagnostic discrepancies identified in the present study and the potential clinical 
implications underscore the need for an expert cardiac pathology service to support 
general pathologists in the evaluation of sudden death, particularly in the young. Such a 
service will ensure a higher probability of accurate interpretation of autopsy findings. 
 
A specialist cardiac pathologist service is also particularly pertinent to primary care 
physicians who are the first port of call for such families and are required to interpret a 







The aim of this study was to investigate the importance of expert opinion in the diagnosis 
of SCD. It is plausible however that some of the referring pathologists intended to send the 
heart for specialist review from the outset and as such they performed limited 
histopathological evaluation. Additionally, discrepancies reported between the autopsy 
conclusions of our specialist centre and that of local pathologists may have been 
overestimated. The over-diagnosis of ARVC by referring pathologists may in part be 
explained by the time frame in which this study was conducted where the older task force 
criteria for ARVC were in effect.83 Although the 1994 criteria did use the term “fibrofatty” 
replacement of the myocardium, the presence of fat in the RV myocardium was still 
considered as the primary diagnostic feature of ARVC. The revised 2010 diagnostic 
criteria emphasise that histology must confirm the presence of fibrosis, which is now 
considered the primary diagnostic feature of ARVC, alone or in combination with fatty 
infiltration.84 Our centre adhered to the new criteria throughout the study, long before their 
official acknowledgement.44 
 
As with chapter 2, the diagnostic criteria reported in table 5 are derived based on National 
and International recommendations but also based on the extensive experience of our 
cardiac pathologist (MNS). As a result certain definitions, such as the differentiation of 
HCM from idiopathic LVH, may be considered arbitrary rather than evidence based. 
Moreover, the CRY Centre for Cardiac Pathology service is based upon analysis 
undertaken by a single pathologist, albeit an acknowledged international expert. Having an 
additional pathologist to corroborate the expert interpretation would be desirable but single 
centres cannot justify more than one pathologist doing cardiac work full time. Moreover, 
there are also few cardiac pathology specialists in the UK. This issue is being addressed 
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by the UK Cardiac Pathology Network by establishing cardiac pathology pathways in the 
country to support and train general pathologists. 
 
Chapter 4: Evaluation of families affected by sudden arrhythmic death 




The finding of a normal post-mortem examination in individuals with no co-morbidities who 
passed away unexpectedly led to the assumption that such deaths were due to cardiac 
arrhythmias. As such the term sudden adult death syndrome was proposed, which has 
been used in death certification in the UK for more than a decade.3 Behr et al.85 ware the 
first to test the hypothesis that a proportion of these deaths may be attributed to primary 
arrhythmogenic syndromes such as long-QT syndrome (LQTS), Brugada syndrome (BrS) 
and catecholaminergic polymorphic ventricular tachycardia (CPVT). Given the inherited 
nature of these conditions, most of which are inherited in an autosomal dominant mode, 
Behr et al. stipulated that investigating first-degree relatives of the deceased should 
identify individuals with quiescent cardiac pathology and therefore a probable cause of 
death. Most importantly, however, identifying asymptomatic individuals with a primary 
arrhythmogenic syndrome would lead to risk assessment and prevention of further 
tragedies within the same families. 
 
4.1.1 Studies in sudden arrhythmic death syndrome that formed the basis of the thesis 
 
The study by Behr et al. was the first to utilize the term sudden arrhythmic death syndrome 
(SADS). The authors invited for limited cardiological evaluation all first-degree relatives of 
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32 individuals who died and fulfilled the following inclusion criteria: 1. white; 2. aged 4–64 
years; 3. no cardiac history; 4. seen alive in the 12 h before death; 5. normal coroner’s 
autopsy and cardiac pathologist’s confirmation of normal heart; and 6. negative 
toxicological screen. Of the potential 147 relatives, 109 (74%) consented to the study. The 
evaluation included historical review, physical examination, a 12-lead electrocardiogram 
(ECG) (98%), echocardiogram (97%), and 48-h Holter monitoring (77%). Cardio- 
pulmonary exercise testing was done on a discretionary basis (13%). Of the 32 families, 6 
(19%) were diagnosed with familial cardiac disease based on the identification of a 
diagnostic phenotype in at least one of the relatives evaluated. Primary arrhythmogenic 
syndromes and in particular LQTS was the predominant diagnosis: 4 with probable LQTS; 
1 with hypertrophic cardiomyopathy (HCM); and 1 with myotonic dystrophy and conductive 
tissue disease. Overall 6 of the 109 (5.5%) evaluated relatives were diagnosed with a 
previously unsuspected condition. The authors were also able to extract DNA from the 
deceased in the 4 families diagnosed with probable LQTS. Genes implicated in LQTS 
(KCNQ1, KCNH2, KCNE1, KCNE2, and SCN5A) were analysed for disease-causing 
mutations. Surprisingly however, no mutations were identified. 
 
This research paper was the first to establish a connection between SADS and inherited 
cardiac disease and in particular primary arrhythmogenic syndromes. It formed the basis 
for further studies including the main study of the thesis. The paper however, exhibited 
several limitations that are worth mentioning. The small number of families evaluated and 
diagnosed with a condition did not allow for any safe conclusions relating to the validity of 
the methodology utilized. The relatives were subjected to a limited number of 
investigations, most probably accounting for the very low diagnostic yield. It is highly likely 
that in the absence of provocative testing with a class-1 antiarrhythmic and exercise 
testing the authors would have been unable to identify individuals with an underlying Brs 
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and CPVT. Finally, all LQTS familial diagnoses were based on a single relative identified 
with a probable diagnosis based on the Schwartz score86 and the authors failed to identify 
a LQTS related mutation in the deceased’s DNA in those families, casting some doubt as 
to accuracy of the diagnoses.  
 
A study in Netherlands by Tan et al.81 investigated 43 consecutive families affected by 
sudden death. In this particular study a normal post-mortem was not a prerequisite. In fact 
only in 22 (51%) families had the deceased undergone a post-mortem. The authors 
evaluated 183 surviving relatives with history, examination, 12-lead ECG, exercise test, 
transthoracic echocardiography and serum lipid analysis. In cases where BrS was 
suspected an Ajmaline provocation was performed and when ARVC was suspected the 
individual was subjected to cardiac magnetic resonance imaging (CMR). Relatives 
diagnosed with a clinical phenotype of cardiac disease were invited to undergo genetic 
testing for the relevant implicated mutations. 
 
An inherited cardiac disease was identified in 17 of the 43 (40%) families. Most importantly 
however, out of the 333 relatives evaluated in the study, 151 were diagnosed with an 
inherited cardiac disease. As in the study of Behr et al., a diagnosis of primary 
arrhythmogenic syndrome was the most common finding being present in 12 (71%) 
families (CPVT: n=5, LQTS: n=4, BrS: n=2, LQTS/BrS: n=1). Four families received a 
diagnosis of cardiomyopathy (ARVC: n=3, HCM: n=1) and one family was diagnosed with 
familial hyperlipidaemia. Molecular genetic analysis confirmed the diagnosis in 10 families 
by revealing mutations in the causative genes. The authors attempted to identify clinical 
predictors of establishing a diagnosis. The number of investigated relatives was 
significantly larger in the families in which a diagnosis was established than in those 
without a diagnosis. Furthermore, the proportion of families with >1 victims was larger 
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among families with than among those without a diagnosis. Based on those predictors, it is 
likely that the higher diagnostic yield in the study by Tan et al. compared to the original 
study of Behr et al. was partly due to the highly malignant family history with an average of 
1.8 deaths per family and the high number of relatives evaluated with a mean of 4.3 
relatives per family. Additionally however, the more extensive investigations and 
particularly the inclusion of exercise testing and Ajmaline provocation testing identified 
conditions such as CPVT and BrS, which are likely to have been missed in the study by 
Behr et al. The diagnostic yield is even more impressive if one considers that it may 
represent an underestimate, since only a limited number of families were subjected to 
Ajmaline provocation testing and as such the authors may have failed to identify some 
families/individuals harboring the Brugada phenotype. 
 
4.1.2 Studies in sudden arrhythmic death syndrome published during the thesis 
 
In a second study, Behr et al.82 investigated a further group of unselected families 
consecutively referred to St George’s Hospital in which a SADS death had occurred. The 
authors hypothesized that a more comprehensive clinical and genetic evaluation of both 
the SADS victims and surviving relatives would identify a greater proportion of inherited 
cardiac diseases that could account for the deaths, as well as a greater number of 
relatives at risk of the same fate. In contrast to the study by Tan et al.81 where half of the 
victims of sudden death did not have a post-mortem, Behr et al. placed particular 
emphasis on the presence of a normal full coroner’s post-mortem and negative toxicology 
screen. To ensure that no subtle cardiac abnormality was missed, the authors endeavored 
for all hearts or at least tissue samples or slides to be reviewed by an expert cardiac 
pathologist, and they managed to do so in 75% of the cases. During the familial evaluation 
the authors obtained as much information as possible for the deceased, including 
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demographics, mode of death and antecedent symptoms. They also utilised a “molecular 
autopsy” approach. When available in sufficient quality and quantity, DNA from the 
deceased was tested for common pathogenic mutations of primary arrhthmogenic 
syndromes implicated in SADS such as LQTS, BrS and CPVT. Unfortunately, the quality 
and quantity of this DNA and subsequent mutation analysis was often limited by the nature 
of retained tissue paraffin blocks. Relatives were subjected to an array of investigations 
including history, physical examination, 12-lead ECG, transthoracic echocardiogram, 
exercise treadmill testing and 24-hour Holter monitor. Where a suspicion of 
cardiomyopathy was raised, the individual was subjected to a CMR. If initial investigations 
failed to identify any underlying cardiac pathology, relatives were subjected to an Ajmaline 
provocation test in an attempt to unmask the Brugada phenotype. Further evaluation was 
guided by initial results. All relatives identified with a clinical phenotype of a potentially 
inherited cardiac disease were offered genetic testing for the respective condition. 
 
Of the 57 families included in the study, 30 (53%) received a definite or possible/probable 
diagnosis of inherited cardiac condition. In one of these families clinical evaluation did not 
contribute to a diagnosis but mutation analysis of the proband’s DNA identified a likely 
LQTS disease causing mutation. As in the previous studies, primary arrhythmogenic 
syndromes comprised the majority of diagnoses (21 of the 30 families) with LQTS 
identified in 16 and BrS in 5 families. In the 9 remaining families a cardiomyopathy was 
diagnosed (ARVC: n=5, isolated left ventricular non-compaction (LVNC): n=2, HCM: n=1, 
DCM: n=1). Of the 222 relatives evaluated in the study, 61 (27%) were diagnosed with a 
previously unsuspected inherited cardiac condition predisposing to sudden death. 
Subsequent genetic analysis identified disease-causing mutations in 8 of the 30 families. 
The authors attempted to identify potential predictors of a positive diagnosis by comparing 
families and individuals with a positive diagnosis versus those where cardiac evaluation 
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was negative. The only statistically significant predictors were the presence of symptoms 
in the relatives and, in particular, the presence of syncope prior to evaluation. This is 
relevant since the authors made the observation that 20% of the SADS victims and 7% of 
surviving relatives had experienced at least one episode of syncope prior to the death that 
prompted the familial evaluation. Furthermore, one quarter of families had a history of 
additional premature (<45 years) sudden deaths, which had not prompted familial 
evaluation, underscoring the potentially missed opportunities to establish a diagnosis 
earlier and prevent SADS. 
 
A second study by the Netherlands group,87 sought to compare the yield of comprehensive 
clinical and genetic evaluation in surviving relatives of sudden unexpected death victims 
aged 1–50 years and in victims of aborted cardiac arrest of the same age. Part of the 
study had been reported before by Tan et al.,81 as described above. This study used the 
same definition for sudden unexplained death, which included individuals who either did 
not have a post-mortem examination or victims with a normal post-mortem examination. 
The authors hypothesised that survivors of cardiac arrest are likely to be affected by 
similar conditions to those resulting in sudden unexplained death since the eventual 
outcome of cardiac arrest is mostly determined by the circumstances at the time of arrest. 
Of the 140 families with a sudden unexplained death, 33% (n=47) were diagnosed with a 
certain or probable condition accounting for the sudden death. In 32% (n=45) of the cases 
a potentially inherited cardiac condition was identified. Two cases of myocarditis were 
established by revision of the autopsy. Primary arrhythmogenic syndromes were the 
predominant diagnosis, accounting for 60% (n=27 of 45 diagnoses) of inherited cardiac 
diseases. Cardiomyopathies accounted for 20% (n=9) of deaths and familial 
hyperlipidaemia for 13% (n=6). The risk locus at chromosome 7q36, which is associated 
which familial idiopathic ventricular fibrillation, was identified in 9% (n=4) of the families but 
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it is unclear as to how many families were investigated for such a diagnosis. Predictors of 
a positive diagnosis included multiple deaths in the family and the age of the victim. The 
diagnostic yield was higher in families where the victim was of a younger age, being 71% 
in the age group 0-10 years compared to only 21% in the age group 41-49 years. 
 
In the 69 victims of aborted cardiac arrest, the diagnostic yield was 61%. Potentially 
inherited cardiac conditions were present in 45% (n=31) of families, with cardiomyopathies 
(19%; n=13) and primary arrhythmogenic syndromes (17%; n=12) accounting for equal 
proportions. The familial idiopathic ventricular fibrillation locus was identified in 6% (n=4) of 
the cases. 14% (n=6) of arrests were attributed to myocardial infarction and 1.5% (n=1) to 
mitral valve prolapse. The study did not identify any significant predictors of a positive 
diagnosis in survivors of cardiac arrest. 
 
The study by van der Werf et al. provides important clues as to the potential value of 
family screening of victims of sudden unexplained death. Based on the results of the 
comprehensive evaluation of the survivors of cardiac arrest, screening of first-degree 
relatives could potentially identify an inherited cardiac condition, accounting for the cause 
of the death, in up to 45% of families. It also highlights however, our limitations in 
knowledge and investigative techniques since even comprehensive investigations of the 
survivors of cardiac arrest failed to identify a cause in almost 40% of the cases. The study 
however also exhibits important limitations worth mentioning. Given the novel area 
investigated and the long-duration of this observational study (13 years), investigative 
tests, the interpretation of such tests and the diagnostic criteria for different conditions are 
highly likely to have changed with time. As such not all families or survivors of cardiac 
arrest were evaluated with a single study protocol. This is likely to have caused a 
considerable underestimation of the true diagnostic yield. In particular, pharmacologic 
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challenge to diagnose Brugada syndrome and epinephrine challenge were performed only 
in a selected minority in which no diagnosis was made. 
 
Hendrix et al.88 also reported on a small cohort of victims and survivors of SCD from a 
single centre in Netherlands. The authors retrospectively identified potential deaths 
representing SCDs and reviewed autopsy results and results of the evaluation of family 
relatives. At the discretion of the authors, families that had not been subjected to all 
necessary investigations were recalled and re-evaluated. Of the 20 families identified, 5 
were attributed to myocardial infarction, 4 to inherited cardiomyopathies, 2 to primary 
arrhythmogenic syndromes and 1 to aortic stenosis. The cardiogenetic screening of 37 
relatives of 12 victims led to a diagnosis of BrS in 3 relatives and the suspicion of ARVC in 
2 relatives. The yield of screening of these relatives was 14%. The conclusions that can be 
derived from this study are fairly limited due to its methodology. Familial evaluation was 
fairly limited and did not include pharmacological provocation testing, which is likely to 
have led to underestimation of the contribution of primary arrhythmogenic syndromes such 
as BrS and LQTS. In 25% of the families no cardiac screening was performed. Moreover, 
the authors performed the screening themselves in only 4 families, as such it is likely that 
there was considerable variation in the interpretation of results depending on the physician 
evaluating the family. 
 
A study by Caldwell et al.89 reported the experience of a tertiary referral centre of 
evaluating families affected by sudden unexplained death or aborted cardiac arrest in 
Manchester. Evaluation of 193 consecutive individuals of 108 families identified an 
inherited cause of sudden death in 23% (n=45) of individuals from 35% (n=38) of 
evaluated families. Of the 84 families where a post-mortem had been performed and did 
not identify any cardiac pathology (SADS deaths), 30% (n=25) of families were diagnosed 
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with an inheritable cause of sudden death, based on the identification of the clinical 
phenotype in at least one of the relatives. A total of 31 out of 146 relatives of SADS victims 
evaluated were diagnosed with an inherited cardiac disease. Primary arrhythmogenic 
syndromes were the predominant diagnosis (n=19), followed by cardiomyopathies (n=12). 
Genetic testing identified pathogenic mutations in 12 relatives. 
 
This study highlights the important role of the inherited cardiac diseases clinics in risk 
modification. Of the 31 relatives identified with an inherited cardiac disease, 21 were 
initiated on medical therapy: 21 on beta-blockers (10 for LQTS, 4 for CPVT, 3 for HCM and 
4 for DCM), 4 on angiotensin converting enzyme inhibitors (ACE-i) for DCM and 1 on 
Spironolactone. Only 1 individual with a diagnosis of LQTS was implanted with a 
permanent pacemaker system. Although no individual was implanted with an intracardiac 
cardioverter defibrillator (ICD), 6 individuals had already an ICD by the time of their referral 
to the specialist inherited cardiac diseases clinic. On the other hand, the study also 
underscores potential pitfalls when assessing individuals in the context of a family history 
of sudden death, where physicians may be more prone to over-interpret results of 
investigations or offer aggressive device therapy as a result of overestimating the potential 
risk of SCD. Four individuals had treatment withdrawn after negative genetic testing for an 
established familial mutation. In one family with a very strong family history of sudden 
unexpected death (4 out of the 5 siblings of the mother had died at a young age (18-22 
years) with a normal post-mortem) the mother and her two sons were commenced on 
beta-blockade, despite the fact that no cardiac disease had been identified on clinical 
evaluation. The mother and one of her sons elected to have an ICD implanted. Neither 
had any appropriate shocks, but the son had inappropriate shocks due to lead fracture. 
Subsequently, an RYR2 mutation was discovered in an asymptomatic maternal 
grandfather of the two boys and in tissue from one of the deceased aunts. Genetic testing 
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showed the mother to be negative for this mutation. Beta-blockers were withdrawn and 
both ICDs were inactivated/removed. No deaths occurred in relatives diagnosed with a 
condition or relatives with a familial diagnosis during a short-term follow-up of 2 years. This 
however is not surprising given the low rates of sudden death and the short follow-up 
period. The follow-up study did not include any of the families with negative evaluation, 
which would probably be the group of most interest and would give an indication for 
potential missed diagnoses. 
 
4.1.3 Isolated genetic screening of family relatives 
 
Unlike the majority of studies evaluating family relatives of SADS victims where genetic 
analysis complemented clinical evaluation,90 Wisten et al.91 utilised genetic screening 
alone. The authors screened DNA from one or more first-degree relatives of SADS cases 
for evidence of mutations in the five major LQTS genes, irrespective of familial phenotype. 
They identified pathogenic LQTS-associated mutations in family members in 3 of the 25 
(12%) cases. This yield is not that dissimilar to the yield of LQTS reported by a number of 
studies after clinical evaluation alone.81,85,87 The same investigators screened for RyR2 
mutations in families without LQTS-associated mutations and found no additional yield.91 
Although this may be a chance finding given the small study sample, it may alternatively 
represent the higher prevalence of de-novo mutations amongst those affected by CPVT.92 
A similar family genetic screening protocol by Allegue et al.93 found four LQTS associated 






4.1.4 The role of molecular autopsy in sudden arrhythmic death syndrome 
 
Molecular autopsy refers to post-mortem genetic analysis of specific candidate genes in 
an attempt to identify pathogenic mutations that may account for the SADS death.  Most 
importantly however, if such a mutation is identified in the deceased, cascade screening of 
surviving relatives for the same mutation can be performed in order to identify those at 
potential risk of the same fate.90 It is important to note, however, that the presence of a 
disease-associated mutation does not equate to phenotypic expression of disease and 
therefore does not necessarily prove a causal relationship between the identified 
mutations and SADS. Moreover, caution needs to be exercised, as recent studies 
assessing the prevalence of rare genetic variants in patients and healthy controls have 
raised concerns relating to the pathogenicity of previously considered disease-causing 
mutations and highlighted the concept of “genetic noise”.94,95 
 
Different candidate genes have been investigated in different studies. These include 
genes for CPVT – RyR2; LQTS – KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2; and 
BrS – SCN5A.96-102 Tester et al.96 sought to determine the prevalence and spectrum of 
LQTS associated mutations in 49 cases of SADS referred to the Mayo clinic’s genomic 
laboratory. The investigators had previously identified 7 cases of CPVT associated 
mutations in the same cohort.103 No victim of SADS or any of their relatives had received a 
diagnosis of an inherited cardiac disease at the time of the study. Genomic DNA was 
extracted from frozen necropsy tissue or autopsy blood. Genetic testing for LQTS 
susceptibility mutations showed 10 putative SADS associated ion-channel 
mutations/polymorphisms in 10 cases (20%). In 7 cases the authors had the opportunity to 
perform genetic screening for the identified mutations in relatives of the deceased. The 
identified mutations were familial in all 7 cases, and a total of 23 genotype-positive family 
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members were identified. If we account for the previously identified CPVT mutations, the 
overall diagnostic yield of disease-associated mutations probably accounting for the 
sudden death, of molecular autopsy increased to 34%. A larger study utilising the same 
methodology by the same group, tested 173 samples of SADS victims for genes 
implicated in LQTS and CPVT.97 On this occasion pathogenic mutations were identified in 
45 (26%) of the cases. 
 
A recent population-based study in New Zealand by Skinner et al.101 identified LQTS 
pathogenic mutations in 15% (5/33) of victims who underwent molecular autopsy. Another 
small, retrospective, molecular autopsy series from Denmark revealed a yield of 8.3% (3 of 
36) following selective RyR2 sequencing.100 This compares reasonably with the 12% (20 of 
173) yield from Tester et al.97 All post-mortem studies thus far have used a targeted 
approach, with up to 64 of the 105 exons of RyR2 being sequenced; the differences in 
yield may therefore partly be explained by variation in the coding sequence evaluated. 
 
The inclusion of cardiomyopathy associated genes may further increase the yield of 
molecular autopsy since familial evaluation has recognized that cardiomyopathies underlie 
some SADS cases with apparently normal hearts.82 Zhang et al.99 identified three (12%) 
possible or probable disease-causing genetic variants in PKP2, the most common ARVC-
risk gene, in 25 SADS cases. One (4%) mutation was a ‘radical’ frame-shift mutation 
strongly associated with disease,95 strengthening the view that ARVC is responsible for a 
small, but clinically significant, minority of SADS cases. Hypertrophic cardiomyopathy 
appears to constitute a smaller proportion of SADS cases on the basis of familial 
evaluation and appears to have a negligible definitive molecular yield.93 
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Fresh or frozen blood and tissue, particularly spleen tissue provide the best quality DNA 
for analysis. In the absence of that, alternative sources include formalin-fixed, paraffin-
embedded tissue. Unfortunately, formalin fixation causes alterations in DNA sequence. 
Residual dried blood spot samples from national newborn screening programmes have, 
therefore, been assessed as a novel source. Gladding et al.102 extracted DNA successfully 
from blood spots and used whole-genome amplification prior to sequencing. They were 
able to perform diagnostic screening of LQTS-risk genes in all 19 cases of their cohort of 
sudden infant death syndrome (SIDS) and SADS cases, despite some blood spots being 
up to 39 years old. They showed that six disease-causing mutations identified were all 
present in at least one blood relative, of whom a proportion exhibited the LQTS phenotype. 
A retrospective population-based study in Denmark utilising blood-spot derived DNA, 
reported a yield of LQTS-associated mutations (11%) in 44 cases of SADS.98 
 
Alternative technologies have also been utilized to reduce costs: the MassARRAY and 
SnapShot systems identify pre-specific pathogenic mutations allowing the screening of 
multiple samples concurrently.90 They lack the ability, however, to detect novel mutations 
that are private to a family and are likely to account for a number of cases. Nonetheless, 
they may be a cost-effective first step in a tiered approach to molecular autopsy in an 
already well-characterized population. 
 
4.1. 5 Brugada syndrome 
 
A comprehensive background of all conditions implicated in SCD and SADS is beyond the 
scope of this thesis. Brugada syndrome however, merits special mention as it is a 
relatively newly described hereditary ion-channel disorder of the cardiac myocytes,104 and 
forms a large part of the thesis with chapter 6 focusing on a novel technique for 
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establishing the diagnosis of BrS and chapter 7 investigates the value of current risk 
stratification protocols. 
 
Brugada syndrome is characterised by ECG repolarization patterns in the right praecordial 
leads. 105,106 Three types of ECG patterns are recognised: Type-1 is characterized by a 
coved ST-segment elevation ≥2 mm (0.2 mV) followed by a negative T-wave; The type-2 
ST-segment elevation has a saddleback appearance with a high takeoff ST-segment 
elevation of ≥2 mm, a trough displaying ≥1 mm ST-segment elevation, and then either a 
positive or biphasic T-wave; Type-3 has either a saddleback or coved appearance with an 
ST-segment elevation of <1 mm. To simplify matters, in a recent consensus report of ECG 
criteria for the diagnosis of BrS the authors suggested the use of only 2 ECG patterns: 
type-1 identical to classic type-1 of the previous consensus documents (coved pattern) 
and type-2 that joins types-2 and 3 of the previous consensus.107 The prevalence of the 
Brugada ECG pattern is highest in Asia and ranges between 0%–0.36% for type-1 
pattern108-119 and 0%–2.23% for type 2 and type 3 patterns.120-132 The low prevalence of 
Brugada-type ECG in the United States may be explained by different ethnic backgrounds 
among the studies. Of note, there are scarcely any data in subjects of African origin. The 
prevalence of type 1 ECG in children is reported to be 0.005%, which is much lower than 
in the adult population.133 Brugada syndrome is diagnosed only in the presence of a type-1 
ST-segment elevation in >1 right praecordial leads (V1-V3) in the presence or absence of 
a sodium channel blocking agent, and in conjunction with one of the following: 
documented ventricular fibrillation (VF) or polymorphic ventricular tachycardia (VT), a 
family history of sudden cardiac death at <45 years old, coved-type ECGs in family 




The genetic yield in BrS remains poor with a mutation being identified in 15%-30% of 
clinically affected individuals.134,135 The first gene linked to BrS was SCN5A which encodes 
the alpha subunit of the cardiac sodium channel (INa) gene.106,136 Since 1998 >100 SCN5A 
mutations have been identified in BrS and currently represent the most common genotype, 
which are predominantly inherited as an autosomal-dominant trait with incomplete 
penetrance.137 Other putative causal mutations have also been reported in calcium 
channel genes (CACNA1C, CACNB2b, CACNA2D1);138,139 sodium channel β-subunit 
genes (SCN1B, SCN3B);140,141 glycerol-3 phosphate dehydrogenase 1-like enzyme 
(GPD1L) and MOG1, which affects trafficking of sodium channels;134,142-144 and in genes 
that affect transient outward current (Ito) (KCNE3, KCND3, KCNE5).145-147 Functional 
studies of an SCN5A mutation in BrS using heterologous expression systems revealed 
loss of function of the sodium channel, which impairs the fast upstroke in phase 0 of the 
action potential and leads to conduction slowing in the heart. Μutations in CACNA1C and 
CACNB2b showed loss of function of basal L-type calcium current; a mutation in SCN1B, 
SCN3B, GPD1L, or MOG1 led to loss of function of INa; and a mutation in KCNE3, KCND3 
or KCNE5 to gain of function of Ito.148 The end-result is an imbalance between the inward 
and outward currents of the cardiac myocytes and heterogeneous loss of the action 
potential dome, leading to marked dispersion of repolarisation, re-entrant tachycardias and 
ventricular fibrillation (VF).149-151 
 
The majority of patients with BrS remain asymptomatic throughout their life. Some patients 
present with syncope and a minority experience sudden death due to VF, which can be 
the first manifestation. The mean age of death or of aborted VF episodes is 41±15 years. 
VF episodes occur predominantly in men, who carry a 5.5-fold risk of sudden death 
compared with women, but arrhythmic events may occur at any age.106 BrS has also been 
implicated in sudden death in infants and young children.137,152 The majority of arrhythmic 
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events are observed at rest or while asleep.153,154 Increased vagal tone during night-time is 
likely to increase the risk of arrhythmic events.155-158 The potential effect of increased vagal 
tone in inducing arrhythmias is also supported by the augmentation of ST-segment 
elevation and unmasking of the diagnostic type-1 Brugada phenotype during the recovery 
phase of exercise treadmill testing.159,160 Increased body temperature also appears to 
induce the Brugada phenotype, malignant arrhythmias and even cardiac arrest which 
resolves with normalisation of the body temperature.152,161-165 Supraventricular tachycardias 
are also fairly common in patients with BrS, with paroxysmal atrial fibrillation observed in 
11% to 14% of cases.166,167 
 
4.1.6 Provocation testing in Brugada syndrome 
 
The ECG in Brugada gene carriers may be normal or fluctuate between normal and the 
Brugada pattern.158,168,169 This has important implications relating to diagnosis in the 
context of tertiary referral centres, where individuals are likely to be evaluated once or at 
best on a small number of occasions. It also has important implications relating to 
prognosis since the presence of the type-1 Brugada phenotype on the baseline ECG is 
considered a risk factor for malignant arrhythmias and sudden death.170-176 A study by 
Veltman et al.169 evaluated fluctuations of ECG phenotypes in 43 patients with a diagnosis 
of BrS. The authors performed in total 310 resting ECGs during a median follow-up of 17.7 
months. All ECGs were performed at rest and none of the subjects exhibited evidence of 
hyperpyrexia or extreme vagal tone, which can provoke the Brugada ECG pattern. The 
patients were compared for different clinical characteristics with respect to the pattern of 
fluctuations. Out of the 310 ECGs, 102 (33%) revealed the diagnostic type-1 Brugada 
phenotype, 91 (29%) a saddle-back type-2 phenotype, and 117 (38%) a normal ECG. 
Only a third of the patients (35%) initially presented with a diagnostic ECG and of those, 
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only one patient (2%) exhibited constantly the diagnostic ECG pattern during follow-up. 
Out of 28 patients (65%) with an initially non-diagnostic ECG, eight (19%) developed a 
diagnostic coved-type ECG during follow-up. Of note, 20 patients (47%) never had a 
baseline type-1 ECG pattern and the diagnosis was based on developing the diagnostic 
ECG during Ajmaline challenge. No significant differences were found in gender and 
clinical characteristics among patients with or without fluctuations between diagnostic and 
non-diagnostic basal ECGs. The rate of inducible VF was significantly higher in patients 
with more than 50% coved-type ECGs than in patients with less than 50% diagnostic 
ECGs, although its value as a risk marker is doubtful as discussed in the next section. 
 
As a result of the dynamic nature of the Brugada ECG pattern, provocation testing with 
class 1 anti-arrhythmics is usually employed to unmask the Brugada phenotype in 
suspected cases.177-180 Although a number of class 1 anti-arrhythmics, such as Ajmaline, 
Procainamide and Flecainide have been used depending on availability, Ajmaline is the 
one most commonly utilised in the literature and clinical practice, primarily due to practical 
considerations. Ajmaline has a considerably shorter half-life compared to Procainamide or 
Flecainide (several minutes versus 3-4 hours and 20 hours, respectively) and therefore it 
is eliminated more quickly and requires a short post-test monitoring period. Additionally, 
Ajmaline appears to have a greater sensitivity. Procainamide displays a more rapid 
dissociation from the sodium channel and consequently a lower level of use-dependent 
sodium channel block, which is believed to underlie its lesser potency compared with class 
1C agents such as flecainide in unmasking the syndrome. In a study by Wolpert et al.181 
the authors subjected 22 patients with a diagnosis of BrS based on the 2002 diagnostic 
criteria105 to both Ajmaline and Flecainide challenge. Ajmaline unmasked the Brugada 
phenotype in all 22 cases, while Flecainide challenge was negative in 7 (32%) cases. In 
addition the authors studied the effect of the two drugs on the Ito current in canine 
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ventricular epicardial cells to determine the mechanisms for possible differences in the 
response to the two sodium channel blockers in patients with BrS. They identified greater 
inhibition of Ito by Flecainide, which may render it less effective. 
 
Ajmaline also has a very favorable safety profile. Out of almost 1,000 Ajmaline tests 
reported in four studies,177-180 no deaths were reported. Four individuals experienced 
persistent VT, which required external defibrillation. In 2 of the 4 cases the Ajmaline test 
was continued to a target dose of 1mg/kg despite achieving a diagnostic type-1 Brugada 
phenotype. In one case, the patient exhibited a brief episode of atrial fibrillation that self 
terminated. Although protocols may differ between different specialist centres, based on 
the results of these studies, the recommended protocol for Ajmaline administration is for a 
dose of up to 1mg/kg over 5-10 mins. The Ajmaline challenge should be discontinued if: 1. 
The diagnostic Brugada pattern is unmasked, 2. The patient develops ventricular ectopy, 
3. The patient develops other ventricular or supraventricular arrhythmias and 4. The QRS 
duration increases >30% compared to the baseline. 
 
Defining the sensitivity and specificity of the Ajmaline provocation test is challenging given 
the low genetic yield in BrS and the absence of an alternative test that could form the “gold 
standard” for the diagnosis of BrS. As a result the majority of studies use the presence of 
type-1 Brugada phenotype with or in the absence of Ajmaline as the main diagnostic test, 
as per the consensus guidelines.105,106 Hong et al. 178 studied 147 individuals from 4 large 
families with SCN5A mutations. The exact SCN5A mutations were not specified. Of the 
104 relatives deemed to be at risk of carrying an SCN5A mutation, all underwent a 12-lead 
ECG and genetic testing. Twenty-four individuals exhibited the type-1 Brugada pattern on 
the baseline ECG while 71 family members underwent Ajmaline provocation testing. All 
patients with a positive baseline ECG were mutation carriers. On the contrary, 2 patients 
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with positive Ajmaline test did not have the mutation, and 7 patients with a negative test 
had the mutation. Penetrance of the disease phenotype increased from 32.7% to 78.6% 
with the use of Ajmaline. Although, it is plausible that the 2 individuals with a positive 
Ajmaline but no SCN5A mutation had a different genetic mutation making them 
susceptible to SADS due to BrS, based on these results the sensitivity, specificity, and 
positive and negative predictive values of the Ajmaline test were 80%, 94.4%, 93.3%, and 
82.9% respectively. Priori et al.135 also attempted to define the diagnostic accuracy of 
pharmacological challenge with sodium channel blockers. Ajmaline or Flecainide 
provocation test was performed in 8 symptomatic probands and 13 silent gene carriers. 
The drug challenge unmasked the ECG pattern in only 4 of the 8 probands and 2 of the 13 
family members (15%), equating to a positive predictive value of 35%. However, the 





The aim of the study was to comprehensively evaluate a large cohort of families referred 
to the inherited cardiac diseases clinics at King’s College Hospital and University Hospital 
Lewisham from throughout the UK. We attempted to determine: the diagnostic yield at a 
family level, the diagnostic yield at an individual level and predictors of positive yield. In 
collaboration with the genetics laboratory at St George’s University London we performed 
testing for gene mutations implicated in ion channel disorders. Finally, in the context of an 
audit study that primarily aimed to evaluate patient satisfaction (not included in the thesis) 
we performed a secondary assessment study to detect potential fatalities, other adverse 
cardiac events and new diagnosis by local specialists. 
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4.3 Personal contribution 
 
The author performed prospectively the clinical evaluation of the great majority (86%, 
n=136 of 159) of families, including performing or supervising, analyzing and databasing 
the majority of investigations (ECG, echocardiography, exercise treadmill test, Ajmaline 
provocation test and Holter monitoring). Collected data on the deceased including data on 






The SCD of several young individuals and the recognition that a considerable proportion of 
such deaths are secondary to hereditary conditions, prompted the United Kingdom (UK) 
government to commission the 8th chapter of the National Service Framework for coronary 
heart disease, aimed at facilitating early identification of individuals at risk of SCD. King’s 
College Hospital St George’s Hospital and University Hospital Lewisham, amongst others, 
implemented dedicated inherited cardiac diseases clinics, serving relatives of individuals 
who experienced SCD, from throughout the UK (Figure 8). The primary supervisor of the 




Figure 8: Map of the UK. The red circles indicate geographical regions from which 
families were referred to our clinic for evaluation after a sudden death. Families 
would travel from as far as Scotland, Northern Ireland and Cornwall. 
 
4.4.1 Inclusion criteria 
 
Between October 2006 and October 2010, 159 families, comprising 501 individuals, were 
referred to our clinics for cardiac evaluation after a SCD. Families were considered for 
inclusion in the study if the deceased fulfilled the following criteria: 1. Unexpected death of 
an apparently healthy individual with no past cardiac history of note; 2. Death from natural 
causes; 3. Last seen alive and well within 12 hours; 4. Complete post-mortem report; 5. 
The absence of an extra-cardiac cause of death; 6. Negative toxicology screen; and 7. 
The absence of an established diagnosis based on evaluation of relatives by another 
specialist. Twenty-three families were excluded from further analysis based on: The 
presence of documented past medical history prior to death (1 with Wolf-Parkinson-White 
electrocardiographic pattern, 1 with atrial fibrillation); One individual with a history 
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consistent with Commotio cordis; The absence of a complete post-mortem report (n=6); 
Positive toxicology (n=8), including the detection of cannabis, cocaine, ecstasy and 
alcohol; and an established diagnosis of an inherited cardiac condition in family relatives 




Figure 9: Flow diagram describing the number of families referred to our inherited 
cardiac disease clinics and their classification according to the post-mortem result. 
ARVC: Arrhythmogenic right ventricular cardiomyopathy; DCM: Dilated cardiomyopathy; 
HCM: Hypertrophic cardiomyopathy; LVH: Left ventricular hypertrophy; SADS: Sudden 
arrhythmic death syndrome. 
 
The post-mortem reports of the 136 SCD cases were subsequently scrutinized by the 
author and Prof Sanjay Sharma and divided into three groups: Group 1: Autopsy findings 
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highly suggestive of structural cardiac pathology accounting for the SCD as defined in 
table 5; Group 2: No identifiable structural cardiac pathology, consistent with a SADS 
death; and Group 3: Autopsies of uncertain causal effect (Table 15 in chapter 5). In cases 
of disagreement a third, senior collaborator was consulted (Prof Sheppard, cardiac 
pathologist or Dr Behr, consultant electrophysiologist with expertise in SADS). The study 
cohort consisted of the 83 families in group 2, comprising of 271 blood relatives (Figure 9). 
 
4.4.2 Familial evaluation 
 
The overwhelming majority of families included in the thesis were evaluated at University 
Hospital Lewisham. In an attempt to minimise the psychological and physical burden of 
screening on the bereaved families, we adopted a novel one-stop model aiming to 
evaluate individuals and families during a single session. Our one-stop model allowed for 
the maximum number of relatives to be evaluated under one roof, without the need for 
repeated visits. This is of particular importance in the context of inherited cardiac 
conditions where uncertainties still exist as to the diagnostic accuracy of investigations and 
clinical outcomes, and results in one family member may affect the interpretation of the 
results or treatment in another relative. 
 
Our multidisciplinary team consisted of cardiologists with expertise in conditions 
predisposing to SADS, an arrhythmia nurse and dedicated physiologists. We also 
collaborated with other leading institutions including the Royal Brompton Hospital and St 
Thomas’ Hospital for cardiac magnetic resonance imaging (CMR), the CRY Centre for 
Cardiac Pathology at the National Heart and Lung Institute at the Royal Brompton Hospital 
for detailed histological evaluation of post-mortem cardiac tissue and St George’s Hospital 
for genetic testing of blood samples from family relatives who were clinically diagnosed 
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with an inherited cardiac condition. The authors also closely collaborated with the 
charitable organization CRY, which has an extensive network around the UK in order to 
provide bereavement support to the family and psychological support to relatives 
diagnosed with a condition predisposing to SADS. 
 
With the consent of the family, the author collected information on the deceased (proband) 
by review of coroner’s reports, autopsy reports, primary care physician’s and hospital 
records, when available, and during interview with the relatives. Information collected 
included demographics; prior cardiac symptoms, including episodes of chest pain, 
shortness of breath (including asthma attacks), palpitations, dizziness/pre-syncope and 
syncope (including epileptic fits); past medical history including hospital admissions, 
information relating to previous cardiac investigations; family history of sudden death, 
epilepsy, asthma, unexplained road traffic accidents or drowning and episodes of syncope; 
and importantly the results of the post-mortem evaluation. When possible, in cases where 
the post-mortem had not been performed by a cardiac pathologist, with the family’s 
consent and the assistance of CRY, we facilitated the transfer and examination of the 
heart at Royal Brompton hospital. When available, we collected blood samples and/or 
spleen tissue for DNA analysis from the deceased as part of an ongoing research project 
on the contribution of “molecular autopsy”, which is not addressed in the current thesis. 
 
Individual family members underwent comprehensive cardiac evaluation aimed at 
identifying inherited cardiac pathology that may have accounted for the SADS death 
according to the algorithm depicted in Figure 10. Although we aimed to investigate first-
degree relatives prior to evaluating more distant relatives of the deceased, that was not 
always possible. As such the authors offered screening to any relative referred to our 
clinic. Evaluation in children <16 years old was limited to ECG and transthoracic 
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echocardiography. In cases where a familial diagnosis was established and/or the children 
exhibited high-risk features such as syncope, a paediatric cardiologist performed further 
comprehensive evaluation. In the great majority of families, results of the 12-lead ECG, 
transthoracic echocardiography, exercise treadmill testing, CMR and Ajmaline provocation 
testing were available on the day of the consultation. Holter monitors were placed at the 
end of the investigations and all were returned back for analysis. During the final 
consultation, the families were presented with the results and treatment options. After the 
consultation we offered support to the family including, medical care and psychological 
support for the ones diagnosed with a condition predisposing to SADS, bereavement 
support for the family and a portal of contact with our medical and nursing staff for further 




Digital 10 sec ECGs were acquired during quiet respiration in a supine position using a 
MAC 5000 (GE Medical, Milwaukee, Wisconsin; 500 Hz, 4.88 mV resolution). The 
electrodes were placed carefully to ensure consistency, and ECGs were recorded at a 
paper speed of 25 mm/s. Electrocardiograms were performed with leads V1 and V2 
placed in the conventional 4th intercostal space. From October 2007 onwards all ECGs 
were also recorded with leads V1 and V2 placed in the higher 2nd and/or 3rd intercostal 
space. Electrocardiograms were subsequently exported to a customised software program 
where tracings could be enlarged to high magnification and amplitude to measure basic 
intervals accurately with on-screen callipers. Heart rate and QRS axis were calculated. P-, 
Q-, R-, S-, and T-wave voltages; ST-segments; QRS duration; PR interval; and QT-interval 
were measured in each lead. The QT-interval was corrected for the heart rate (QTc) using 
the Bazett’s formula.182 Left and right axis deviations were defined as a frontal cardiac axis 
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≤ -30° or ≥ 120° respectively. Left ventricular hypertrophy (LVH) was identified using the 
Sokolow–Lyon criterion.183 T-wave inversions in two or more leads were considered 
significant, excluding leads aVR, V1 and III. T-wave inversions in leads V1-V3, outside the 
context of symptoms or a familial diagnosis of cardiomyopathy and in particular ARVC, 
were considered to represent the juvenile ECG pattern in individuals <16 years old.184 
Adolescent individuals with anterior T-wave inversions were monitored serially until 
adulthood to ensure resolution of the T-wave inversions. Deep T-wave inversion was 
defined as a negative T-wave of -0.2 mV or more in any lead. Partial right bundle branch 
block (pRBBB) was defined as QRS duration > 0.1 but < 0.12 seconds, with rSR’ 
morphology in lead V1 and qRS in V6.185 Additional electrocardiographic markers 
compatible with ARVC were also sought, including terminal activation duration of the QRS 
complex ≥ 55ms in leads V1, V2 or V3, and the epsilon (ε) wave.83,84 
 
Electrocardiographic recordings from study V were reviewed retrospectively for the 
presence of early repolarization (ER), based on the results of recent studies which 
indicated that early repolarization in the inferior and lateral leads may represent a 
potentially heritable marker of malignant arrhythmias, particularly in the context of 
SADS.186-188 Inferior (II, III, AVF) and lateral (I, AVL, V4-V6) leads were assessed for the 
presence of J-point elevation defined as ≥0.1 mV in ≥2 leads in the same territory. The ER 
pattern was further classified according to the morphology of the terminal QRS in the 
majority of the leads as notched, slurred or indeterminate. In the presence of ER, the ST-
segments were assessed for the presence of ST-segment elevation and a distinct ST-






Figure 10: Diagnostic algorithm for families referred with a diagnosis of sudden 
arrhythmic death syndrome death 
* Electrocardiograms were performed with leads V1 and V2 placed in the conventional 4th 




Two-dimensional echocardiography was performed by a cardiologist or a senior cardiac 
physiologist, with the subject at rest, in the left lateral decubitus position using the 
following commercially available ultrasound systems: GE Vivid I, GE Vivid 7 (GE 
Healthcare, Milwaukee, WI, USA) and Philips iE33 (Philips Medical, Bothel, Washington, 
USA). A complete echocardiographic study of the left and right heart was performed 
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according to guidelines from the European Society of Cardiology and the American 
Society of Echocardiography.189,190 
 
Two-dimensional continuous- and pulsed-Doppler, as well as colour tissue-Doppler 
imaging were performed using standard parasternal and apical views. Left ventricular wall 
thickness was measured from two-dimensional short-axis views at end-diastole and the 
greatest measurement within the left ventricular wall was defined as the maximal wall 
thickness. The systolic pulmonary artery pressure was estimated using the simplified 
Bernoulli equation (4V
2
max + right atrial pressure) where Vmax is the maximal velocity of the 
tricuspid regurgitant jet measured using continuous-wave Doppler.191 In the absence of a 
raised jugular venous pressure during cardiovascular examination the right atrial pressure 
was assumed to be 5 mmHg. 
 
Exercise tolerance testing 
 
All subjects ≥16 years of age who were physically able to exercise were subjected to an 
upright treadmill test to volitional exhaustion. The investigators utilized the standard Bruce 
protocol.192 Signals from a 12-lead ECG were displayed continuously, looking specifically 
for the development of arrhythmias,193 ischaemic changes, paradoxical prolongation of the 
QT interval194-196 or the Brugada phenotype.160 Blood pressure was measured by 
auscultation over the brachial artery at 1 min intervals during the test and for the first 3 min 
after the test using a manual sphygmomanometer. A systolic blood response of >25 
mmHg from baseline to peak exercise is considered normal.197-201 
 
24-hour Holter monitoring 
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Ambulatory ECG monitoring (Lifecard CF Holters, Spacelabs Healthcare, USA) was 
analysed for any evidence of supra-ventricular and/or ventricular arrhythmias.202 
Individuals were encouraged to continue their usual daily activities, including exercise 
during the recordings. 
 
Ajmaline provocation test 
 
Ajmaline provocation testing to identify the type-1 Brugada phenotype was performed in 
the event of normal ECG recordings and echocardiograms or in the presence of type-2 or 
type-3 Brugada ECG patterns. Selected individuals with a LQTS type-3 ECG phenotype 
were also subjected to an Ajmaline provocation test due to the documented overlap 
between the two syndromes.203-207 Ajmaline provocation test was performed with verbal 
consent in individuals ≥16 years of age. In all cases an advanced life support certified 
cardiology trainee and an arrhythmia nurse or cardiac physiologist were present. Standby 
resuscitation facilities, including isoprenaline,208-210 were available. Ajmaline was infused 
either as boluses of 10mg/minute or as a continuous infusion over 5 mins to a target dose 
of 1mg/kg.177-180 The test was discontinued prematurely if the patient exhibited significant 
side effects, such as symptoms secondary to hypotension, developed multiple premature 
ventricular beats or ventricular arrhythmias or the ECG developed the diagnostic type-1 
Brugada pattern in the standard or higher right precordial leads. In contrast to some 
studies in the literature,179 QRS prolongation was not utilized as a criterion for 
discontinuing Ajmaline infusion. 
 
Digital 10 sec ECGs were performed during quiet respiration in a supine position using a 
MAC 5000 (GE Medical, Milwaukee, Wisconsin; 500 Hz, 4.88 mV resolution) and were 
acquired at short intervals (every 15 s) during Ajmaline administration and for up to 10 min 
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after drug administration in the case of a negative test or until all ECG changes had 
resolved completely in the case of a positive test. All ECGs were subsequently exported to 
a customised software program where tracings could be enlarged to high magnification 
and amplitude to measure basic intervals accurately with on-screen callipers. 
Electrocardiograms were recorded continuously with leads V1 and V2 placed in the 
conventional 4th intercostal space. All individuals evaluated in our clinic from October 2007 
onwards, underwent Ajmaline provocation testing with leads V1 and V2 placed in the 
higher 2nd intercostal space (217 out of the 261 (83%) Ajmaline provocation tests reported 
in this thesis). Towards the later part of the thesis, the ECG configuration consisted of the 
four limb leads, V1 and V2 leads recorded from the 4th, 3rd and 2nd intercostal spaces (six 
electrodes), and the remaining three electrodes recorded V4-V6, omitting the standard V3 
position (75 out of the 261 (29%) Ajmaline provocation tests reported in this thesis), as our 
experience and recent observations suggested that this lead is rarely positive or central to 
the diagnosis of BrS.211 Baseline and maximum drug effect ECGs were analysed. The 
maximum drug effect was determined based on the broadest QRS width. The maximal J 
point elevation was measured at baseline and during the maximal drug effect in standard 
and high right precordial leads. 
 
Cardiac magnetic resonance imaging 
 
All cardiac magnetic resonance imaging (CMR) was performed and analysed at Royal 
Brompton hospital. All relatives with ECG or echocardiographic features suggestive of 
cardiomyopathy were subjected to CMR. Cardiac magnetic resonance imaging was 
performed with a Siemens Sonata 1.5 T (Erlangen, Germany) using steady-state, free 
precession breath-hold cines (TE/TR 1.6/3.2ms, flip angle 608) in long-axis planes and 
sequential 7 mm short-axis slices (3 mm gap) from the atrioventricular ring to the apex. 
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Late gadolinium enhancement images were acquired 10 min after intravenous gadolinium-
DTPA (Schering, 0.1mmol/kg) in identical short-axis planes using an inversion-recovery 
gradient echo sequence. Inversion times were adjusted to null normal myocardium 
(typically 320–440ms; pixel size 1.7 x 1.4 mm). Late gadolinium enhancement images 
were phase swapped to exclude artefact. Ventricular volumes and function were 
measured for both ventricles using standard techniques and analysed using semi-
automated software (CMR tools, Cardiovascular Imaging Solutions, London, UK). All 
volumes and masses were indexed for age, gender, and body surface area (BSA).212,213 
 
Further evaluation 
Further evaluation was dictated by initial results and included computer tomographic 
coronary angiography (CTCA), conventional coronary angiography, tilt-table testing and 




Mutation analysis was offered to all relatives with phenotypic abnormalities suggestive of 
inherited arrhythmogenic syndromes or cardiomyopathies, after appropriate counselling, 
as recommended by UK guidance.214 Following appropriate counselling and consent, 
targeted mutation analysis was performed in one phenotypically affected member of each 
family, dependent upon the suspected clinical condition. Gene testing was performed for 
known mutations in the following genes: KCNQ1, KCNH2, KCNE1, KCNE2 and SCN5A in 
LQTS; SCN5A in BrS; selected exons (7–9, 13–16, 43–50, 82–84, and 87–105) of RYR2 
in CPVT; MYH7, MYBPC3, TNNT2, TNNI3 and TPM1 in HCM; PKP2, DSP, DSC2 and 
DSG2 in ARVC; lamin A/C gene (LMNA) in dilated cardiomyopathy (DCM) with evidence 
of conductive tissue disease. 
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Genomic DNA samples were extracted from peripheral lymphocytes in blood using 
standard techniques (Nucleon® Genomic DNA Extraction Kit, Tepnel PLC) and 
normalized to a concentration of 50 ng/ml. Genotyping was carried out using the ABI 3130 
System (Applied Biosystems) to investigate potentially novel mutations in exonic regions 
and intron/exon boundaries. Exons and flanking intronic regions were amplified from 
genomic deoxyribonucleic acid (DNA), using standard polymerase chain reaction (PCR) 
techniques with primer sequences by Sigma-Genosys. Amplification was carried out with 
the use of a Touchdown Thermal Cycler (Hybaid); any product that did not amplify 
successfully was subjected to a different PCR method using HotStar Taq polymerase 
(Qiagen) following the manufacturer’s protocol. In some cases it was necessary to add 4 µl 
of a PCR additive, Q solution (Qiagen), in a total 25 µl reaction. Products were bi-
directionally sequenced to identify coding variants using the Applied Biosystems kit, v3.1 
for a 10µl reaction in an automated capillary DNA Sequencer (ABI3130, Biomics Centre, 
St George’s University of London). 
 
Identified mutations were reviewed by our geneticist relating their association or likely 
association with disease. If a mutation considered to be pathogenic or likely pathogenic 
(known or highly probable) was identified in a relative, the family was offered cascade 
screening. Variants were labeled as pathogenic if they were: previously reported to be 
associated with disease-susceptibilty;215-222 in-frame or frameshift-causing insertions or 
deletions; affecting splice sites; missense mutations likely to be pathogenic, as identified 
by two in-silico models [affect protein function by a tolerance index score of <0.05 in 








Standard diagnostic criteria for the diagnosis of Brugada syndrome were used as 
proposed in the second consensus document.106 A diagnosis of definite BrS was only 
established in the presence of the type-1 Brugada pattern (coved ST-segment elevation 
≥2mm followed by a negative T-wave) in >1 right praecordial leads (V1 to V3) in the 
presence or absence of a sodium channel-blocking agent. The authors utilized the higher 
intercostal leads, as described in the 12-lead ECG and Ajmaline provocation testing 
sections, which were also considered diagnostic.225-227 Given the nature of the study all 
individuals included had a family history of SCD. The majority of the deceased were <45 
years old and in a considerable proportion of families more than one of the relatives 
investigated exhibited the type-1 Brugada pattern. As part of the familial evaluation, the 
authors enquired about prior history of syncope, epileptic seizures or nocturnal agonal 
respiration and attempted to document arrhythmias including polymorphic VT. No 
individual was subjected to electrophysiological studies for inducible ventricular 
tachycardia for diagnostic purposes given the controversies relating to the value of the test 




Standard LQTS diagnostic criteria (Schwartz score) were utilized for LQTS and the 






Short QT syndrome was considered in individuals with a QTc <320 msec with tall peaked 
T waves.229,230 
 
Catecholaminergic polymorphic ventricular tachycardia 
 
Cathecholaminergic polymorphic ventricular tachycardia was considered in the context of 
symptoms (palpitations, pre-syncope or syncope) induced by adrenergic surges such as 
vigorous physical activity or emotional stress. Diagnosis of CPVT required the 
documentation of polymorphic ventricular tachycardia, but not necessarily typical 
bidirectional VT with a beat-to-beat 180 degrees rotation of the QRS complex, during 
exertion and in the absence of ECG features suggestive of an alternative 
diagnosis.92,231,232 Epinephrine testing was not utilized during the course of this study and 
exercise tolerance testing was the predominant diagnostic tool. 
 
Progressive conductive tissue disease 
 
Progressive conductive tissue disease was considered in the presence of premature 
conduction tissue disease, as evident by the presence of a high degree atrioventricular 
block on the 12-lead ECG. Other ECG indicators examined included a long p-wave, 








Hypertrophic cardiomyopathy was defined as LVH on transthoracic echocardiography with 
a maximal end-diastolic left ventricular wall thickness (max-LVWT) ≥15 mm in the absence 
of a systemic cause such as hypertension or aortic valve stenosis. A max-LVWT <15 mm 
was also considered diagnostic of HCM in the context of electrocardiographic 
repolarization anomalies suggestive of the disease and identification of HCM in another 
relative. Athletic activity, gender and ethnicity was taken into account given the experience 
of our group which suggests that a considerable proportion of athletes and particularly 
athletes of African/Afro-Caribbean descent may develop a max-LVWT between 13-16 mm 
in response to regular exercise.57,72,236 Other echocardiographic indices assessed included 
ventricular cavity size, atrial cavity size, the presence of systolic anterior motion of the 
anterior mitral valve leaflet, the presence of a left ventricular outflow tract gradient at rest 
or during provocation with Valsava manoeuvre or exercise and systolic and diastolic 
function indices.237,238 
 
Arrhythmogenic right ventricular cardiomyopathy 
 
During the initial stages of the research project the 1994 diagnostic criteria were used for 
the diagnosis of ARVC.83 The authors applied the updated 2010 criteria after their 
publication and retrospectively reviewed all cases raising suspicion of ARVC but which did 








A familial form of DCM was suspected in the presence of left ventricular dilatation and left 
ventricular systolic dysfunction in the absence of abnormal loading conditions such as 
hypertension or valvular disease and in the absence of significant coronary artery 
disease.239 The individual’s demographics and athletic activity were taken into account 
based on evidence and our group’s experience suggesting that regular exercise can result 
in considerable ventricular dilatation as a result of cardiovascular adaptation to exercise, 
which is more pronounced in males compared to females, in terms of absolute 
dimensions.240,241 
 
Left ventricular non-compaction 
 
Left ventricular non-compaction (LVNC) was considered when prominent left ventricular 
trabeculations and inter-trabecular recesses were observed on trasthoracic 
echocardiography.239 Left ventricular non-compaction was diagnosed on 2-D trasthoracic 
echocardiograms utilizing both the Chin et al.242 and Jenni et al criteria.243 The individual’s 
demographics, athletic activity, any co-morbidities such as sickle-cell anaemia and 
pregnancy status were taken into account based on published experience from our group 
suggesting that regular exercise, sickle-cell anaemia and pregnancy can result in 







4.4.4 Short-term follow-up 
 
We set out to investigate the short-term outcomes of families evaluated in the inherited 
cardiac diseases clinics and in particular, compare outcomes between families (and 
individuals) with a diagnosis of an inherited cardiac pathology to families (and individuals) 
in whom no pathology was identified. The author investigated any morbidity or death 
resulting after the family’s initial assessment in our clinic. We collected follow-up data on 
individuals under regular follow-up in our clinic. For individuals that were either discharged 
from our clinic after a negative familial evaluation or were followed-up by a local specialist 
we sent out a questionnaire as part of a clinical audit evaluating the service provided in our 
novel inherited cardiac diseases clinics. An introductory letter and a questionnaire were 
mailed to all individual family members, aged ≥16 years, reviewed in our clinics. For 
individuals <16 years the letter was addressed to the parent or guardian. Individuals were 
asked: 1. Any further unexpected deaths in your family since the consultation? 2. Anyone 
in your family with unexplained fainting episodes since the consultation? 3. Have you or 





Data collection was performed as part of the clinical evaluation of the families as proposed 
by the Government in the 8th chapter of the National Service Framework for Heart 
Disease, which includes guidelines for early identification of individuals at risk of sudden 
cardiac death and better support for families of victims. The follow-up project was 
performed as part of a clinical audit evaluating the services provided in our inherited 
cardiac diseases clinics. The opinion of the Outer South East London Research Ethics 
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Committee was sought who recommended that the project represented a service audit 




Data interpretation and analyses were performed using SPSS software, version 14 (SPSS 
Inc., Chicago, IL, USA). Means and standard deviations (SD) or median and interquartile 
range (IQR) were calculated for continuous variables. Group differences are examined 
using t-test and Mann–Whitney U test for parameters with normal and non-normal 
distributions, respectively. Chi-square or Fisher’s exact test was used to test group 
differences of proportions. Binary logistic analysis was used to investigate the presence of 
an independent association between age, gender, presence of symptoms, number of 
family relatives evaluated and family history of sudden death and the presence of an 





Out of 159 families referred to the inherited cardiac diseases clinics as a result of a sudden 
death, 83 families, comprised of 271 blood relatives, fulfilled the SADS criteria (Figure 9).  
 
4.5.1 Characteristics of probands 
 
The majority of SADS probands were male with a male to female ratio of 2.3 : 1 (Table 
10). Most deaths (70%) occurred either during sleep or at rest, with only 15% of deaths 
related to exercise. One of the victim’s death was provoked by the alarm clock going off.246 
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A pre-morbid 12-lead ECG and subsequent familial evaluation revealed a diagnosis of 
LQT type 2 in the proband, her mother and maternal cousin. 
 
Table 10: Probands’ characteristics 
Total number of probands 83 
Mean age [range] (years) 29 [1-56] 
Gender (male) 58 (70%) 
Ethnicity:  
          Caucasian 
          Asian 
          Afro-Caribbean 
 
74 (89%) 
  6   (7%) 
  3   (4%) 
Mode of death:  
          Asleep  
          At rest       
          Daily activities 






Antecedent cardiovascular symptoms: 
          Syncope 
30 (37%) 
14 (17%) 
Family history of sudden death 




          Abnormal 
16 (20%) 
10 (12%) 
Cardiac pathologist post-mortem 38 (47%) 
 
 
Of importance, 37% of the victims had reported cardiovascular symptoms prior to their 
death. Syncope (n=14) and palpitations (n=13) were the most common symptoms, 
followed by episodes of dizziness/pre-syncope (n=6), shortness of breath (n=4) and chest 
pain (n=1). Of the 30 victims who reported cardiovascular symptoms, only 8 (27%) were 
investigated by a specialist. In 4 individuals the presenting symptom was witnessed 
generalised seizures. All 4 were investigated by a neurologist and 2 received a diagnosis 
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of epilepsy (Table 11); in both cases familial evaluation identified an ion-channel disease, 
namely BrS and LQTS. 
 
Table 11: Characteristics of the 8 SADS victims who exhibited cardiovascular 
symptoms that prompted specialist evaluation prior to their death. The table also 
depicts the results of the familial evaluation prompted by the SADS death. 
Gender 
Age of death 







VF arrest ECG: ST-elevation 









Not for ICD as VF 










palpitations ECG: partial RBBB, 
minor anterior ST-
elevation, Normal 







1 episode of 
generalised 
seizure 




No treatment Brs 
Female 
56 years 
1 episode of 
syncope 
CT head (Normal) Possible TIA 
Neurologist 







CT head & EEG 
(Normal), ECG: 
Type-2 Brugada 

































wave inversions in 
V1-V3, LBBB VE 
(Figure 11C) 
ECHO: Normal, 
Holter: LBBB VEs 
No diagnosis 
Cardiologist 





Almost a quarter of the victims had a prior family history of SCD at a relatively young age 
(<50 years), of which a considerable proportion was in first-degree relatives. We were 
unable to obtain any post-mortem reports of those relatives. Of the 7 death certificates 
obtained, 4 were attributed to myocardial infarction or coronary artery atherosclerosis, 2 to 
cardiac arrhythmia and 1 to sudden adult death syndrome. All were associated with a 
verdict of death from natural causes. None of the families was advised to seek cardiac 
evaluation for inherited conditions predisposing to SCD. 
 
The author was able to obtain a 12-lead ECG in 16 victims of SADS. The majority of ECGs 
(14 out of 16) were performed as a result of cardiovascular symptoms. In 2 cases the 
ECGs were performed as part of routine investigation for unrelated conditions. Six of the 
ECGs exhibited diagnostic phenotypes, highly suggestive of a condition predisposing to 
sudden death. One ECG depicted ST-segment elevation in the lateral leads consistent 
with myocardial ischaemia in an individual with a diagnosis of coronary artery spasm 
(Table 11). The other 5 ECGs were suggestive of an inherited cardiac condition (LQTS, 
n=3; BrS, n=1; ARVC, n=1) (Figure 11). In 3 out of these 5 cases, subsequent familial 





Figure 11: Examples of diagnostic ECGs of SADS victims obtained prior to the fatal 
cardiac arrest. None of the victims had received the diagnosis suggested by the 
ECG. A. ECG demonstrating a long-QT interval (QTc: 500 msec) obtained by 
ambulance paramedics in a 32-year-old male with recurrent episodes of epileptic fits 
on treatment with Levetiracetam (Table 11); B. ECG demonstrating the type-1 
Brugada phenotype performed during a hospital admission for viral gastroenteritis 
in a 20-year-old male. The victim was pyrexial during the admission. He had never 
reported any cardiovascular symptoms; C. ECG demonstrating anterior T-wave 
inversion and a ventricular ectopic beat of LBBB morphology in a 16-year-old 
female. The ECG was obtained during cardiovascular evaluation for episodes of 
palpitations and pre-syncope. The echocardiogram was reported as normal. A 24-
hour Holter monitor demonstrated >1,000 ventricular extrasystoles (Table 11). 
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4.5.2 Characteristics of family relatives evaluated 
 
The great majority (n=227; 84%) of individuals evaluated were 1st-degree relatives of the 
deceased. In only 29 out of the 82 families (36%) we had the opportunity to evaluate both 
natural parents of the deceased. This was predominantly due to a considerable number of 
parents being divorced or separated, or as a result of the fact that parents were not keen 
to be investigated themselves as long as their offspring was evaluated, particularly in 
cases where the parents did not have siblings with children that could have potentially 
inherited a condition predisposing to SADS. In a small number of families (n=6) where the 
deceased was of an older age (>45 years), parents were either deceased or of advanced 
age. Nineteen families (23%) comprised of only one relative who was referred for 
evaluation. 
 
Of the 271 relatives evaluated, 225 (83%) completed the whole array of investigations that 
were considered necessary by the investigators, based on the family history and initial 
findings in the individual and his/her relatives. The majority of individuals that did not 
complete the evaluation did so because of a young age (<16 years). All children were 
subjected to a resting ECG and those over the age of 8 years also underwent a 
transthoracic echocardiogram. All children were followed-up in our clinic with a view to 
receive all necessary investigations when they attain age of 16 years. Children with 
symptoms or family history causing concern were referred for comprehensive evaluation 
by a paediatric cardiologist at the Royal Brompton hospital and St George’s hospital. 
 
Fifty-three of the family members (19%) had experienced cardiovascular symptoms 
including syncope (n=26), palpitations (n=22), dizzy spells/pre-syncope (n=19), chest pain 
(n=14) and shortness of breath (n=3). Half of the symptomatic individuals (n=27), including 
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19 of the 26 individuals who had experienced syncope, had sought medical attention. 
Syncope had been attributed to vaso-vagal syncope (n=8), vertigo (n=2), primary epilepsy 
(n=1), epileptic fit due to intracranial bleed (n=1), migraine attack (n=1). In the other 6 
cases no diagnosis was reached. 
 
Table 12: Family relatives characteristics 
Total number of relatives evaluated 271 
Number of relatives evaluated/family 3.33 
Relatives who underwent full investigations 225 
Reasons for not completing full complement 
of investigations: 
          Young age 
          Refused investigations 
          Did not attend 
          Co-morbidities 
          Pregnancy 
 
 
  25 
    9 
    8 
    2 
    2 
Mean age [range] (years) 34 [1-78] 
Gender (male) 129 (48%) 
Prior cardiovascular symptoms: 




4.5.3 Results of clinical evaluation 
 
Of the 83 families evaluated in our clinics, 40 (48%) were diagnosed with a definite or 
probable/possible inherited cardiac disease based on the results of the comprehensive 
cardiac evaluation (Figure 12). In the majority of families diagnosed with a condition (34 
out of 40 families, 85%), an inherited arrhythmogenic syndrome was identified. Brugada 
syndrome (n=26) and BrS related overlap syndromes (n=4) accounted for 74% of the 
conditions identified. The remaining diagnoses were LQTS (n=4), DCM (n=2), ARVC 
(n=2), familial AF (n=1) and coronary artery spasm (n=1). 
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Figure 12: Pie chart depicting the diagnoses reached in SADS families as a result of 
the comprehensive cardiac evaluation of surviving relatives. Results are expressed 
as percentage (%) of the total number of families included in the study. 
AF: Atrial fibrillation; ARVC: Arrhythmogenic right ventricular cardiomyopathy; BrS: 
Brugada syndrome; CA: Coronary artery; DCM: Dilated cardiomyopathy; LQT3: Long QT 
syndrome type-3; PCTD: Premature conductive tissue disease. 
 
Of the 271 relatives who attended our clinic, 65 (24%) were diagnosed with a definite or 
probable/possible cardiovascular pathology, which had not been previously identified. 
Fifty-three relatives were diagnosed with BrS or a BrS overlap syndrome, 7 relatives 
received a diagnosis of LQTS, 3 individuals were labeled with a diagnosis of familial DCM, 





4.5.4 Predictors of a positive diagnosis 
 
The authors tested a number of variables to identify predictors of a positive diagnosis on a 
family (Table 13) and an individual (Table 14) level. On a family level, families who 
received a diagnosis had a higher mean number of relatives assessed compared to 
families with no diagnosis, but the difference was not statistically significant. On an 
individual level, the presence of syncope in family relatives appeared to correlate with an 
underlying cardiac pathology. Moreover, all of the individuals who received a diagnosis 
were subjected to the entire complement of investigations as outlined in figure 10. On the 
contrary only 78% of individuals with no diagnosis were subjected to all necessary 
investigations. Both groups were otherwise of similar characteristics. 
 
 
Table 13: Predictors of diagnosis of inherited heart disease in evaluated families. 





No of relatives evaluated 3.9±3.1 2.8±1.7 p=0.056 
Both parents of victim evaluated 14 (35%) 15 (35%) p=1.000 
Age (yrs) 29.0±12.2 28.8±10.8 p=0.950 
Male gender 27 (68%) 31 (72%) p=0.637 
FH of SCD 10 (25%) 9 (21%) p=0.794 






Table 14: Predictors of diagnosis of inherited heart disease in evaluated relatives. 





Age (yrs) 37.3±14.5 33.3±17.8 p=0.110 
Male gender 28 (44%) 101 (49%) p=0.472 
Cardiac symptoms 18 (28%) 35 (17%) p=0.100 
Syncope 12 (19%) 14 (7%) p=0.007 
Completed all necessary 
investigations 
65 (100%) 161 (78%) p<0.001 
 




Twenty-six families, comprised of 108 relatives, received a diagnosis of BrS based on the 
identification of the type-1 Brugada phenotype in 43 relatives evaluated in our clinic. Of 
note, 16 relatives did not complete all necessary investigations and in particular they were 
not subjected to an Ajmaline provocation test, primarily due to young age at the time of the 
evaluation. As a precaution, all 16 individuals were offered the conventional life-style 
modification advice and regular follow-up in our clinic. We aim to perform the Ajmaline 
provocation tests once individuals reach the age of 16 years, unless they present with new 
onset of sinister symptoms, suggestive of malignant arrhythmias. 
 
Two families, comprised of 10 individuals, were diagnosed with a LQT-3/Brugada 
phenotype. The first family was referred to our clinic after the death of a 29-year old male 
while driving. His father had died suddenly at the age of 52 years and was attributed to 
“heart attack” and there was a family history of 2 sudden infant death syndrome (SIDS) 
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deaths at 3 and 10 months. One of the deceased’s sisters was under investigations for 
recurrent episodes of syncope. Six of the 8 family members evaluated exhibited a positive 
Ajmaline provocation test, of whom 3 also demonstrated a long QT interval with the typical 
LQT-3 phenotype (long-ST segment with small T-wave). The second family, was 
comprised of 2 brothers who were referred after their mother experienced a fatal cardiac 
arrest at the age of 41 years. She had previously reported episodes of palpitations and 
pre-syncope. Her father died suddenly at the age of 53 years and there was another 
sudden death in a paternal aunt. No further details were available given that the family 
was originally from south Italy. One of the brothers had an LQT-3 pattern on his 12-lead 
ECG and a positive Ajmaline provocation test. 
 
One family, comprised of 4 individuals, was diagnosed with a DCM/Brugada overlap 
phenotype. The family was referred to our clinic after the death of the son at the age of 19 
years. He had never reported any cardiovascular symptoms. He died in his sleep and 
subsequent post-mortem evaluation by our cardiac pathologist revealed a normal heart. 
Cardiac evaluation identified LBBB with QRS duration of 150 msec and moderate left 
ventricular systolic dysfunction in his mother. There was no evidence of scarring on the 
CMR. Due to the considerable QRS prolongation she was not subjected to an Ajmaline 
test. One of the deceased’s half-brothers (maternal) exhibited the Brugada phenotype 
during Ajmaline testing but imaging studies were unremarkable. 
 
A 27-year-old male was diagnosed with progressive conductive tissue disease/Brugada 
overlap. He was referred to our clinic after the death of his brother. The rest of the family 
lived in India. Review of the family history revealed that 2 of their brothers had died at a 
young age (45 years, 48 years) and 2 other siblings had been implanted with a permanent 
pacemaker for recurrent episodes of syncope at a young age (<35 years). The patient 
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reported episodes of pre-syncope and syncope. His 12-lead ECG demonstrated sinus 
rhythm with a normal PR and QRS interval. An Ajmaline provocation test identified the 
Brugada phenotype. On a Holter monitor the patient exhibited intermittent Mobitz type-2 (2 
to 1) second degree heart block and complete heart block. 
 
Exercise testing in Brugada syndrome 
(Case report publication attached in appendix 3) 
 
Of the 108 relatives evaluated in families with a diagnosis of BrS or BrS overlap 
syndromes, 85 were subjected to an exercise treadmill test, including 43 individuals with 
an established diagnosis. Of these 43 individuals, 3 (7%) developed the diagnostic, type-1 
Brugada phenotype, predominantly during the recovery phase.247 Of interest, in contrast to 
reports in the literature which describe normalisation of the ST-segment elevation, with 
increased sympathetic activity during exercise and unmasking of the Brugada phenotype 
with increased parasympathetic tone in recovery, one of the individuals developed the 
Brugada phenotype during peak exertion, refuting this simplistic theory as the sole 
explanation (Figure 13). Moreover, one individual developed multiple, monomorphic 
ventricular ectopic beats of left bundle branch block pattern with inferior axis indicating a 
right ventricular outflow tract origin. The ectopic beats were first noted at the beginning of 
recovery and subsided quickly (Figure 14). We had the opportunity to repeat exercise 
testing in 2 out of the 3 individuals and they consistently developed the Brugada pattern 










Figure 13: ECG strips of leads V1–V3. ST-segment changes before, at peak and 





Figure 14: (A) ECG strips of leads V1–V3. ST-segment changes before, at peak and 
during the recovery phase of the treadmill exercise stress test. (B) Rhythm strip 
demonstrating multiple ventricular extrasystoles of increasing frequency 40 sec into 





Four families, comprised of 15 individuals, received a diagnosis of LQTS. The first family 
was referred to our clinic after the death of a 17-year-old female when the alarm clock 
went off. She had previously reported episodes of palpitations and dizzy spells and in 
retrospect a 12-lead ECG performed by her GP exhibited bifid T-waves with a QTc 
duration of 470 msec, consistent with an LQT-2 syndrome. There was also a family history 
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of sudden death in her maternal aunt. On familial evaluation both the deceased’s mother 
and her cousin (daughter of the maternal aunt) were diagnosed with LQTS. The second 
family was referred after the death of their 17-year-old son during sleep. His mother and 3 
of his sisters exhibited a prolonged QT interval (QTc: 481-533 msec) associated with 
paradoxical prolongation of the QT interval during exercise testing. The third family was 
diagnosed with LQTS based on the presence of a QTc of 490 msec in the mother of a 26-
year-old female that died at rest, with no prior symptoms or sinister family history. Finally, 
the diagnosis of LQTS in the fourth family relied solely on the review of the family history 
and the 12-lead ECG of the deceased (Figure 11A and Table 11). The father and the 
deceased’s paternal half-brother and half-sister (from the father’s second marriage) were 
referred for evaluation after the death of a 32-year-old male who had experienced several 
episodes of epileptic seizures and was on treatment with Levetiracetam under the care of 
a neurologist. The ECG obtained during one of his hospital admissions exhibited a 
corrected QT-interval of 550 msec. Moreover, review of the family history revealed that the 
deceased’s mother (father’s first wife) had also died suddenly at the age of 33 years, as 
had his maternal grand-mother (early thirties). As expected, clinical evaluation of the father 
and paternal half-siblings of the deceased was negative, given that they were not 




Two families, comprised of 8 individuals, were diagnosed with familial DCM. In the first 
family the diagnosis was based on the identification of LBBB on the 12-lead ECG with 
associated dilated LV cavity (LVIDd: 62 mm), moderate left ventricular systolic dysfunction 
and global hypokinesia in the sister of the deceased. Due to her age (56 years) a CT 
coronary angiogram was performed which revealed only mild atheroma of the left anterior 
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descending coronary artery. In the second family the diagnosis of DCM was based on the 
identification of a dilated LV cavity with mild LV systolic dysfunction in the father and 
brother of the deceased. 
 
Arrhythmogenic right ventricular cardiomyopathy 
 
Two families were diagnosed with possible ARVC. In the first case the diagnosis was 
suspected after review of investigations of the deceased. Her post-mortem, including 
slides reviewed by our cardiac pathologist, was negative. The deceased was a 16-year-old 
female who had been investigated for episodes of palpitations and pre-syncope. Her 12-
lead ECG (Figure 11C) demonstrated T-wave inversion in leads V1-V3 with associated 
ectopy of LBBB morphology. Her 24-hour Holter monitor demonstrated >1,000 ventricular 
extrasystoles. An echocardiogram had been reported as normal. Evaluation of her mother 
was negative. In the second case the daughter of a 40-year-old man was referred for 
evaluation after he was found dead in his bed. The daughter’s ECG revealed T-wave 
inversions in leads V1-V5 but ECHO and CMR did not reveal any convincing evidence of 
cardiomyopathy. She subsequently developed one episode of syncope but had no 
documented episodes of arrhythmia. She is currently under regular review. 
 
Familial atrial fibrillation 
 
One family was diagnosed with familial AF. A 36-year-old female died in her sleep. She 
had a past medical history of paroxysmal AF and was on beta-blockers as and when 
required. Her 46-year-old sister was noted to be in atrial flutter during her evaluation in our 
clinic. A Holter monitor revealed sinus rhythm with frequent episodes of atrial fibrillation 
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and atrial flutter. An echocardiogram and CMR were normal. An Ajmaline test was 
negative. 
 
Coronary artery spasm 
 
The diagnosis of coronary artery spasm was based on the review of the hospital records of 
a 31-year-old male whose family was referred to our clinic after he died suddenly at home. 
The deceased 5 years prior to his death had been admitted with VF arrest, preceded by 
chest pain. His ECG demonstrated ST-segment elevation in the lateral leads and he was 
thrombolysed. A subsequent coronary angiogram did not identify any significant coronary 
artery atheroma and an echocardiogram was normal. There was a very mild Troponin rise. 
He was commenced on treatment with calcium channel blockers. An ICD was not deemed 
necessary based on the fact that VF arrest had occurred in the context of ischaemia due 
to coronary artery spasm. The post-mortem was performed by our cardiac pathologist and 
failed to identify any significant pathology and in particular macroscopic or microscopic 
findings consistent with coronary artery spasm (Table 5). Alternative diagnoses such as an 
acute embolic event or acute myocarditis may have accounted for the initial presentation 
and subsequent death. Comprehensive evaluation of the deceased’s mother, brother and 
maternal half-sister was negative. 
 
4.5.6 Families with no diagnosis 
 
In almost a third of the families (15 out of 43) where no diagnosis was established, one or 
more relatives did not complete all necessary investigations. The majority of them did not 
undergo an Ajmaline provocation test. As a result a diagnosis of BrS may have been 
missed in a considerable proportion of families. 
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4.5.7 Further evaluation 
 
Only a small number of relatives evaluated in our clinic required further investigations. 
Those included computer tomographic coronary angiography (CTCA) (n=7) and 
conventional coronary angiography (n=2) to exclude coronary artery disease and one case 
with negative clinical evaluation and recurrent episodes of vaso-vagal sounding syncopal 
episodes who was referred for a tilt-table test and neurological evaluation. 
Electrophysiological studies were performed in only 3 cases; in one case of an individual 
with negative familial evaluation who was reporting episodes of palpitations and 
associated syncope and in two cases for inducible VT in order to offer further reassurance 
after both were diagnosed with the Brugada phenotype on Ajmaline provocation testing. 
 
4.5.8 Mutation analysis 
 
We performed mutation analysis in 21 out of the potential 38 families with phenotypes 
suggestive of inherited cardiac conditions. Of the 17 families with a positive phenotype but 
no mutation analysis: 10 BrS families genetic testing was either referred to their local 
geneticist or is still pending in our genetics laboratory due to funding restrictions; 3 families 
(2:BrS, 1:possible ARVC), individuals declined genetic testing after counselling; 1 family 
with a diagnosis of LQTS and 1 family with a diagnosis of possible ARVC no genetic 
testing was performed since the diagnosis was based on review of the deceased’s ECG, 
family history and past medical history but the phenotype was absent in evaluated 
relatives; 2 families diagnosed with DCM mutation analysis was not performed due to the 
absence of co-existing atrio-ventricular block.214 
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Of the 30 families with a diagnosis of BrS and BrS related overlap syndromes, we 
performed genetic testing in 18 families. Four families had SCN5A mutations thought 
highly likely to be disease causing (E1784K; n=2, D349H; n=1, Q1112X; n=1). The 
E1784K mutation in the SCN5A gene has been described in the literature and is 
associated with BrS, LQTS and premature conduction tissue disease. In agreement with 
existing literature, the 2 families with an E1784K mutation expressed a LQT-3/BrS 
overlapping phenotype.204,207,233,248,249 D349H is a novel mutation, which affects a highly 
conserved residue (R349) located in the first pore segment of the SCN5A channel, at the 
loop between segments 5 and 6, where several missense mutations have been associated 
with sodium channel “loss-of-function”, consistent with BrS. Finally, Q1112X is a stop 
mutation in exon 18 of the SCN5A gene resulting in truncation of protein and predicted 
nonsense mediated decay, which in general are related to disease. 
 
In one family an I1377V mutation of SCN5A was detected. This is a novel heterozygous 
missense variant that is rare and absent from over 12,000 alleles in the multi-ethnic NHLBI 
Exome Variant Server. The variant affects a moderately conserved residue (I1377), 
producing a change from non-polar isoleucine to non-polar valine. This change is 
predicted to produce a small change in the mass (Grantham Distance: 29 [0-215]). The 
amino acid I1377 is located in the loop between the segments 5 and 6 of transmembrane 
domain 3 of the alpha subunit that forms the sodium channel. We performed in silico 
analysis: both Polyphen-2 and SIFT predict a benign protein effect. In contrast, topological 
analysis, which is recognised as superior to non-specific in-silico models in the long QT 
syndrome, would suggest that 88% of missense variants in this region associate with 
functional ion channel disease.250 
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Pathogenic mutations were identified in the two of the 3 LQTS families tested. A G168R 
mutation was identified in the KCNQ1 gene. The mutation affects a highly conserved 
residue and has been extensively described as a cause of LQTS.251-254 In the second family 
we identified a A561V mutation in HERG. The mutation results in substitution of valine for 
a highly conserved alanine at codon 561, altering the S5 transmembrane segment of the 
KCNE2 encoded protein.218,255,256 
 
4.5.9 Immediate management 
 
All of the 65 relatives who received a definite or probable/possible diagnosis of an 
inherited cardiac condition, received the necessary life-style modification 
advice.161,162,164,165,257-265 Life style modification advice was also offered to a small number 
(n=2) of individuals with inconclusive investigations who were not labelled with a diagnosis 
and individuals with a familial diagnosis who did not complete the investigations (n=16), 
predominantly due to young age. Of the 271 relatives evaluated 26 (10%) received some 
from of medical intervention. Medical therapy was initiated in 11 individuals; 7 individuals 
diagnosed with LQTS received prophylactic therapy with a beta-blocker and 4 individuals 
with DCM were commenced on treatment with a beta-blocker and an angiotensin 
converting enzyme inhibitor (ACE-i). Fifteen individuals, all with a diagnosis of BrS (n=8) or 
BrS/LQT-3 (n=7) overlap syndrome were implanted with an ICD. Five individuals with BrS 
were considered to be at high risk of sudden death based on the presence of previous 
unheralded syncope. In two individuals an ICD was implanted based on an inducible type-
1 Brugada pattern during the recovery phase of the exercise treadmill test. Although there 
is no established association between unmasking of the Brugada phenotype during 
exercise and increased risk of SADS, some studies have reported ST-elevation during 
exercise testing as a predictor of prognosis.159,258 One 17-year-old female who did not 
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exhibit any of the conventional risk factors opted for an ICD after detailed discussion 
relating to the uncertainties of risk stratification in BrS and the potential complications of an 
ICD implantation. Of the 7 relatives with a familial diagnosis of BrS/LQT-3 overlap 
syndrome, we recommended ICD implantation in all of them, based on evidence indicating 
that such individuals are at excess risk of sudden death.53,193,259,260 One exhibited 
episodes of unheralded syncope and two others had exhibited a number of syncopal 
episodes, which were associated with prodromal symptoms and probably represented 
vaso-vagal syncope. Finally, the one individual with evidence of frequent episodes of 
paroxysmal Atrial Fibrillation/Atrial flutter was initially commenced on anticoagulation 
therapy with Warfarin and was subsequently offered an AF ablation, which was judged to 
be successful on initial follow-up. 
 
4.5.10 Short-term follow-up study 
 
We were able to obtain follow-up data either through subsequent follow-up in our clinic or 
from an audit study in 55% of the families included in our SADS study. Data were available 
on 30 out of the 40 (75%) families where a diagnosis was identified after familial 
evaluation, but only in 16 out of the 43 (37%) families where no pathology was identified 
(p=0.001). The mean follow-up was 25.5±16.8 months versus 19.1±12.5 months (p=0.188) 
for families with a diagnosis compared to the ones without a diagnosis, respectively. 
 
The 30 families diagnosed with a condition comprised of 119 relatives. The respective 
follow-up period equated to 244 person-years. During that period there was an appropriate 
ICD discharge, one unexpected death and a new diagnosis of BrS. The death occurred in 
a family with a diagnosis of BrS where 4 of the deceased’s relatives had been 
investigated, namely the deceased’s mother, sister and two maternal half-siblings. The 
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mother and the half-brother had been diagnosed with BrS based on the presence of the 
Brugada phenotype during Ajmaline provocation test. The sudden death occurred in the 
sister of the proband who initiated the familial evaluation. She died in her sleep at the age 
of 37 years, 6 years after her initial evaluation in our clinic. A subsequent post-mortem 
evaluation of the heart by our specialist cardiac pathologist failed to identify any underlying 
cardiac abnormality and, therefore, by definition she was a victim of SADS. Review of her 
clinic evaluation and further discussion with her parents, revealed that the victim had never 
experienced any symptoms and all investigations including an Ajmaline provocation test 
had been normal, indicating a potential false negative Ajmaline provocation test. The half-
sister of both victims of SADS that had been cleared in our clinic after negative Ajmaline 
provocation testing also received a diagnosis of BrS after repeat Ajmaline testing at her 
local centre and was implanted with an ICD. 
 
Of the 15 patients implanted with a defibrillator, during a follow-up period of 31.6 person-
years one individual received an appropriate treatment and two developed complications 
during initial implantation of the device. The ICD discharge occurred in an individual 
diagnosed with BrS who was offered an ICD as a result of having experienced syncope. 
On review of the ICD traces the patient initially developed polymorphic VT, which 
disintegrated to VF. Sinus rhythm was restored after a single shock. Of the two individuals 
who experienced early complications, one developed right ventricular perforation with 
tamponade at the time of implantation and required lead repositioning and the second 
experienced multiple inappropriate shocks within 24 hours of implantation due to lead 
displacement, which also required repositioning. 
 
No events or new diagnosis occurred in the 16 families with no diagnosis, comprised of 59 




This study is one of the largest, prospective studies investigating SADS deaths. In contrast 
to most of the existing studies, referral of all families included in our study was triggered by 
a “true” SADS death, as evident by the post-mortem report, and most importantly all 
relatives were evaluated in a single centre, under the same team and largely with the 
same screening protocol. Results from the comprehensive familial cardiovascular 
evaluation in our inherited cardiac diseases clinics indicate that in almost 50% of SADS 
families an underlying cardiac pathology was detected, allowing for a probable cause of 
death to be identified but most importantly for individuals at potential risk of sudden death 
to be recognised. Nearly a quarter (24%) of family relatives assessed were diagnosed with 
a previously unsuspected cardiac pathology and managed according to established 
protocols in an attempt to minimise their risk of SADS. That percentage rises to 29% if we 
consider only relatives who underwent comprehensive cardiovascular investigations, since 
almost a fifth (17%) of individuals attending our clinic had limited screening, predominantly 
as a result of their young age. 
 
Our study suggests that some of the SADS deaths may have been preventable, since 
more than a third (37%) of SADS victims had reported cardiovascular symptoms prior to 
their death and 17% had experienced at least one episode of syncope, which is likely to be 
considered a sinister symptom and trigger medical consultation. Unfortunately in a small 
number of cases (n=5) the syncope and seizures had triggered a neurology referral and 
the deceased had been diagnosed with epilepsy and possible transient ischaemic attack. 
In two cases the 12-lead ECG was available and demonstrated features that should have 
raised suspicion on underlying primary arrhythmogenic syndrome, namely a prolonged QT 
interval and a type-2 Brugada pattern (Table 11 and Figure 11A). Furthermore, almost a 
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quarter of victims had a family history of premature sudden death, with 12% involving a 
first-degree family relative. Based on the 8th chapter on arrhythmias and SCD of the 
National Service Framework for heart disease, which has been in place since 2005, such 
deaths should trigger a referral for specialist review in an attempt to prevent further 
tragedies.8 
 
4.6.1 Comparison of the thesis results with existing studies 
 
The diagnostic yield of cardiac pathology in 48% of SADS families in our study is in 
keeping with existing studies, although direct comparisons are not always possible due to 
the different definitions and methodology used. The Netherlands group published two 
studies in individuals with a sudden unexplained death, but not necessarily SADS.81,87 
They reported a diagnostic yield of familial evaluation of up to 40% with primary 
arrhythmogenic syndromes accounting for the majority of the diagnoses (31 of 47; 66%). 
Although in their initial cohort the predominant diagnosis was CPVT, in the second, larger 
cohort LQTS (n=10), BrS (n=9) and CPVT (n=8) were equally represented. As expected, 
given that the inclusion criteria did not require a normal post-mortem, a diagnosis of 
structural heart disease accounted for 34% of the conditions identified compared to only 
13% in our cohort. The study by Caldwell et al89 reported a lower diagnostic yield of 30% 
but only a limited number of relatives received comprehensive screening similar to our 
study. Finally, the study by Behr et al.82 is the one that most closely resembles the 
inclusion criteria and methodology employed in our study. Behr et al. reported a diagnostic 
yield of 53% with the predominant diagnosis being LQTS. In contrast to our study where 
molecular autopsy was not performed, the study by Behr et al. utilised molecular autopsy 
alongside clinical evaluation, which is likely to have enhanced to some extent their 
diagnostic yield. The authors performed molecular autopsy in 24 victims, 5 of whom 
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identified a pathogenic mutation. In one case the familial diagnosis was based on the 
molecular autopsy result alone, while in the other 4 cases the interpretation of the clinical 
findings are likely to have been affected by the knowledge of a positive mutation. Similarly 
to the Netherlands group cardiomyopathies accounted for a considerable proportion (30%) 
of the established diagnoses, despite the strict inclusion criteria of victims with a normal 
post-mortem alone. 
 
4.6.2 Brugada syndrome 
 
In our study the predominant familial diagnosis was of BrS or BrS related overlap 
syndromes, which accounted for 75% of the diagnostic yield and 36% of the overall SADS 
deaths. On an individual level, 53 out of the 65 relatives (82%) who were diagnosed with a 
definite or probable/possible cardiovascular pathology exhibited the Brugada phenotype. 
This is in contrast to existing studies where BrS formed a relatively small proportion of the 
diagnostic yield and other primary arrhythmogenic syndromes such as LQTS and CPVT 
predominated. In the studies by the Netherlands group BrS was identified as a potential 
cause of sudden death in only 6%-7% of families,81,87 while the UK studies by Behr et al.82 
and Caldwell et al.89 reported a diagnostic yield of BrS of 9% and 2%, respectively. There 
are several factors that may account for the predominance of BrS in our cohort including 
differences in the baseline cohort characteristics, the frequency of Ajmaline provocation 
testing and most importantly the use of the higher intercostal V1 and V2 ECG leads. 
 
Activity levels at death 
 
The great majority of the SADS victims in our study (70%) died at rest, with 40% dying in 
their sleep. Brugada syndrome is strongly associated with sudden death at rest and in 
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particular during sleep due to increased vagal tone that appears to play an important role 
in inducing ventricular arrhythmias. In contrast most other relatively prevalent primary 
arrhythmogenic syndromes such as LQT-1, LQT-2 and CPVT and most cardiomyopathies 
are predominantly linked to deaths during exertion or emotional stress. In the initial study 
by the Netherlands group only 37% of sudden death victims died at rest or in their sleep, 
with 44% dying on exertion, which was reflected in the pathologies identified (CPVT, 
LQTS, HCM, ARVC). In the second, larger study by the same group the proportion of 
individuals who died at rest or in their sleep increased to 62% while those dying on 
exertion reduced to 31%, which was reflected in the pathologies identified with BrS 
accounting for a similar proportion of deaths to LQTS and CPVT. A similar proportion of 
individuals died at rest in our study (70%) and the study by Behr et al. (63%) indicating 
that other potential contributors may have influenced the diagnostic yield differences 
between the two studies. 
 
Ajmaline provocation test 
 
One fundamental difference in our methodology compared to most of the existing studies 
is the frequency of performing provocation testing with class-1 anti-arrhythmics to unmask 
the Brugada phenotype. It is well established that the baseline ECG is of limited diagnostic 
value given that in the majority of Brugada patients it may be normal or fluctuate between 
normal and the Brugada pattern.158,168,169 This is further reinforced by our study where only 
2 individuals exhibited an unequivocal type-1 ECG pattern in the absence of Ajmaline. In 
our SADS cohort 206 out of the 271 relatives (76%) evaluated were subjected to an 
Ajmaline provocation test. The great majority of individuals underwent Ajmaline testing 
because of a normal ECG and echocardiogram and the absence of an alternative 
diagnosis. In contrast to our study, the Netherlands group performed only a limited number 
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of provocation tests with class-1 anti-arrhythmics in individuals “when BrS was suspected”, 
without specifying what were the exact characteristics that raised suspicion of BrS. In the 
study by Caldwell et al. only 20 out of the 193 (10%) individuals were subjected to 
Ajmaline provocation testing based on “a history and/or ECG suggestive of BrS”. 
 
Utilizing the higher intercostal leads 
 
Detailed discussion of the utility and implications of higher intercostal leads is included in 
the discussion of chapter 6. Based on the results form the familial evaluation of SADS 
victims, the use of higher intercostal leads more than doubled our diagnostic yield of BrS. 
Performing ECG with leads V1 and V2 placed in the 4th IS, only, would have missed the 
diagnosis in 7 out of the 26 Brugada families of our SADS cohort reducing the diagnostic 
yield of BrS to 23%. The overall diagnostic yield would drop from 48% to 40%, which is 
more in keeping with that of the Netherlands group and Caldwell et al. Additionally, we 
would have failed to identify 18 out of the 43 individuals diagnosed with BrS, reducing the 
overall yield on an individual level from 24% to 17%. 
 
Exercise testing in Brugada syndrome 
 
Both the American Heart Association and the European Society of Cardiology recommend 
disqualification of Brugada patients from all competitive sports with a potential exception 
only for low-dynamic and low-static sports. Most experts however, view these 
recommendations as an overcautious approach, since there is no clear association 
between exercise and sudden death in BrS. In addition, exercise testing is not routinely 
used for the evaluation of Brugada patients or suspected carriers. In our cohort however, 
almost 15% of Brugada victims died during or shortly after exertion and almost 10% of the 
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family relatives diagnosed as carriers of the Brugada gene developed the Brugada 
phenotype at peak or immediately post exertion, which in two individuals was associated 
with brief episodes of multiple ventricular extrasystoles. These cases highlight the need to 
assess the role of exercise testing in the diagnosis and risk stratification of BrS and infer 
that BrS should be considered in the differential diagnosis in athletes presenting with 
syncope. This is of particular relevance since most physicians would consider syncope 
occurring immediately post exertion of fairly innocent nature, most probably representing a 
form of vasovagal syncope. 
 
4.6.3 Short-term follow-up study 
 
Due to the small number of events and the relatively short follow-up period we are unable 
to draw any safe conclusions form our follow-up study. Our data however, raise important 
issues that worth mentioning. The individual that tragically passed away despite being 
reassured after comprehensive evaluation was part of a family who received a diagnosis 
of BrS after identifying the diagnostic phenotype on Ajmaline provocation testing in the 
mother and the half-brother of the deceased. Her post-mortem by our expert cardiac 
pathologist was negative and as such she was by definition a victim of SADS. At repeat 
evaluation by another specialist after the second death, the half-sister that had also been 
reassured in our clinic, was diagnosed with BrS based on a positive repeat Ajmaline test. 
This particular family was screened in our clinic at the time when we utilized the 
conventional V1 and V2 leads, alone, which may account for the “false negative” results. 
Based on the results of chapter 5, evaluating the impact of higher intercostal leads, the 
diagnosis of BrS would be missed in half of the individuals and families if Ajmaline 
provocation testing were performed in the conventional leads only. There is also a paucity 
139 
of data relating to the sensitivity and specificity of Ajmaline testing with respect to gender 
and repeated tests. 
 
This case also highlights the limitations of our risk stratification protocols in BrS, discussed 
in detail in chapter 6. This female victim did not exhibit any of the conventional risk factors, 
namely diagnostic ECG or symptoms suggestive of malignant arrhythmias. Based on 
current evidence, even if the Ajmaline provocation test had been positive, the patient 
would have been considered to be at low risk of SADS (around 0.5% per year) and as 
such would not have been offered an ICD. The risk of sudden death needs to be balanced 
against the potential risk of complications as a result of the ICD implantation. Current 
evidence suggests that the risk of ICD related complications, including inappropriate 
shocks, in Brugada patients can be up to 9% per year.261,262,266 Inappropriate shocks are 
particularly relevant in individuals with BrS since they appear to be more prone to 
supraventricular tachyarrhythmias with reports of up to a fifth of the patients developing 
paroxysmal arrhythmias.267,268 
 
4.6.4 Families with no diagnosis 
 
In almost 50% of the families no diagnosis was established despite comprehensive clinical 
evaluation. Although no events or new diagnoses were noted during follow-up, given the 
limited number of families included and the short-term period, concerns still exist as to 
their potential risk of sudden death in these individuals. Potential explanations for the 
absence of any identifiable pathology include: 1. The pathogenic mutation was private to 
the victim of SADS either because it was a spontaneous mutation that the parents did not 
exhibit or because it was not passed down the family tree. Given that we did not perform 
molecular autopsy it would have been impossible to detect such mutations; 2. Our 
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evaluation failed to identify all affected relatives, as shown in one of the families diagnosed 
with BrS, where a new diagnosis of BrS in one of the relatives and a SADS death in 
another occurred, despite initial reassurance. This may be pertinent when one considers 
the impact of higher intercostal leads, given that in 44 out of the 261 (17%) individuals who 
underwent Ajmaline provocation in studies IV and V, the ECGs were performed with leads 
V1 and V2 placed in the conventional 4th IS only; 3. The death was secondary to idiopathic 
VF. In the study by the Netherlands group the investigators identified the risk locus at 
chromosome 7q36,269 which is associated with familial idiopathic VF, in 3% of families;87 4. 
The death was due to a condition yet to be identified; and 5. The death was due to a non-





The predominant diagnosis was of BrS. The authors concede that given the relative 
novelty of the condition and the considerable impact of the higher intercostal leads in the 
diagnostic yield, it is possible that some of the relatives exhibiting the Brugada phenotype 
did not have a genuine arrhythmogenic syndrome. However, all individuals who were 
diagnosed with BrS underwent comprehensive evaluation including a detailed 
echocardiogram and a significant proportion were subjected to CMR and none exhibited 
any evidence suggesting cardiac inflammation, ARVC or other structural cardiac 
anomalies. Further support for the presence of BrS is underscored by the genetic yield of 
pathogenic SCN5A mutations, which is similar to existing literature.106 
 
The omission of regular epinephrine testing in individuals without an established diagnosis 
despite comprehensive cardiac screening may have underestimated the prevalence of 
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CPVT.81 However, all relatives were subjected to maximal exercise testing and the 
superiority of epinephrine testing over exercise testing in inducing bidirectional arrhythmia 
and aiding a diagnosis of CPVT is still debated. Earlier studies suggested a higher 
sensitivity for epinephrine testing,270 whereas a recent study indicated that exercise testing 
is of equal value, if not superior, to epinephrine testing and without the additional risk of 
inducing arrhythmias to non-affected family relatives.271 
 
In the families in whom a pathogenic mutation was identified, we were unable to perform 
post-mortem analysis in the tissues of the victims for confirmation of the genotype since no 
tissue was available by the time the relatives were evaluated in our clinic. In the UK, the 
Human Tissue Act does not permit retention of tissue as part of a deceased patient’s 
record, and retention for research requires familial consent at the time of post-mortem.75 
As such, in the majority of cases histological slides are prepared, reported and imaged at 
the time of the post-mortem examination, allowing early return of the tissue for burial or 
cremation. 
 
Chapter 5: Familial evaluation of victims of sudden cardiac death with 
autopsy findings of uncertain significance 




Post-mortem evaluation of cases of SCD is an increasingly complex task and uncertainty 
may exist regarding the causal relationship between the pathological findings and the 
sudden death.44 The significance of myxoid degeneration of the mitral valve with prolapse, 
stable atherosclerotic coronary plaque with limited (<50%) luminal stenosis and focal 
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myocarditis, which are relatively prevalent in the general population, may be erroneously 
overestimated. Not infrequently, post-mortem diagnosis of HCM is based on the presence 
of left ventricular hypertrophy (LVH) in the absence of myocardial disarray. Left ventricular 
hypertrophy however, is a recognized feature of physiological adaptation to exercise.43,57 
Similarly, despite the requirement for the presence of myocardial fibrosis on histological 
evaluation since the development of the original arrhythmogenic right ventricular 
cardiomyopathy (ARVC) criteria back in 1994,83 commonly ARVC is still diagnosed solely 
on the presence of fatty infiltration of the right ventricular wall. Isolated fatty infiltration of 
the right ventricle however, is commonly present in obese individuals.272 The distinction 
between pathology and normal variants may, therefore, be challenging in the context of 
SCD. 
 
Overestimation of the significance of pathological findings can be associated with 
important consequences since the pathologist’s report determines whether surviving 
relatives are referred for familial evaluation for potentially inherited cardiac conditions and 
more specifically whether subsequent investigations in surviving relatives are directed 
towards structural disorders or primary arrhythmogenic syndromes. This is reflected in the 
guidelines for autopsy investigation of SCD on behalf of the Association for European 
Cardiovascular Pathology, where the authors highlighted the concepts of “different 
degrees of certainty in defining the cause–effect relationship between the cardiovascular 




This study explored the hypothesis that a proportion of SCDs with autopsy findings of 
uncertain significance may represent part of the SADS spectrum, and in particular 
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inherited arrhythmogenic syndromes. The hypothesis was the product of the experience 
gained by the group’s experience with screening family relatives after a SCD, which 
suggested that there was considerable variability in the interpretation of the causative 
effect of the pathological findings by non-cardiac pathologists, who tend to overestimate 
their significance, and accumulating evidence that individuals with arrhythmogenic 
syndromes attributed to genetic mutations may exhibit structural cardiac changes. 
 
5.3 Personal contribution 
 
The author performed prospectively the clinical evaluation of the 20 families assessed at 
Lewisham hosptial, including performing or supervising, analyzing and databasing the 
majority of investigations (ECG, echocardiography, exercise treadmill test, Ajmaline 
provocation test and Holter monitoring). Collected data on the deceased including data on 
previous admissions or GP consultations. The author reviewed and analysed all the data 
(form Lewisham and St George’s hospitals) and drafted the published manuscript. The 
author was not involved with the post-mortem evaluation of any of the subjects that was 






This study was performed in collaboration with an inherited cardiac disease clinic 
established at St George’s Hospital since 2003. The clinic is lead by Dr E Behr, consultant 
electrophysiologist with expertise in conditions predisposing to SCD and SADS. Between 
2003 and 2010, 41 families were referred to Lewisham hospital (n=20; see group 3 in 
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figure 9) and St George’s hospital (n=21) cardiogenetics clinics, where the deceased’s 
post-mortem revealed findings with structural abnormalities of uncertain causal effect as 
outlined in table 15. All deaths represented SCD from natural causes of apparently healthy 
individuals, as outlined in the inclusion criteria in the methods section of chapter 4. All 
victims had been subjected to a post-mortem where an extra-cardiac cause had been 
excluded and toxicology screen was negative. 
 
Familial cardiological evaluation 
 
The 41 families comprised of 157 blood relatives who underwent identical comprehensive 
cardiac evaluation according to the standard protocol for SADS families, as outlined in 
methods section of chapter 4 and figure 10. In the SADS cohort reported in chapter 4, 
CMR was performed only in relatives with ECG or echocardiographic features suggestive 
of cardiomyopathy. In this cohort with autopsy findings of uncertain significance all 
relatives diagnosed with an arrhythmogenic syndrome, where the deceased’s post-mortem 
findings could be interpreted to represent a cardiomyopathy (LVH, myocardial fibrosis, 
ventricular dilatation and fatty infiltration of the myocardium) underwent CMR, even when 
the ECG or echocardiogram did not suggest structural heart disease. Further 






Table 15: Pathological criteria classified of uncertain significance in sudden 
cardiac death autopsies (Group 3). For comparison with respective cardiac 
pathology associated with sudden cardiac death please refer to table 5. 
Macroscopic appearance Microscopic appearance 
Left Ventricular Hypertrophy NOT Hypertrophic cardiomyopathy 
Left ventricular wall thickness ≥15 mm and 
or heart weight ≥500g in males or ≥400g in 
females. 
Myocyte hypertrophy with or without 
fibrosis. No myocyte disarray.* 
Fatty infiltration NOT Arrhythmogenic right ventricular cardiomyopathy 
Fatty infiltration of the right ventricle. Fatty infiltration of the right ventricular wall 
in the absence of fibrosis. 
Dilated ventricles NOT Dilated cardiomyopathy 
Enlarged heart with heart weight ≥500g in 
males or ≥400g in females. Mild ventricular 
dilatation. No fibrosis. 
Absence of interstitial fibrosis or myocardial 
inflammation. 
Mild coronary artery disease NOT significant coronary artery pathology 
Atherosclerosis with estimated luminal 
narrowing ≤ 50% or 2mm probe patent in 
the absence of acute or chronic infarction 
Absence of rupture/thrombosis of coronary 
artery and/or acute/chronic infarction in the 
LV 
Scattered lymphocytic infiltrate NOT Myocarditis 
Normal Scattered lymphocytic inflammatory foci 
with no fibrosis. No necrosis and/or 
degeneration of adjacent myocytes. 
Mitral valve prolapse NOT Mitral valve rupture 
Floppy mitral valve with mild ballooning 
between chordae in one or both leaflets 
Myxoid change in the valve 
Bicuspid aortic valve NOT Aortic valve stenosis 
Two leaflets associated with no significant 
nodular calcification or aortic orifice 
stenosis. 
Absence of left ventricular hypertrophy and 
fibrosis. 
 
* isolated myocyte disarray confined to the anteroseptal and posteroseptal junctions  




Data collection was performed as part of the clinical evaluation of the families as proposed 
by the Government in the 8th chapter of the National Service Framework for Heart 
Disease, which includes guidelines for early identification of individuals at risk of sudden 




Data interpretation and analyses were performed using R version 2.15.2 (R Development 
Core Team). Data were expressed in mean ± SD. Comparison of population proportions 





5.5.1 Characteristics of cases of sudden cardiac death and blood relatives 
 
The majority of cases of SCD were male (male to female ratio of 4:1). Most deaths (61%) 
occurred at rest or during sleep. A significant proportion (37%) had previously reported 
cardiac symptoms, and in 25% of cases there was prior family history of premature SCD 






Table 16: Characteristics of victims of sudden cardiac death with autopsy findings of 
uncertain significance. 
Number of victims 41 
Mean age [range] (years) 29.9±14.4 [4-59] 
Gender (male) 80% 
Ethnicity (Caucasian) 93% 
Mode of death 
      Asleep/At rest 
      During/post exertion 





Antecedent cardiac symptoms* 
      Syncope 
37% 
15% 
Prior family history of premature (<50 years) SCD 25% 
Post-mortem review by expert cardiac pathologist 39% 
 
* chest pain, palpitations, shortness of breath, pre-syncope, syncope 
 
One hundred and fifty-seven blood relatives (48% male) were evaluated, with a mean age 
of 33.7±17.9 years, (range 9-70 years). Almost a quarter (23%) of the evaluated relatives 
reported cardiac symptoms with 10% having experienced at least one episode of syncope 
in the past. 
 
5.5.2 Autopsy findings and results of familial evaluation 
 
The post-mortem findings of uncertain aetiological significance in the 41 cases are 
illustrated in Figure 15. Following familial evaluation, 21 (51%) out of the 41 SCD cases 
were considered to have died from a definite or probable inherited cardiac disorder. Of the 
157 relatives who underwent cardiac evaluation, 36 (23%) were diagnosed with a cardiac 




Figure 15: Histogram depicting the diagnostic yield of familial evaluation in victims 
of sudden cardiac death. The x-axis represents the number of families and the y-
axis the pathology identified in the deceased during post mortem evaluation of the 
heart. The different colours within the columns represent the diagnosis established 
after cardiac evaluation of surviving relatives with absolute numbers of families 
stated within the relevant colour. 
Abbreviations: CPVT: Cathecholaminergic polymorphic ventricular tachycardia; LVH, left 
ventricular hypertrophy. 
 
5.5.3 Diagnosis of arrhythmogenic syndromes 
 
A hereditary arrhythmogenic syndrome was diagnosed in the majority of families (19 of 21) 
in whom an underlying inherited cardiac condition was identified. Brugada syndrome 
(n=14) was the predominant diagnosis, followed by LQTS (n=4) and a single case of 
CPVT. 
 
An arrhythmogenic syndrome was detected following familial evaluation in 42% (11/26) of 
cases where the autopsy findings were suggestive of a possible cardiomyopathy (LVH, 
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myocardial fibrosis, ventricular dilatation, or myocardial fatty infiltration) (Figure 15). In 
these cases, all relatives with an arrhythmogenic syndrome phenotype underwent CMR 
scans, in addition to standard evaluation, to exclude potential myocardial disease mimics. 
All CMR scans were reported as normal. Of interest, in the 19 SCD cases where LVH or 
myocardial fibrosis (isolated LVH: n=10; myocardial fibrosis alone: n=6 or in conjunction 
with LVH: n=3) was reported at post-mortem, evaluation of family relatives identified an 
arrhythmogenic syndrome in almost 50% of families (5 out of 10 cases with isolated LVH 
and 4 out of 9 cases with myocardial fibrosis) (Figure 15). A cardiomyopathy was 
diagnosed in only one case in either group. In the remaining 8 (42%) cases we were 
unable to identify any features of inherited cardiac pathology despite comprehensive 
evaluation of the deceased’s relatives. 
 
Brugada syndrome was also diagnosed in one of the three families whose proband 
exhibited isolated fatty infiltration of the right ventricle (Figure 16.4). One of the families 
where the pathologist reported marked right ventricular dilatation was subsequently 
diagnosed with CPVT, based on the identification of typical bi-directional ventricular 
tachycardia on exercise testing in two relatives. 
 
Moreover, 2 out of the 6 families whose probands exhibited atheromatous disease at post-
mortem were diagnosed with BrS. Both probands were young, aged 28 and 34 years-old 
respectively, and exhibited up to 50% coronary artery lesions in the left anterior 
descending and right coronary arteries (Figure 16.1). In one of the two families where an 
inflammatory infiltrate commonly attributed to myocarditis was present, BrS was diagnosed 
during Ajmaline provocation testing in the deceased’s father. In similar fashion, one of the 
three families whose proband exhibited pathological features of mitral valve prolapse was 
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Figure 16: Histopathological slides of individuals with autopsy findings of uncertain 
significance. 1. Histopathological slides of an individual who exhibited coronary 
artery disease on autopsy and subsequent familial evaluation identified Brugada 
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syndrome: A. Macroscopic examination of the left anterior descending coronary 
artery in an otherwise normal heart shows eccentric atheroma. This can be opened 
with a 2mm probe (black arrow), indicating that there would have been normal blood 
flow during life; B. Histology staining with Trichrome stain (Elastin Van Gieson) 
confirmed eccentric atheroma in the left anterior descending coronary artery. The 
coronary lumen has a collapsed appearance, but would have been likely to have had 
normal ante-mortem blood flow. 2. Histopathological slides of an individual who 
exhibited isolated left ventricular hypertrophy on autopsy and subsequent familial 
evaluation identified Long-QT syndrome: A. Short axis slice showing a 
circumferentially thickened left ventricular wall measuring 2cm. The left ventricular 
cavity diameter is also reduced; B. Haematoxylin and eosin staining confirms 
idiopathic myocyte hypertrophy with enlarged box-shaped nuclei. No myocyte 
disarray is noted. 3. Histopathological slides of an individual who exhibited 
myocardial fibrosis on autopsy and subsequent familial evaluation identified 
Brugada syndrome: x2 (A) and x10 (B) magnification of picro-sirius red staining 
shows extensive myocardial replacement with collagen (stained red) in the left 
ventricular wall from epicardium into mid-myocardium. There is also fine interstitial 
collagen surrounding individual myocytes (yellow). Mild fatty infiltration is also 
noted within the collagen areas. 4. Histopathological slides of an individual who 
exhibited right ventricular fatty infiltration on autopsy and subsequent familial 
evaluation identified Brugada syndrome: x4 (A) and x20 (B) magnification of 
haematoxylin and eosin stain of the right ventricular wall showing significant fatty 





5.5.4 Diagnosis of cardiomyopathy 
 
Only 2 families were diagnosed with an inherited cardiomyopathy based on the results of 
the familial evaluation; 1 dilated cardiomyopathy (DCM); and 1 HCM. The first case was of 
a 17-year-old boy who died in his sleep. The post-mortem revealed circumferential 
subendocardial haemorrhage with extensive myocardial fibrosis of the left ventricle. 
Evaluation of his relatives revealed a dilated, globally hypokinetic left ventricle in his 
mother and one of his sisters. The second case was of a 20-year-old male who died at 
rest. The post-mortem revealed a heavy heart (>500g) with LVH but no evidence of 
myocardial fibrosis or myocyte disarray. There was no documented history of hypertension 
or regular exercise. Familial evaluation revealed asymmetric septal hypertrophy in the 
context of a non-dilated left ventricular cavity in his father, raising suspicion of HCM. 
Unfortunately the father declined further investigations with CMR and genetic testing. 
 
5.5.5 Mutation analysis 
 
Mutation analysis in relatives with phenotypes suggestive of inherited cardiac conditions 
was undertaken in 17 out of the potential 21 families. In 2 families (1:HCM, 1:BrS), 
individuals declined genetic testing after counselling. In 2 LQTS families genetic testing 
was performed by their local geneticist. Due to the absence of co-existing atrio-ventricular 
block, mutation analysis was not performed in the family diagnosed with DCM.214 Of the 13 
families with BrS who underwent genetic testing, three carried pathogenic SCN5A 
mutations (R376H, H558fs, A1680T). Pathogenic mutations were also identified in the two 
LQTS families tested (E1784K and G840R in SCN5A) and in the CPVT family (A4556T in 
RYR2). Four of the identified mutations are previously reported as disease-associated 
(SCN5A R376H, A1680T, E1784K and RYR2 A4556T).218,219 One novel SCN5A mutation 
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(H558fs) is a deletion resulting in a frame-shift, while the other (G840R) is a missense 
mutation with in-silico confirmation of disease-causation.223,224 The post-mortem findings of 
the 6 families with a positive genotype are tabulated in table 17. 
 
Table 17: Detailed presentation of the characteristics of victims of sudden cardiac 
death, including post-mortem findings, and relatives diagnosed with a condition in 
families where the presence of an inherited arrhythmogenic syndrome was 












Clinical findings in relatives 
diagnosed with a hereditary 
arrhythmogenic syndrome 
  27 years 
  Female 






QTc (Bazett) of 479ms½ (65bpm) 
and non-sustained VT in father, in 
context of family history (Schwartz 
score 4.5). Brother has QTc of 
450ms½ (84bpm) with prolongation 
late in recovery post-exercise 
(Schwartz score 2). 
  34 years 
     Male 






Resting QT prolongation in 2 
daughters (Bazett QTc 497ms½ at 
70bpm and 490ms½ at 71bpm) 
with syncope in one consistent 
with Schwartz score 4 in both. 
17 years 
Male      
At rest 






sustained ventricular tachycardia 
in mother; bidirectional ventricular 
couplets and triplets in sister. 
  39 years 
     Male 
   Cycling 
Mitral valve 
prolapse          
(floppy mitral 




Type-1 Br phenotype post 
Ajmaline in father and brother of 
deceased.  Brother had 
experienced 2 episodes     of 
unheralded syncope. 
  30 years 
     Male 









Type-1 Br phenotype post 
Ajmaline in father and paternal 
aunt of deceased. Father exhibited 
inducible Br  phenotype and 
ventricular ectopy     post exertion 
during exercise test. 
  37 years 
     Male 





Type-1 Brugada ECG post 
Ajmaline in sister of deceased. 
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5.5.6 Prevalence of early repolarization 
 
Of the 157 relatives evaluated, 10.2% (n=16) exhibited the ER pattern in the inferior and/or 
lateral leads and less than 2% (n=3) demonstrated a slurred terminal QRS complex with a 
descending ST-segment, which is the ER pattern predominantly linked to the risk of 
sudden death in the general population.186 Although the prevalence of ER was higher in 
relatives without a diagnosis of arrhythmogenic syndrome or cardiomyopathy compared to 
relatives with a diagnosis, the difference did not achieve statistical significance (11.6% 
versus 5.6%, p=0.366). Only one family consisted of ≥2 relatives who exhibited ER. In that 
particular family the deceased’s post-mortem revealed mitral valve prolapse and no 
diagnosis was established after comprehensive cardiac evaluation of blood relatives. 
 
5.5.7 Immediate management 
 
All affected 36 relatives received appropriate life style modification and drug avoidance 
advice. Eleven patients were prescribed beta-blockers: 7 LQTS; 2 CPVT; 2 DCM. The two 
DCM patients were also initiated on an angiotensin converting enzyme inhibitor treatment. 
Prophylactic cardioverter defibrillators (ICD) were implanted in five patients: 3 BrS; 2 LQTS 




In a significant proportion of SCDs the pathologist may observe findings that are relatively 
common in the general population, or those that only partially fulfil diagnostic criteria for 
structural cardiac disease, leaving uncertainty with regard to causality and further 
management of the surviving relatives. In this study of 41 families of patients with SCD 
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with post-mortem findings of uncertain significance, 46% were diagnosed with a hereditary 
arrhythmogenic syndrome. This yield is similar to the diagnostic yield in our large, “true” 
SADS cohort, where primary arrhythmogenic syndromes accounted for 42% of deaths 
(p=0.703). (study IV) The causes of SCD were also similar, with BrS accounting for the 
majority of the diagnoses in both cohorts (34% in the cohort with post-mortem findings of 
uncertain significance versus 36% in the SADS cohort; p=1.00). Additionally, a similar 
proportion of the relatives evaluated in both the autopsy findings of uncertain significance 
and the SADS cohorts were diagnosed with a cardiac condition (23% versus 24%, 
p=0.906). This is of particular importance since by convention the absence of any cardiac 
pathology is regarded a prerequisite for the definition of a death as SADS.7,31 
 
5.6.1 Implications of autopsy findings of uncertain significance 
 
The causal effect of the autopsy findings is unclear. The authors offer four plausible 
hypotheses: 
 
(a) Innocent bystander 
 
Bicuspid aortic valve and floppy mitral valve are present in 1-2% of the general population 
and may represent innocent bystanders. Likewise, coronary atherosclerosis without 
significant narrowing of the arterial lumen and without macroscopic or microscopic 
evidence of acute or chronic ischaemia is common. It is well documented that the degree 
of coronary artery stenosis can be overestimated by the pathologists as a result of post-
mortem collapse of the vessel wall. This was also evident in our study of comparing the 
results of post-mortem evaluation between general and expert cardiac pathologist (study 
III), where coronary artery atheroma was considered a significant cause of death in 3 
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cases by the referring pathologist but was determined to be non-significant by our expert 
cardiac pathologist who reassigned all 3 cases as SADS deaths. Support for this 
hypothesis is evidenced by the fact that out of the 6 victims who exhibited minor coronary 
artery disease, 5 died at rest. Paradoxically, in the remaining case that died post exertion, 
familial evaluation diagnosed BrS in 5 relatives (Figure 16.1). Finally, foci of lymphocytes 
are common in the normal heart and a degree of myocardial inflammation may be the 
effect of prolonged resuscitation efforts in young individuals rather than evidence of 
myocarditis resulting in SCD. This is again highlighted in study III, where 4 out of 9 cases 
assigned a diagnosis of myocarditis based on the presence of myocardial inflammation by 
the referring pathologist, were reassigned to a diagnosis of SADS by our expert 
pathologist. 
 
(b) Primary cause of sudden cardiac death 
 
Most of the conditions identified at autopsy in our cohort have been associated with 
malignant ventricular arrhythmias and sudden death. Sudden cardiac death in both athletic 
and non-athletic individuals have been attributed to mitral valve prolapse and 
myocarditis.14 Similarly the absence of severe luminal narrowing of the coronary arteries 
does not preclude ventricular arrhythmias due to myocardial ischaemia,273 particularly as a 
result of coronary artery vasospasm274 and isolated fatty infiltration involving the cardiac 
conduction system has been implicated in sudden death of obese people.275 
 
(c) Trigger in the context of an arrhythmogenic syndrome 
 
Consideration must also be given to the fact that structural cardiac disorders may serve as 
triggers for malignant arrhythmias in the context of a coexistent inherited arrhythmogenic 
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syndrome. One-third of SCD cases in our cohort with minor coronary disease were 
subsequently attributed to an arrhythmogenic syndrome following familial evaluation. 
Current evidence suggests that the presence of coronary artery disease is an independent 
risk factor for LQTS-related symptomatic events.276 It appears likely that transient 
ischaemia alters the arrhythmic substrate in susceptible individuals, by reducing the 
threshold for after-depolarisations or increasing transmural dispersion of repolarization, 
both recognized mechanisms for arrhythmogenesis in ion-channel disease.277 
 
(d) Spectrum of arrhythmogenic syndromes 
 
There is mounting evidence that individuals with ion-channel defects may exhibit structural 
cardiac changes.277 The majority of BrS patients possess a structurally normal heart, 
consistent with the notion that this is a primary electrical heart disease. A minority, 
however, appears to exhibit evidence of ventricular wall motion abnormalities, ventricular 
dilatation, myocardial inflammation and fibrosis.278,279 Such structural abnormalities may 
be subtle and echocardiography may appear normal, requiring more sophisticated 
diagnostic tools including CMR, positron emission tomography, and endomyocardial 
biopsy.280,281 Several theories have been postulated to correlate ion-channel dysfunction 
with structural abnormalities, ranging from impaired excitation-contraction coupling and 
energy production to a hibernation-like state, which over time may even lead to 
intracellular lipid accumulation.277 Support for potential structural abnormalities in patients 
with BrS despite normal conventional imaging is also lent by the study of Nademanee et 
al. where the authors identified the anterior aspect of the RVOT epicardium as the 
substrate for the Brugada type 1 ECG pattern.282 Future correlation with detailed 
pathological evaluation of this area may provide further insights to the exact 
pathophysiology of BrS. 
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Additionally, there are reports in the literature of identical mutations presenting with either 
a cardiomyopathy or an arrhythmogenic syndrome phenotype, suggesting that structural 
and ion-channel defects may be part of a spectrum incorporating myocardial disease and 
primary arrhythmogenic syndromes. Mutations in the cardiac ryanodine receptor gene 
(RYR2), commonly implicated in CPVT, have been reported in individuals exhibiting an 
ARVC phenotype.283 Moreover, a mutation in the SCN5A gene, implicated in BrS, may 
present with arrhythmia, conduction disease and atrial or ventricular dilatation.284 
 
5.6.2 Left ventricular hypertrophy and myocardial fibrosis 
 
In our cohort isolated LVH and myocardial fibrosis were by far the most prevalent findings. 
Idiopathic LVH is an increasingly recognized entity in cases of SCD and was the only 
finding in almost a third of post-mortems in our athletic cohort (study II). It remains unclear 
at this stage whether it represents an innocent bystander, a pathological variant of 
physiological LVH in genetically predisposed individuals or part of the spectrum of HCM. 
Although LVH is a well-recognized feature of cardiovascular adaptation to exercise,57,72 in 
our study only 4 out of the 10 individuals exhibiting isolated LVH exercised on a regular 
basis. Data from the Framingham study also indicate that individuals with LVH have a four-
fold risk of sudden death compared to controls without LVH.285 In addition, experimental 
studies suggest that LVH alters ion-channel expression and function in a similar fashion to 
ion-channel disease, predisposing to re-entry arrhythmias and ventricular fibrillation.286 
Although in the majority of individuals such adaptations are unlikely to result in increased 
risk of arrhythmias, the development of LVH in an individual with an underlying hereditary 




Myocardial fibrosis also predisposes to malignant arrhythmias. Both the amount of fibrosis 
and the collagen texture appear to play a role in vulnerability to arrhythmia.287 Moreover, 
myocardial fibrosis may represent incomplete expression of underlying cardiomyopathy, 
including the recently recognized arrhythmogenic left ventricular cardiomyopathy. Finally, 
myocardial fibrosis has been reported in marathon runners and in cases of SCD in athletic 
individuals raising concerns whether prolonged arduous exercise can lead to repeated 
myocardial injury, necrosis and subsequent fibrosis. 
 
5.6.3 Early repolarization 
 
The prevalence of ER pattern in the inferior and/or lateral leads in our cohort was lower 
than that observed by Nunn et al., and comparable to the prevalence reported in healthy 
controls.188 More importantly, only 1 of the 41 families included more than one member 
with the ER pattern, offering little support to the theory of a potentially inheritable pro-
arrhythmic trait. 
 
5.6.4 The role of the cardiac pathologist 
 
This study further highlights the importance of accurate interpretation of the autopsy 
findings by the pathologist since false conclusions may misguide familial evaluation to a 
probable diagnosis of structural disorders or offer false reassurance to surviving relatives 
and dissuade physicians from initiating familial screening altogether, with potentially 
devastating consequences in future generations. Given the relative rarity of SCDs from 
inherited conditions and the challenges associated with their diagnosis, the authors 
propose that all cases of SCDs, and particularly SCDs in young (≤35 years) individuals, 
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where an inherited condition is suspected or diagnostic uncertainty remains, as to the 
cause of death, should be referred for further evaluation to an expert cardiac pathologist. 
 
5.6.5 Limitations of clinical evaluation of families 
 
The limitations of the current study reflect the limitations of our investigative protocol and 
predominance of BrS and are very similar to the limitations reported in chapter 4. As with 
the “true” SADS cohort the predominant diagnosis in the cohort of individuals with autopsy 
findings of uncertain significance was of BrS. The authors concede that given the relative 
novelty of the condition, the considerable impact of the higher intercostal leads in the 
diagnostic yield and the association of the Brugada phenotype with structural cardiac 
abnormalities, it is possible that some of the relatives exhibiting the Brugada phenotype 
did not have a genuine arrhythmogenic syndrome. However, all individuals who were 
diagnosed with BrS underwent comprehensive evaluation including a detailed 
echocardiogram and a significant proportion were subjected to CMR, based on the 
histopathologic features identified in the deceased, and none exhibited any evidence of 
structural cardiac anomalies. Further support for the presence of BrS is underscored by 
the genetic yield (25%) of pathogenic SCN5A mutations, which is similar to existing 
literature.106 
 
The omission of regular epinephrine testing in individuals without an established diagnosis 
despite comprehensive cardiac screening may have underestimated the prevalence of 
CPVT.81 Finally, in the families in whom a pathogenic mutation was identified, we were 
unable to perform post-mortem analysis in the tissues of the victims for confirmation of the 
genotype since no tissue was available by the time the relatives were evaluated in our 
clinic. 
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The majority of studies in patients with BrS have relied on the presence of the Type-1 ECG 
Brugada pattern in the conventional right praecordial leads with leads V1 and V2 placed 
on the 4th intercostal space. Shimizu et al.225 performed an eighty-seven-lead body surface 
potential mapping with simultaneous 12-Iead ECGs recordings in 25 patients with BrS and 
40 control patients. The amplitude of the ST segment was measured from all 87 leads, 
and an ST isopotential map was constructed. The maximum ST elevation was distributed 
in an area of the right ventricular outflow tract in all Brugada patients, and it was larger 
than that in control patients (0.37 ± 0.13 versus 0.12 ± 0.04 mV; p < 0.001). In 18 (72%) of 
the Brugada patients who exhibited the typical type-1 Brugada pattern in leads V1 and V2 
of the standard 12-lead ECG, the maximum ST elevation was observed on the level of the 
4th intercostal space. In the remaining seven patients only a mild saddleback-type ST 
elevation was seen in leads V1 and V2 on the 4th intercostal space but the typical Brugada 
phenotype was observed in leads V1 and V2 recorded on the second or third intercostal 
space. In those patients the maximum ST elevation was located on the second intercostal 
space. The authors concluded that leads V1-V3 should be recorded on both the 4th and 
the higher (2nd and 3rd) intercostal spaces, when BrS is suspected. 
 
A further study evaluated the usefulness of ECG recordings in the 3rd intercostal space.288 
The authors recorded ECGs in both the 4th and 3rd intercostal spaces in 17 patients with a 
diagnosis of BrS and 206 consecutive males, who acted as the control group. In the 
Brugada patients group the prevalence of the type-1 Brugada pattern increased from 
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23.5% to 64.7% when an ECG was recorded in the 3rd ICS. In the control group, the type-
1 Brugada phenotype was present in 1 (0.5%) individual at baseline ECG and 2 (1%) 
individuals at the higher intercostal leads. In only 1 of the 206 controls did a normal 
baseline ECG convert to a diagnostic pattern by placing leads V1 and V2 in the higher 
intercostal spaces. 
 
A subsequent study by Miyamoto et al.226 evaluated the prognostic value of the type-1 
Brugada phenotype recorded on the higher intercostal leads compared to the conventional 
4th intercostal space. The authors evaluated 98 male individuals with a diagnosis of BrS. 
They divided them in 3 groups: 68 individuals who had a spontaneous type-1 Brugada 
pattern in the standard V1 and V2 leads; 19 individuals who exhibited the type-1 ECG in 
the higher intercostal leads only; and 11 individuals who exhibited the type-1 pattern only 
during provocation testing with a class 1 antiarrhythmic. There were no significant 
differences in baseline clinical characteristics. During prospective follow-up of about 2 
years a similar proportion of cardiac events (documented VF, syncope or SADS) occurred 
in men with the Brugada pattern in the standard ECG leads and in men with the Brugada 
pattern in the higher intercostal leads (16% versus 11%; p=0.725). None of those who 
exhibited the Brugada pattern after provocation testing, only, suffered any cardiac events. 
Even in high-risk individuals with previous episodes of VF, subsequent cardiac events 
occurred in 44% of men with the Brugada pattern in the standard ECG leads and 50% of 
men with the Brugada pattern in the higher intercostal leads (p=1.00). In conclusion, men 
with a spontaneous type-1 Brugada pattern had similar prognosis, irrespective of whether 
the Brugada phenotype was identified in the conventional or the higher V1 and V2 leads. 
 
A number of studies have also assessed the impact of higher intercostal leads during 
provocation testing with class 1 antiarrhythmics.227,289,290 In the first study Sangwatanaroj 
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et al.227 performed a Procainamide provocation test in 10 SADS survivors (individuals who 
survived a cardiac arrest as a result of documented VF or polymorphic VT and subsequent 
clinical evaluation failed to identify an underlying cause) and 48 of their relatives who had 
a normal baseline ECG. Electrocardiograms were recorded with leads V1 and V2 recorded 
in both the 4th and the higher (3rd and 2nd) intercostal spaces. Thirteen spouses served as 
the control group. After the Procainamide infusion, the type-1 Brugada phenotype could be 
demonstrated in 7 SADS survivors (70%) and 7 (14·6%) relatives with the standard ECG 
and in 9 (90%) (P = 0·26) and 23 (47·9%) (P = 0·0004) with the additional six-lead ECG, 
respectively. All the controls were negative for the Brugada sign. Based on these results it 
appears that raising the position of the V1 and V2 leads increases the sensitivity of the 
Procainamide challenge in detecting the Brugada phenotype, without compromising 
specificity. It should be emphasized, however, that the sample sizes were small, 
particularly the control group, and all positive Procainamide tests were presumed to be 
true positive results. None of the individuals was subjected to genetic testing to confirm a 
pathogenic mutation. A study by Meregalli et al.289 reported on 160 Flecainide provocation 
tests performed in subjects considered to be at risk of BrS (n=82 as part of family 
screening). Of the 160 tests, 64 unmasked the diagnostic Brugada phenotype. All 
Flecainide tests were performed with the conventional ECG leads. The authors had the 
opportunity to perform ECGs utilizing the higher intercostal leads with leads V1 and V2 
placed in the 3rd intercostal space, in 47 of the 64 positive tests and in all of the negative 
tests. In 21 of the 47 (45%) individuals with a positive test, a type-1 ECG was only 
obtained when the 3rd intercostal leads were used, while in 26 of the 47 (55%) a type-1 
ECG was also recorded in the conventional leads. Of note, the proportion of mutation 
carriers was similar in both groups: 9/21 (43%) in the higher intercostal leads group and 
10/26 (38%) in the conventional leads group (p =	  0.8). 
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Finally, a recent study by Govindan et al.290 evaluated the utility of higher intercostal leads 
during Ajmaline testing for the diagnosis of BrS. The authors performed 183 Ajmaline tests 
in individuals suspected of having the BrS. All ECGs were performed with leads V1-V3 
placed at the conventional position. A repeat ECG was then performed with leads V1-V3 
placed in the 3rd intercostal space. Towards the end of the study the authors used a 15-
lead configuration, omitting lead V3 based on their own and others observation of its poor 
diagnostic yield,211 and utilizing 6 V1 and V2 leads placed in the 4th, 3rd and 2nd intercostal 
space. Of the 183 tests, 31 (17%) were positive based on the second consensus 
criteria.106 In all positive studies, at least one high lead became positive. In 13/31 (42%) 
cases, the type-1 ECG pattern could be observed only in the high right praecordial leads. 
Standard or high V3 were never positive before standard or high V1-V2. In seven patients, 
a type-1 pattern was seen in one standard and one high right praecordial lead (vertical 
relationship). The authors concluded that high V1-V2 leads are valuable for the diagnosis 
of BrS and appear to increase the detection rate by about 35%, without compromising 
specificity, either at baseline or during provocation testing. A vertical relationship of type-1 
ECG patterns also appears to have a similar implication to a standard horizontal 
relationship. Use of the conventional 12-lead ECG alone may therefore result in loss of 




There is a paucity of data relating to the impact of utilizing higher intercostal leads on the 
diagnostic yield of BrS during familial evaluation after a SADS death. The authors 
performed a study to compare the diagnostic yield of the Brugada phenotype utilizing the 
conventional V1 & V2 leads placed in the 4th intercostal space versus higher intercostal 
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leads (V1 & V2 placed in the 3rd and/or 2nd intercostal space) during comprehensive 
clinical evaluation. 
 
6.3 Personal contribution 
 
The author performed prospectively the clinical evaluation of all families, including 
performing or supervising, analyzing and databasing the majority of investigations (ECG, 
echocardiography, exercise treadmill test, Ajmaline provocation test and Holter 
monitoring). Collected data on the deceased including data on previous admissions or GP 





The study cohort included 31 families, comprised of 133 relatives, who received a 
diagnosis of SADS secondary to BrS or Brugada overlap syndrome during the studies in 
chapter 4 (“true” SADS families) and chapter 5 (autopsy findings of uncertain significance), 
where relatives had undergone a baseline ECG and Ajmaline testing, as appropriate, with 
both the conventional and higher lead configuration. Only families assessed in Prof S 




Family relatives were evaluated as per the methodology in chapter 4. As outlined in 
chapter 4, since the beginning of the thesis in October 2007 all individuals assessed in our 
cardiogenetics clinics were subjected to a baseline 12-lead ECG with leads V1 and V2 
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placed in the conventional 4th intercostal space as well as the 2nd intercostal space. 
Towards the end of the thesis ECGs were also performed with leads V1 and V2 placed in 
the 3rd intercostal space. Ajmaline provocation tests were also performed with the same 
ECG lead configuration. Ajmaline testing was considered the gold standard test for the 
diagnosis of BrS in the context of this study given the lack of alternative diagnostic tools 
and the limitations of genetic testing.106 As such all Ajmaline provocation tests were 




Data collection was performed as part of the clinical evaluation of the families as proposed 
by the Government in the 8th chapter of the National Service Framework for Heart 
Disease, which includes guidelines for early identification of individuals at risk of sudden 




Data interpretation and analyses were performed using SPSS software, version 14 (SPSS 
Inc., Chicago, IL, USA). Means and standard deviations (SD) or median and interquartile 
range (IQR) were calculated for continuous variables. Group differences are examined 
using t-test and Mann–Whitney U test for parameters with normal and non-normal 
distributions, respectively. Chi-square or Fisher’s exact test was used to test group 







6.5.1 Baseline ECG 
 
We compared baseline ECG features in leads V1 and V2 with leads placed in the 
conventional 4th intercostal and higher (3rd and/or 2nd) intercostal spaces (Table 18). 
Although raising the lead position did not affect the prevalence of ST-segment elevation 
(defined as ≥1mm of ST-elevation) to any significant degree, it increased considerably the 
prevalence of partial-RBBB and T-wave inversion. Of the 133 relatives, 56 exhibited the 
diagnostic type-1 Brugada phenotype. Only one individual had a highly suspicious 
baseline ECG with a type-1 Brugada pattern in lead V2. 
 
Table 18: Comparison of baseline ECG phenotypes in leads V1 and V2 with 
leads placed in the 4th intercostal space (IS) and higher intercostal spaces (2nd 
&/or 3rd IS) 





RBBB 2 (2%) 6 (4.5%) 0.282 
partial-RBBB 14 (11%) 64 (48%) <0.001 
Left atrial enlargement 1 (1%) 21 (15.8%) <0.001 
T-wave inversion in V1 62 (47%) 105 (79%) <0.001 
T-wave inversion in V2 11 (8%) 33 (25%) <0.001 
ST-elevation in V1 10 (8%) 9 (7%) 1.000 
ST-elevation in V2 24 (18%) 14 (11%) 0.114 
 
Abbreviations: RBBB: Right bundle branch block 
 
6.5.2 Ajmaline provocation test 
 
One hundred and ten of the 133 relatives were subjected to an Ajmaline provocation test, 
based on the criteria reported in the methodology of chapter 4. Due to the lack of a control 
group from the general population, the authors used as controls relatives within the 31 
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families. Controls comprised of family members who were investigated as part of the 
family screening but were not genetically linked to the family members diagnosed with 
BrS. The controls were selected from families where both parents of the deceased were 
assessed and subjected to Ajmaline testing and comprised of 18 spouses of a parent of 
the deceased with a diagnostic Brugada phenotype and 2 half-siblings. The final groups 
for comparison comprised of 90 individuals in the study group and 20 individuals in the 
control group. 
 
Of the 56 individuals diagnosed with BrS based on a positive Ajmaline provocation test, 
only 21 (38%) exhibited the Brugada phenotype in the conventional leads (4th IS). On the 
contrary, the great majority of individuals (n=53, 95%) demonstrated the type-1 Brugada 
phenotype in the higher intercostal spaces (Table 19). Utilising the higher intercostal 
leads, increased the sensitivity of Ajmaline testing from 38% to 95%. On Ajmaline testing 
the presence of a type-2 and/or type-3 Brugada pattern was more common in the higher 
intercostal leads although it did not achieve statistical significance (17% in 4th IS versus 
26% in higher IS; p=0.141). None of the relatives assigned to the control group fulfilled the 
diagnostic criteria for a diagnosis of Brugada syndrome. 
 
 
On a family level, of the 31 families with a diagnosis of BrS or BrS overlap syndrome, 15 
(48%) families had at least one relative who exhibited the diagnostic Brugada phenotype 
Table 19: Identification of the type-1 Brugada pattern at post-Ajmaline ECG with 
leads V1 and V2 placed in the 4th intercostal space (IS) and higher intercostal 
spaces (2nd &/or 3rd IS) 
Total No of Ajmaline 
tests (n=110) 
Type-1 Br phenotype 
at 4th IS 
Type-1 Br phenotype 
at higher IS 
p-value 
Relatives (n=90) 21 (23%) 53 (59%) <0.001 
Control group (n=20) 0 0 1.000 
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in the 4th intercostal space. All 31 families however, had at least one relative with the 
Brugada phenotype in the higher intercostal leads (p<0.001). 
 
There were no differences in the baseline characteristics of individuals (and families) 
exhibiting the type-1 Brugada phenotype in the higher intercostal leads alone, compared to 
those who exhibited the diagnostic phenotype in the conventional leads (Table 20). 
 
 
Abbreviations: SD: Sudden death 
 
In one family referred to our clinic after the death of a 23-year-old female at rest, both 
parents and the sister of the deceased were evaluated. The family was diagnosed with 
BrS based on a positive Ajmaline provocation test in the father. However the mother also 
exhibited the type-1 Brugada phenotype in a single lead, namely V2 placed in the 3rd 
intercostal space (Figure 17). Although the test was not considered diagnostic based on 
the absence of the type-1 Brugada pattern in ≥2 leads, the mother was advised to follow 
life-style modification advice as for BrS and further familial evaluation of both sides of the 
Table 20: Characteristics of cohorts with a positive Ajmaline test with leads V1 
and V2 placed in the 4th intercostal space (IS), compared to those with a 
positive test on higher intercostal leads (2nd &/or 3rd IS), alone. 
Family level Diagnostic at 4th IS 
n=15 
Diagnostic at higher IS 
n=16 
p-value 
Age of death (mean) 29 29 0.883 
Gender (Male) 87%   63% 0.220 
Family history of SD 
(<50 years) 
20% 25% 1.000 
Genetic yield 3/8 (38%) 1/8 (13%) 0.570 
Individual level Diagnostic at 4th IS 
n=21 
Diagnostic at higher IS 
n=35 
p-value 
Age (mean) 42 39 0.490 
Gender (Male) 57% 51% 0.785 
Symptoms 







family was recommended. Both parents were subjected to SCN5A genetic testing, which 
was negative in both cases. 
 
 
Figure 17: ECG rhythm strips during Ajmaline provocation testing in the three family 
members of the deceased. The family received a diagnosis of BrS based on the 
presence of the type-1 Brugada phenotype in leads V2 in the 3rd and the 2nd IS. The 
case highlights the challenges of accurately interpreting the ECG findings. The 
mother of the deceased exhibited a type-1 phenotype in lead V2 in the 3rd IS. 
Moreover, both the mother and the sister of the deceased exhibited the type-3 
phenotype in a number of leads. 
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Working on the assumption that all Ajmaline provocation tests were considered to 
represent true positive and true negative results and allowing for a single false positive 
test, the sensitivity of Ajmaline provocation testing improved from 38% to 95% by raising 
the position of leads V1 and V2, while the specificity reduced by a small degree only from 
100% to 98%. Respectively, negative predictive value (NPV) increased from 61% to 95% 




The majority of studies in patients with BrS have relied on the presence of the Type-1 ECG 
Brugada pattern in the conventional right pre-cordial leads, with leads V1 and V2 placed 
on the 4th intercostal space. Studies by Shimizu et al.225 and Hisamatsu et al.288 were the 
first to demonstrate that a significant proportion of patients with BrS exhibit the diagnostic 
type-1 phenotype in the higher intercostal leads only, with leads V1 and V2 placed in the 
3rd and/or 2nd intercostal space. Hisamatsu et al. demonstrated an impressive 3-fold 
increase of the prevalence of the type-1 Brugada pattern from 23.5% in the 4th ICS to 
64.7% in the 3rd ICS. A number of studies have also assessed the impact of higher 
intercostal leads during provocation testing with class-1 antiarrhythmics and have 
demonstrated an increase of the diagnostic yield between 35% and 45%.227,289,290 
 
To our knowledge this is the first study to report on the impact of higher intercostal leads in 
the context of systematic familial evaluation after a SADS death. In agreement with 
existing literature, we observed an increase of the diagnostic yield, based on the presence 
of the type-1 Brugada phenotype on Ajmaline provocation test, from 23% to 59%. While 
only 38% of individuals with a positive Ajmaline test exhibited the Brugada phenotype in 
the 4th IS, the great majority (95%) demonstrated the diagnostic pattern in the higher 
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intercostal leads. On a family level, of the families diagnosed with BrS 48% had at least 
one relative who exhibited the diagnostic Brugada phenotype in the 4th IS, while all 
families had at least one relative with the Brugada phenotype in the higher intercostal 
leads. Based on these observations the use of higher intercostal leads more than doubled 
our diagnostic yield of BrS. In absolute terms the diagnostic yield increased by almost 
107% on a family level and 105% on an individual level. 
 
6.6.1 Considerations relating to the use of the higher intercostal leads 
 
Utilizing higher intercostal leads raises the potential for an increased false positive rate 
that artificially raises the diagnostic yield of BrS. Such concerns are reinforced by the 
higher prevalence of partial-RBBB and T-wave inversion in leads V1 and V2 by raising the 
lead position, as demonstrated in the 133 individuals who had baseline ECGs with both 
lead arrangements (Table 18). Given the relatively small number of individuals diagnosed 
with the condition, when one considers the poor genetic yield, we were unable to correlate 
pathogenic mutations with Ajmaline test results. As such, in the absence of a gold 
standard test for the diagnosis of BrS all positive Ajmaline tests were presumed to 
represent true positive results. Our results are however in keeping with existing literature 
which has consistently demonstrated that higher intercostal leads increase the sensitivity 
without significantly compromising the specificity of the ECG in detecting the Brugada 
phenotype, particularly in the context of provocation testing with a calss-1 anti-arrhythmic. 
In our cohort, raising the position of leads V1 and V2 increased the sensitivity of Ajmaline 
provocation testing by a factor of 2.5, from 38% to 95%. Only one individual exhibited a 
potentially false positive Ajmaline test in the higher leads (Figure 17) resulting in a very 
modest reduction of the specificity from 100% to 98%. This specificity is similar to the 
173 
specificity of 94.4% quoted by Hong et al.178 for Ajmaline tests performed with the 
conventional leads in SCN5A mutation positive families. 
 
The 2005 Heart Rhythm Society and European Heart Rhythm Association consensus 
document recommends that this group be treated no different than those with ECG 
changes in standard leads.106 Evidence that the positive Ajmaline tests in the higher 
intercostal leads are likely to represent true positive results come from the study of 
Miyamoto et al.226 which demonstrated that men with a spontaneous type-1 Brugada 
pattern had similar prognosis, irrespective of whether the Brugada phenotype was 
identified in the conventional or the higher V1 and V2 leads. In addition, Meregalli et al.289 
reported on 47 individuals with a positive Flecainide test, who underwent provocation 
testing at both the conventional and higher intercostal leads. The authors reported a 
similar proportion of mutation carriers in both groups (43% in the higher intercostal leads 
group versus 38% in the conventional leads group; p=0.80). In our study comparison 
between individuals with a positive Ajmaline test in the conventional versus the higher 
intercostal leads did not identify any significant differences either at family or at individual 
level. Our overall genetic yield was similar to existing literature.106 
 




Patients with BrS who have survived a ventricular fibrillation cardiac arrest are 
recommended to receive an ICD for secondary prevention in light of the significant risk of 
recurrent events.106,171 The other recognized high-risk group recommended for an ICD 
consists of patients with symptoms secondary to a presumed self-terminating malignant 
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arrhythmia such as unheralded syncope, nocturnal agonal respiration and seizures, as 
well as the presence of a spontaneous type-1 Brugada ECG pattern. 172,174,291 A number of 
studies have evaluated the additional value of specialist ECG and invasive assessments 
such as electrophysiological studies for the induction of ventricular arrhythmias in risk 
stratification, although conclusions regarding their impact have been inconsistent. 170-176,291 
 
The first study relating to risk stratification in BrS was published in 2002 by Brugada et 
al.171 The authors reported on follow-up data of 334 patients with a diagnosis of BrS from 
an international registry. Based on the published manuscript a unified protocol was used 
during electrophysiological studies. The protocol used a single site of stimulation (right 
ventricular apex), three basic pacing cycle lengths (600, 500, and 430 ms), and induction 
of 1, 2, and 3 ventricular premature beats down to a minimum of 200 ms. A patient was 
considered inducible if sustained ventricular arrhythmias (ventricular fibrillation, 
polymorphic ventricular tachycardia, or monomorphic ventricular tachycardia lasting more 
than 30 seconds or requiring emergency intervention) were induced. The patients were 
grouped in individuals who were diagnosed after a cardiac arrest (group A; n=71), those 
who experienced episodes of syncope (group B; n=73) and asymptomatic individuals 
(group C; n=190). During 54±54, 26±36 and 27±29 months of mean follow-up, 
respectively, 62% of patients in group A, 19% of patients in group B and 8% of patients in 
group C had a new arrhythmic event defined as sudden death or documented ventricular 
fibrillation. Inducibility of ventricular arrhythmias during electrophysiological studies was an 
independent predictor of arrhythmia occurrence in all groups. Based on their results the 
authors quoted an incidence of malignant arrhythmic events of 13.7% per year in patients 
with aborted SCD and 8.8% per year in syncope patients. In asymptomatic individuals, a 
basal diagnostic ECG was a predictor of an arrhythmic event with 14% of individuals with a 
spontaneous type-1 Brugada pattern versus none of those who exhibited the Brugada 
175 
pattern only after provocation with a sodium channel blocker challenge, experiencing 
arrhythmia during follow-up. Of the asymptomatic individuals with a spontaneous Brugada 
pattern, a positive electrophysiological study was predictive of an arrhythmic event during 
follow-up. 
 
In a further study based on the same registry led by Brugada et al. a total of 547 patients 
with BrS but no previous episode of aborted SCD were followed-up for a mean of 2 
years.174 Forty-five patients (8.2%) suffered sudden death or documented ventricular 
fibrillation. Multivariate analysis identified the inducibility of a sustained ventricular 
arrhythmia during electrophysiological studies as the strongest predictor of future 
malignant events (RR 5.9, 95%CI 2.0-16.7; p<0.0001), followed by a history of syncope 
(RR 2.5, 95%CI 1.2-5.3; p=0.017). During logistic regression analysis inducibility during 
electrophysiological studies conferred a significant additional risk even to asymptomatic 
individuals with a normal baseline ECG, with 0.5% of non-inducible but 4.5% of inducible 
patients exhibiting an event during the mean follow-up of 2 years. Although the authors 
conceded that a longer follow-up study would be necessary to draw safe conclusions, the 
current study indicated that most patients with an established diagnosis of BrS who are 
inducible during electrophysiological studies, are at sufficient risk to justify the implantation 
of an ICD. 
 
In contrast to the registries led by Brugada et al.,171,174 two subsequent reports from 
national and international registries failed to demonstrate a correlation between a positive 
programmed ventricular stimulation test and an increased risk of arrhythmic events. A 
review of an Italian registry of 200 BrS patients, 86 individuals underwent programmed 
ventricular stimulation, which failed to detect increased risk of arrhythmic events.172 In this 
particular study the most reliable predictors of increased risk of sudden cardiac death were 
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the combination of a spontaneous ECG pattern and syncope (Hazard ratio of 6.4). The 
presence of a spontaneous ECG pattern on its own conferred an intermediate risk (Hazard 
ratio of 2.1), while the presence of syncope alone was not an independent predictor of risk.  
 
In 2010, the results of the FINGER registry were published.176 The registry included 1029 
consecutive individuals with a diagnosis of BrS, including previously published 
cohorts.292,293 An electrophysiological study was performed in 638 patients and included 
maximum of 3 ventricular extrastimuli delivered to 2 ventricular sites. During a median 
follow-up of 32 (14 to 54.4) months, 5% (n=51) of patients experienced cardiac events (44 
patients experienced appropriate implantable cardioverter defibrillator shocks and 7 died 
suddenly). The cardiac event rate per year was 7.7% in patients with aborted SCD, 1.9% 
in patients with syncope, and 0.5% in asymptomatic patients. In agreement with the Italian 
registry data, a spontaneous type-1 ECG conferred increased risk of arrhythmic events, 
whereas gender, family history of SCD, inducibility of ventricular tachyarrhythmias during 
electrophysiological study, and the presence of an SCN5A mutation were not predictive of 
arrhythmic events. In contrast to the Italian registry however, the FINGER study also 
identified the presence of syncope as an independent risk factor, with or without the 
presence of a spontaneous type-1 pattern. 
 
As all registry reports are based on multicentre data, criticism has been raised relating to 
the potential use of different stimulation protocols. However, results from single centre 
studies have also been conflicting even when similar stimulation protocols were utilised. 
Kanda et al.170 studied 34 symptomatic patients with a diagnosis of BrS based on the 
presence of a spontaneous type-1 ECG pattern. All patients underwent programmed 
ventricular stimulation at 2-ms and twice the diastolic threshold current from the right 
ventricular apex and the RVOT, using two basic cycle lengths (500 and 600 ms) and a 
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maximum of three premature beats. Patients were classified into two groups according to 
the inducibility of VF: 22 patients with induced VF requiring direct cardioversion for 
termination (Induced VF group) and 12 patients without induced VF (Non-induced VF 
group). The great majority of patients had an ICD in situ allowing for accurate 
documentation of arrhythmic events. During a mean follow-up of 38 months (range 1 to 
149 months) there was no significant difference in the recurrence of cardiac events 
(documented VF or sudden cardiac death) between the two groups (36% of induced VF 
versus 58% of non-induced VF; p=0.620).  
 
Finally, the PRELUDE (programmed electrical stimulation predictive value) registry, led by 
Priori et al.291 is the only prospective registry designed specifically to assess the value of 
programmed electrical stimulation and induction of ventricular tachycardia or fibrillation as 
a predictor of arrhythmic events in BrS. In contrast to some of the retrospective registries 
all the participants used the same stimulation protocol. During a median follow-up of 34 
months, 14 arrhythmic events (4.5%) occurred. Programmed electrical stimulation induced 
ventricular tachyarrhythmias in 40% of patients but was not a predictor of events at follow-
up. Of interest, of the 111 inducible patients who were subjected to a second 
electrophysiological study, in only 34% were the investigators able to reproduce the initial 
result. In agreement with previous registries, both the history of syncope and the presence 
of a spontaneous type-1 ECG were independent predictors of malignant arrhythmia, with 
the combination of the two being the strongest predictor (hazard ratio [HR]: 4.20). In 
addition, ventricular refractory period <200 ms (HR: 3.91) and QRS fragmentation (HR: 
4.94) were significant predictors of arrhythmias. 
 
Based on the interpretation of the available evidence, most specialist centres in the UK 
recommend the implantation of an ICD in patients with a diagnosis of BrS who have either 
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survived a cardiac arrest or have experienced symptoms secondary to documented or 
presumed self-terminating malignant arrhythmia. The great majority of asymptomatic 
patients are reassured of a relatively low risk of sudden death compared to the risk of 
potential complications from the ICD implantation and are treated conservatively with 
regular follow-up and the advice to report any new symptoms. Electrophysiological studies 
are rarely performed for risk stratification purposes, outside the context of research. 
Occasionally a negative study is used in very anxious asymptomatic patients in order to 




Based on our experience, we were concerned that in the majority of SADS families where 
a diagnosis of BrS was assigned following familial evaluation, the SADS victims were not 
known to have high-risk features. As such even if the victims had been evaluated prior to 
their death they would not have been offered an ICD and the death would not have been 
prevented. We therefore systematically reviewed the data available on individuals who 
experienced SADS due to presumed BrS, established following familial evaluation, to 
determine the prevalence of conventional high-risk characteristics. The objective of this 
study was to determine the prevalence of conventional risk factors for sudden death, such 
as VF arrest, symptoms secondary to a presumed self-terminating malignant arrhythmia 
and the presence of a spontaneous type-1 Brugada ECG, in sudden arrhythmic death 






7.3 Personal contribution 
 
The author performed prospectively the clinical evaluation of the 30 families assessed at 
Lewisham hosptial, including performing or supervising, analyzing and databasing the 
majority of investigations (ECG, echocardiography, exercise treadmill test, Ajmaline 
provocation test and Holter monitoring). Collected data on the deceased including data on 
previous admissions or GP consultations. The author reviewed all the data (form 







The study was performed in collaboration with an inherited cardiac disease clinic at St 
George’s Hospital. Between 2003 and 2010, 49 consecutive families (Lewisham hospital, 
n=30; St George’s hospital n=19) were diagnosed with BrS in the context of a SADS 
death. Families included in this study are families with a diagnosis of BrS from the studies 
reported in chapter 4 and chapter 5. The diagnosis was based on the identification of the 
type-1 Brugada pehenotype in at least 1 family member as previously described. A total of 
50 probands were included, with 1 family having 2 individuals with confirmed SADS. In 2 
families reviewed, the proband was older than 45 years. One of these 2 families had 
stereotypical Brugada ECG changes in more than 1 blood relative, thereby fulfilling the 




Familial evaluation and characteristics of probands 
 
Criteria for a familial diagnosis of BrS and a detailed account of the clinical evaluation of 
relatives have been reported in chapters 4 and 5. The presence of symptomatic events in 
each proband were determined by interviews with all evaluated family members and 
review of medical examiner and coroner reports. Structured clinical questions regarding 
the presence of prior transient loss of consciousness, seizures, or faints were 
retrospectively coded as probable syncopal events for the study analysis. All decisions 
regarding relevance of symptoms described were made by 2 investigators (Dr Hariharan 
Raju and Dr Michael Papadakis), with disputed results adjudicated by a senior 
investigator. The presence of an antemortem ECG for all probands was sought by detailed 
questioning of evaluated family members. This included review of history of attendance at 
health screening events, any hospital attendance, or presence of any prior cardiovascular 
symptoms (palpitations or chest pain) that may have prompted an ECG. When any family 
members suggested the SADS proband may have attended for medical assessment prior 
to his or her death, the existence of an antemortem ECG was questioned by written 
communication to any medical professional involved in the proband’s investigation. As with 
familial ECGs, all ECGs of probands taken before death were reviewed by 2 investigators 




Data collection was performed as part of the clinical evaluation of the families as proposed 
by the Government in the 8th chapter of the National Service Framework for Heart 
Disease, which includes guidelines for early identification of individuals at risk of sudden 





Data interpretation and analyses were performed using SPSS software, version 14 (SPSS 
Inc., Chicago, IL, USA). Means and standard deviations (SD) were calculated for 
continuous variables. Group differences are examined using t-test. Chi-square or Fisher’s 
exact test was used to test group differences of proportions. A value p<0.05 was 






In total, 202 blood relatives of probands were cardiologically evaluated and contributed to 
the reported proband histories. Details of associated familial evaluation are provided in 
Table 21. 
 
Table 21: Breakdown of SADS Familial Evaluation 
Number of family members evaluated 202 
Mean no. evaluated per family ± SD 4.0±2.4 
Total diagnosed with BrS 83 
Mean no. Diagnosed with BrS per family ± SD 1.7±1.1 
 
Demographic characteristics and reported symptoms in the included probands are 
summarized in table 22. The mean age of death of probands was 29.1±10.6 years (range 
4 to 56 years). A predominance of male BrS deaths was noted (41 male; 82%). 
Circumstances of death were obtained for 46 probands. Of these, 18 deaths (39%) 
occurred during sleep, with a further 19 (41%) at rest during the daytime; only 5 (11%) 
occurred during or immediately after significant exertion. 
182 
Table 22: clinical characteristics of Sudden arrhythmic death syndrome probands 
with familial diagnosis of Brugada syndrome 
Clinical Presentation Syncope Asymptomatic Unknown 
No of probands 9 36 5 
Male/Female 5/4 31/5 5/0 
Age, yrs 29±16 29±10 31±6 
Type-1 BrS pattern/no. of ECGs available 0/2 1/3 0/0 
Family history of prior SCD 1 (11) 6 (17) 0 (0) 
Died in sleep or rest 8 (89) 28 (78) 1 (20) 
Definite mutation/SCN5A analysis 1/5 4/22 1/1 
 




Details of families for whom SCN5A mutation analysis was undertaken (n=28) are given in 
table 17. Of the 5 families with unequivocal mutations, 2 have mutations that have 
previously been reported as disease causing (E1784K) and 3 have highly probable novel 
mutations (I1377V, D349H and H558fs). Overall, unequivocal mutations have been found 
in 18% of families for whom SCN5A mutation analysis was undertaken. 
 
Risk profile of probands 
 
Antemortem ECGs were available for 5 probands (Figure 18), 1 of whom demonstrated a 
spontaneous type 1 pattern (Figure 18A) and was taken during presentation with 
gastrointestinal symptoms in a previously asymptomatic individual. A further proband had 
evidence of a prior resting type 3 Brugada pattern in just 1 right ventricular lead (Figure 
18B). Both of these ECGs were taken more than 1 year before each proband’s terminal 
event. None of the probands had undergone prior provocation testing for investigation of 
inducible Brugada ECG pattern or invasive electrophysiological assessment; none had a 
pre-established personal or familial diagnosis of BrS or other inherited cardiac disease. 
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Figure 18: Antemortem ECGs in                                                                                         
5 SADS probands with BrS. 
(a) The sole spontaneous type-1                                                                              
antemortem ECG seen in our                                                                                    
cohort of SADS probands                                                                                             
with BrS. 
(b) An antemortem borderline                                                                                      
type-3 Brugada phenotype                                                                                           
seen in lead V2 only.                                                                                                                  
(c) A non-diagnostic antemortem                                                                                   
adult ECG.                                                                                                                          
(d) An antemortem ECG taken at                                                                                   
age 8 years, with no spontaneous                                                                         
Brugada phenotype.                                                                                                          
(e) An antemortem ECG taken at                                                                                       












Probands’ symptoms before death were reported reliably by family members in 45 cases, 
with the remainder uncertain of any prior medical history or symptoms. Only 9 of these 45 
probands (20%) were reported to have experienced at least 1 syncopal episode before the 
fatal event. Seven probands (14%) had a prior family history of premature SCD, 1 of whom 
also had a personal history of syncope. Fifteen probands (30%) had either a prior family 
history of SCD or personal reported history of syncope. Among those who were previously 




Current data regarding risk stratification in patients with BrS have predominantly been 
determined on the basis of short- and medium-term prospective cohort observation of 
those identified in life. The FINGER study remains the largest cohort studied thus far, with 
1,029 consecutive patients and indicates that a prior cardiac arrest, spontaneous type-1 
ECG, and syncope were the only independent indicators of arrhythmic risk in patients with 
the Brugada ECG.176 This is a valuable tool in terms of primary prevention in a cohort 
setting. It is however less useful during consultation with individual families as the majority 
of sudden deaths in BrS are likely to occur in individuals at low risk, who comprise the 
overwhelming majority of individuals with BrS. In our cohort of SADS probands with BrS, 
only 18% (9 of 50) had a confirmed prior syncopal event, as determined by reported 
symptoms and medical history from relatives. This suggests that the majority of sudden 
deaths in BrS occurred in asymptomatic individuals. The absence of symptoms, however, 
does not necessarily ensure absence of significant prior arrhythmia. An observational 
study of ICD interrogations in 19 patients with BrS and prior aborted sudden death 
detected 64 episodes of ventricular fibrillation, 26 of which were asymptomatic by virtue of 
them being nocturnal and self-limiting, requiring no device discharge.106 This evidently 
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limits the sensitivity of reported symptoms as a marker of prior ventricular arrhythmias. 
Furthermore, the specificity of syncope for ventricular arrhythmias among patients with BrS 
may be limited by the observation that there is a preponderance of other aetiologies of 
syncope, including increased susceptibility to significant vasovagal responses with head-
up tilt testing.294 
 
Although ECGs were available for a minority of probands, only 1 demonstrated a 
spontaneous type-1 pattern, calling into question the utility of its absence as a marker of 
low risk. The limited value of the ECG as a risk marker for SADS is further underlined by 
the knowledge that in the majority of Brugada gene carriers it may be normal or fluctuate 
between normal and the Brugada pattern.158,168,169 This has important implications in the 
context of tertiary referral centres where individuals are likely to be evaluated once or at 
best on a small number of occasions. 
 
Of the total cohort, only 18% were identified as fulfilling 2005 consensus106 criteria for ICD 
implantation on the basis of prior syncope. A further 14% may have warranted risk 
stratification with electrophysiological study according to the consensus criteria because of 
the presence of a type-1 ECG before death (1 of 50) or a family history of prior SCD (6 of 
50). Hence, current markers of risk for cardiac events and sudden death would have been 
insensitive, with at least 68% of our cohort categorized as low risk. Therefore, these 
markers may not have predicted the BrS deaths, even if a diagnosis of BrS had already 
been established. Current data suggest that these asymptomatic individuals’ risk would 
have been low, <1% per year,176 even if a spontaneous type-1 ECG pattern was seen. 
Given that current treatment is limited to ICD implantation, with its inherent complications 





Despite being the largest cohort of its kind reported, this study remains limited by the 
relatively small number of SADS probands with BrS included. Only 5 probands had a 
documented prior ECG in this study. Hence, it is difficult to make judgments on the 
presence or absence of a spontaneous type 1 Brugada ECG in the absence of prior 
investigation. This is an important consideration, given its apparent importance in risk 
stratification,106 although syncope is a much more significant risk factor.176 Unsurprisingly, 
in light of their predominantly asymptomatic status, none of the SADS probands had 
undergone comprehensive cardiological evaluation before the terminal event. It is also 

















CONCLUSIONS OF THE THESIS 
 
The thesis uses an integrative approach, involving clinical and laboratory disciplines, in an 
effort to improve our understanding of SADS and avert further deaths. The incorporation of 
data from the office of national statistics, the evaluation of cardiac tissue by a cardiac 
pathologist, the systematic clinical evaluation of family relatives in a specialist setting and 
the input of a clinical geneticist provide a comprehensive investigation of SADS. 
 
The studies of the Office of National Statistics data (chapter 1) and the post-mortem 
evaluation of 118 athletic individuals (chapter 2) underscore the impact of SADS, which 
contributes a significant number of deaths per annum in the UK.  
 
Evaluation of one of the largest cohorts of SADS families reported in the literature, 
confirms that a significant proportion of SADS deaths are caused by an underlying primary 
arrhythmogenic syndrome, highlighting the importance of recognition of such deaths and 
screening of all first-degree family relatives, to identify those at risk and avoid further 
tragedies. Given the novelty of some of the conditions implicated in SADS and their 
inherited nature we would recommend that familial evaluation be performed in specialist 
centres that adopt our “one-stop-shop” model. Our thesis also underscores the need for 
increased awareness among primary care physicians and specialists alike, to ensure 
recognition of cardiac conditions in young people since warning symptoms often precede 
SCD. Physicians should be vigilant since malignant arrhythmias might masquerade as 




In contrast to published cohorts, this study identified BrS, a fairly novel primary 
arrhythmogenic syndrome, as the predominant cause of SADS. Our study highlights the 
value of higher intercostal V1 and V2 leads in the diagnosis of BrS, predominantly by 
increasing the sensitivity of the Ajmaline provocation test in detecting silent carriers. Based 
on our results we would recommend that all relatives of SADS victims, where no cardiac 
pathology is identified should undergo a baseline ECG and Ajmaline provocation testing 
with leads V1 and V2 placed in both the conventional and higher intercostal spaces. 
 
Moreover, this thesis highlights certain knowledge gaps in our understanding of BrS, 
particularly in respect to risk stratification for sudden death and the potential detrimental 
effect of exercise. Our findings suggest that the great majority of SADS victims due to 
presumed BrS do not fulfill current criteria for consideration for an ICD. This places 
evaluating physicians in a difficult position, given the limited therapeutic options, and calls 
for an open-minded approach when advising patients relating their risk of sudden death. 
As more therapeutic strategies become available the use of ICD implantations will be 
limited to the patients at highest risk. In almost 10% of individuals affected by BrS, 
exercise can provoke the Brugada ECG phenotype and even result to ventricular 
extrasystoles during the recovery period, suggesting that is some cases exercise could be 
a potential trigger of malignant arrhythmias. 
 
The comprehensive familial evaluation of victims of SCD with autopsy findings of uncertain 
significance has led the authors to re-evaluate the definition of SADS. Our results suggest 
that any death with autopsy findings that do not meet conventional criteria for structural 
heart disease should be considered a SADS death and first-degree relatives should 
undergo comprehensive evaluation including screening for primary arrhythmogenic 
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syndromes. This is of particular importance since by convention the absence of any 
cardiac pathology has been regarded a prerequisite for the definition of a death as SADS.  
 
Finally, our collaboration with a specialist cardiac pathologist has highlighted the 
importance of an expert cardiac pathology service for the evaluation of victims of SCD and 
particularly SCD in young (≤35 years) individuals, where an inherited condition is 
suspected. Accurate interpretation of the autopsy findings is of utmost importance since 
false conclusions may misguide familial evaluation or offer false reassurance to surviving 
relatives and dissuade physicians from initiating familial screening altogether, with 
potentially devastating consequences in future generations. A prime example of the 
complexity associated with the interpretation of post-mortem findings and the potential 
implications is the entity of idiopathic LVH, which is increasingly recognised. Based on the 
results of our studies idiopathic LVH can be misinterpreted as HCM but may be associated 














FUTURE WORK STIMULATED BY THE THESIS 
 
The thesis has contributed to the existing scientific knowledge in the field of SADS but at 
the same time it has highlighted important scientific gaps that should further be explored in 
future projects. Our results are based primarily on clinical evaluation of family relatives with 
very limited contribution from genetic studies and in particular molecular autopsy. Existing 
studies have demonstrated that molecular autopsy can contribute to the diagnostic yield, 
although poor quality DNA samples, time-consuming techniques, financial burden and 
poor genetic yield hinder its widespread application. As such the field of molecular 
autopsy, particularly utilising fairly novel techniques such as next generation sequencing, 
remains largely unexplored. 
 
It is clear from this study that our knowledge of risk stratification in BrS is limited and 
further studies that will explore novel risk markers are essential. Most studies seem to 
conclude that induction of VT or VF during electrophysiological testing is not a predictor of 
risk for SADS. Although novel ECG indices such as the width of the S-wave in V1, the 
amplitude of the ST-segment in V2 and fragmentation of the QRS complex have been 
suggested, these remain to be tested in large, prospective cohorts.291,295-297 
 
Another potential area of interest which requires further exploration is the utility of Ajmaline 
provocation testing and the higher intercostal leads in diagnosing BrS. Given the impact of 
the higher intercostal leads and the potential implications of labelling an individual with a 
diagnosis of BrS it is imperative that we assess within the context of a large cohort: 1. The 
sensitivity and specificity of Ajmaline provocation test in the higher intercostal leads within 
a genotype positive population; 2. The sensitivity and specificity of higher intercostal leads 
(at baseline and during provocation testing) within a control cohort from the general 
191 
population; 3. Assess the influence of certain demographic factors such as gender; and 4. 
Assess the test-retest reproducibility of Ajmaline provocation testing. 
 
Our study also confirmed the existence of idiopathic LVH, which was identified in a 
significant proportion of athletic individuals and individuals with autopsy findings of 
uncertain significance. We also demonstrated that idiopathic LVH may be associated with 
a familial diagnosis of HCM and primary arrhythmogenic syndromes and formulated a 
number of potential hypotheses as to the contribution of the hypertrophy in the sudden 
death. However, we did not have the opportunity to perform molecular autopsy in the 
victims and our numbers were fairly limited. A large study is required to clarify the exact 
significance of idiopathic LVH. Such a study should prospectively perform detailed 
histopathological evaluation of SCDs with idiopathic LVH, associated molecular autopsy 
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Appendix 1: Abbreviations 
 
ACE-i:  angiotensin converting enzyme inhibitors  
ARVC: arrhythmogenic right ventricular cardiomyopathy 
AV:  aortic valve 
BrS:  Brugada syndrome 
BSA:  body surface area 
CI:  confidence interval 
CM:  cardiomyopathy 
CMR:  cardiac magnetic resonance imaging 
CPVT: catecholaminergic polymorphic ventricular tachycardia 
CRY:  Cardiac Risk in the Young 
CTCA: computed tomography coronary angiography 
DCM:  dilated cardiomyopathy 
DNA:  deoxyribonucleic acid 
ECG:  electrocardiogram 
HCM:  hypertrophic cardiomyopathy 
ICD:  implantable cardioverter defibrillator 
ICD-9: International Classification of Diseases-ninth edition 
ICD-10: International Classification of Diseases-tenth edition 
LBBB:  left bundle branch block 
LQTS: long-QT syndrome 
LVH:  left ventricular hypertrophy 
LVNC: left ventricular non-compaction 
LVWT: left ventricular wall thickness 
NCEPOD: National Confidential Enquiry into Patient Outcome and Death 
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ONS:  Office of National Statistics 
pRBBB: partial right bundle branch block 
PCR:  polymerase chain reaction 
PolyPhen: polymorphism phenotyping 
QTc:  corrected QT-interval 
RBBB: right bundle branch block 
SADS: sudden arrhythmic death syndrome 
SCD:  sudden cardiac death 
SD:  standard deviation 
SIFT:  sorting intolerant from tolerant 
SQTS: short-QT syndrome 
UK:  United Kingdom 
US/USA: United States of America 
VF:  ventricular fibrillation 
VT:   ventricular tachycardia 












Appendix 2: Definitions 
 
Sudden death: Unexpected death (within 1–12 hours of apparent well being) from natural 
causes, of an apparently healthy individual, with no prior cardiac disease. 
 
Sudden cardiac death: Sudden death where no extra-cardiac pathology is identified at 
post-mortem examination and a cardiac disease is identified or presumed as the most 
probable cause of death. 
 
Sudden arrhythmic death syndrome: Sudden death where no definitive cardiac or extra-
cardiac cause is identified despite detailed histopathological examination and toxicology 
screen. The death is presumed to be secondary to a malignant cardiac arrhythmia. 
 
Athletic individual: An individual who participates in at least 2 hours per week of organised 
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Aims In the UK, the true impact of cardiac and sudden death in the young (!35 years) is speculative. The authors critically
appraised the office of national statistics (ONS) data for causes of death in the 1–34 years age group in England and
Wales in an attempt to present an estimate of the incidence of such deaths and their underlying causes.
Methods
and results
The investigators analysed the ONS mortality data for 2002–2005, inclusive. International classification of diseases-10
codes representing possible cardiac deaths were selected and divided into four classes; A1: definite cardiac deaths
with no structural heart disease identified at post-mortem, A2: definite cardiac deaths with structural heart
disease identified at post-mortem, A3: definite cardiac deaths with indeterminate cause, and B: possible cardiac
deaths. Analysis of the data revealed an average of 419 (SD 16.5) definite cardiac deaths per annum (Class
A1 þ A2 þ A3) equating to 1.8 per 100 000 per year (SD 0.08) or 8 deaths/week. There were also 433 (SD 6.2)
deaths per year in class B which comprised primarily of deaths from drowning and epileptic seizures. The most preva-
lent causes were ischaemic heart disease (33.5%), cardiomyopathies (27%), sudden arrhythmic death syndrome
(14%), myocarditis (11%), valvular heart disease (5%), and hypertensive cardiomyopathy (2%).
Conclusion Our findings suggest that the number of cardiac and sudden deaths in the young identified is sufficiently high to
command attention even without the inclusion of potential misclassifications (Class B). Awareness of such deaths
among primary-care physicians, pathologists, and coroners should be raised to ensure that those at risk are identified
and further tragedies are avoided.
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Keywords Sudden cardiac death † Sudden arrhythmic death syndrome † Death certificates † Epidemiology
Introduction
Sudden cardiac death accounts for 50% of cardiovascular mortality
with an estimated annual toll of 300 000 deaths in the USA and
60 000 deaths in the UK.1,2 The majority of sudden cardiac
deaths are of ischaemic aetiology secondary to atherosclerotic
coronary artery disease and affect the older section (.35 years)
of the population.3 In a significant proportion of sudden deaths,
no specific cause is identified despite detailed histopathological
examination and toxicology screen, and a diagnosis of sudden
arrhythmic death syndrome (SADS) is advocated.3,4 The
recognition of such deaths is of utmost importance since evalu-
ation of first-degree blood relatives of the deceased commonly
results in the identification of an ion-channel disorder and less fre-
quently a cardiomyopathy in just over half of families evaluated,
thereby providing a potential cause of death and identifying surviv-
ing relatives at risk.5,6
The epidemiology of sudden cardiac death in the young (!35
years) is less well established. A population-based study in
Minnesota reported an incidence of 6.2 per 100 000 per year
among residents aged 20–40, whereas an autopsy review of US
military recruits aged 18–35 revealed a rate of 13 per 100 000
* Corresponding author. Tel: þ44 2087255939, Fax: þ44 2087253328, Email: ebehr@sgul.ac.uk
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.







recruit-years.7,8 Studies in the young athletic population in Italy and
the USA have suggested much lower rates of sudden cardiac death
with an incidence of 2.1 per 100 000 per year and 0.5 per 100 000
per year, respectively.9,10 Inherited cardiomyopathies are the com-
monest cause of sudden cardiac death in athletes, whereas coron-
ary artery pathology including coronary artery anomalies and
atherosclerotic disease predominate in the non-athletic popu-
lation.7–9,11 The reported frequency of structurally normal
hearts (SADS) varies widely, ranging from 3% in American young
athletes to 35% in US military recruits.8–12
In the absence of a systematic national registry documenting
sudden cardiac deaths in the young, the true impact of such fatal-
ities in the UK is speculative. The objective of this study was to
examine and critically appraise the office of national statistics
(ONS) data for causes of death in the 1–34 years age group in
England and Wales in an attempt to present an estimate of the inci-
dence of sudden cardiac death and underlying cardiac causes.
Methods
The ONS is the government agency responsible for compiling, analys-
ing, and disseminating many of the UK statistics including periodic
census of the population and health statistics.13 The data used in
the mortality statistics are derived from information obtained by the
doctor certifying the death, the coroner, and details supplied by
the informant to the Registrar. The deaths in males and females are
reported at 5-yearly age intervals. The causes of death are registered
according to the International Classification of Diseases-10 (ICD-10).14
The investigators analysed the ONS mortality data stating the cause
of death for England and Wales for four consecutive years 2002–2005,
inclusive. Five of the ICD-10 chapters were included in the analysis
(Table 1). Within these chapters, two of the senior authors (E.R.B.
and M.N.S.) scrutinized the ICD-10 classification codes to identify
codes that may represent cardiac deaths. Data were then summed
from the existing age subgroups to include deaths of individuals from
the age of 1 year to the age of 34 years. The selected ICD-10 codes
were subsequently divided into four classes as deemed relevant by
the investigators (Table 2): Class A1: definite cardiac deaths with no
structural heart disease identified at post-mortem representing
SADS; Class A2: definite cardiac deaths with structural heart disease
identified at post-mortem comprising sudden and non-sudden deaths
with likely causation by structural heart disease; Class A3: definite
cardiac deaths with indeterminate cause comprising sudden and non-
sudden deaths where the presence or absence of underlying heart
disease was either not recorded or ill defined; and Class B: possible
cardiac deaths since a proportion of these deaths may represent mis-
classifications of cardiac deaths and in particular SADS as epilepsy or
drowning. Where there was disagreement relating to the class of an
ICD-10 code, a third senior author (S.S.) was consulted. Although
the great majority of deaths referred to ‘natural causes’ (non-
accidental, non-malicious), a small proportion of the total cohort is
likely to represent accidental deaths since ICD-10 codes W65–W74
from Chapter XX representing accidental drowning and submersion
were included in Class B.
Incidence rates were calculated based on the ONS census data of
the resident population for individuals aged 1–35 years in England
and Wales. Data were further analysed according to age subgroup
and gender in order to identify potential trends or gender differences.
Crown copying material is reproduced with the permission of the
controller of Her Majesty’s Stationery Office.
Statistical analysis
Data manipulation and analysis were undertaken using SPSS software,
version 14 (SPSS Inc., Chicago, IL, USA). Data are expressed in means
and standard deviations. Annual mortality incidence per 100 000 was
calculated as the mean of the 4 years using the following type:
(100 000 ! number of deaths)/population size. x2 or Fisher’s exact
test was used to test group differences of proportions.
Results
The number of deaths in the 1–34 years age group is reported in
Table 3 according to class and year of death. Analysis of the ONS
data revealed an average of 419 (SD 16.5) definite cardiac deaths
per annum (Class A1 þ A2 þ A3) equating to eight young
cardiac deaths per week in England and Wales. On the basis of
the average estimated size of the resident population of
23 564 050, these data indicate an incidence of young cardiac
death of 1.8 (SD 0.08) per 100 000 per year. There were also an
average of 433 (SD 6.2) deaths per year, corresponding to more
than 8 deaths/week, in Class B which comprised primarily deaths
from drowning, epileptic seizures, and other ill-defined causes of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Examples of the most frequent International
Classification of Diseases-10 codes included in each class
(presented in order of frequency)
Class ICD-10 code
Class A1 R96: other sudden death, cause unknown
I49.9: cardiac arrhythmia, unspecified
I46.1: sudden cardiac death, so described
I45.6: pre-excitation syndrome (WPW)
Class A2 I21.9: acute myocardial infarction, unspecified
I25.1: atherosclerotic heart disease
I42.0: dilated cardiomyopathy
I42.9: cardiomyopathy, unspecified
Class A3 I50.9: heart failure, unspecified
I51.9: heart disease, unspecified
I50.1: left ventricular failure
I50.0: congestive heart failure
Class B G40.9: epilepsy, unspecified
G41.9: status epileptics, unspecified
W69: drowning and submersion while in natural water
J46: status asthmatics
Table 1 List of the World Health Organisation
international classification of diseases-10 chapters
included in the analysis16
Chapter VI Diseases of the nervous system
Chapter IX Diseases of the circulatory system
Chapter X Diseases of the respiratory system
Chapter XVIII Symptoms, signs, and abnormal clinical and
laboratory findings, not elsewhere classified
Chapter XX External causes of morbidity and mortality






mortality (Figure 1). There was no significant variation in the
number of the resident population or the number of deaths per
year.
The most prevalent causal cardiovascular pathology was ischae-
mic heart disease comprising one-third (33.5%) of the definite
cardiac deaths (A1 þ A2 þ A3). Although the majority of ischae-
mic deaths (56%) were attributed to acute myocardial infarction
(ICD-10 code: I21.9), in a significant proportion (32%), the pres-
ence of atherosclerotic heart disease alone (ICD-10 code: I25.1)
was documented as the principal cause of death, comprising 19%
and 11% of the definite cardiac deaths, respectively (Figure 2). Car-
diomyopathies were the second commonest cause of cardiac
death corresponding to 27% of definite cardiac deaths in the
cohort with dilated and hypertrophic cardiomyopathies accounting
for 12% and 5% of the deaths, respectively. Sudden arrhythmic
death syndrome accounted for 14% of definite cardiac deaths fol-
lowed by myocarditis (11%), valvular heart disease (5%), and
hypertensive cardiomyopathy (2%) (Figure 2).
Causes of death by gender and age
Definite cardiac deaths (Class A1 þ A2 þ A3) were more preva-
lent among males with a male to female ratio of 2.4 : 1. The only
pathology associated with a statistically significant difference
between the male and female gender was ischaemic or potentially
ischaemic causes which accounted for 22% of all deaths in males
but only 13% in females (P, 0.001). The same gender difference
was also observed for possible cardiac deaths (Class B) with a
male to female ratio of 2.0 : 1. Deaths attributed to epilepsy com-
prised a greater proportion of female deaths (male vs. female; 22%
vs. 31%, P, 0.001), whereas drowning-related deaths were more
prevalent among males (9% vs. 4%, P, 0.001) (Figure 3).
There was a rising incidence of definite cardiac deaths with
advancing age, with individuals "30 years old having a 10-fold
risk compared with children aged ,10 years. The only underlying
causes of definite cardiac deaths exhibiting a significant age trend
were ischaemia and cardiomyopathies. Ischaemic deaths exhibited
an increasing trend with advancing age, accounting for almost
one-third (31%) of all deaths in the 30–34 years age group but
Figure 1 Causes of death in the young expressed as percen-
tage of the total number of deaths in Class B (possible cardiac
deaths). SIDS, sudden infant death syndrome.
Figure 2 Causes of cardiac death in the young expressed as
percentage of the total number of definite cardiac deaths
(A1 þ A2 þ A3). CM, cardiomyopathy; DCM, dilated cardiomyo-
pathy; HCM, hypertrophic cardiomyopathy; HD, heart disease;
SADS, sudden arrhythmic death syndrome.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Number of deaths according to class per year






Mean mortality rate per 100 000
per annum (SD)
2002 2003 2004 2005
A1 60 50 57 61 228 57.00 (4.97) 0.24 (0.02)
A2 363 358 324 324 1369 342.25 (21.17) 1.45 (0.09)
A3 19 20 21 20 80 20.00 (0.82) 0.09 (0.00)
A1 þ A2 þ A3 442 428 402 405 1677 419.25 (19.10) 1.78 (0.08)
B 438 424 434 436 1732 433.00 (6.22) 1.84 (0.03)
Total
(A1 þ A2 þ A3 þ B)
880 852 836 841 3409 852.25 (19.67) 3.62 (0.08)






only 1% in children aged ,10 years (P, 0.001). In contrast,
cardiomyopathy-related deaths peaked during adolescence,
accounting for a greater proportion of deaths at the 10–19
years age group (18%) and accounting for only 11% of deaths in
the 30–34 years age group (P ¼ 0.001) (Figure 4).
A similar trend was observed with possible cardiac deaths in
Class B, with individuals 30–34 years old having a five-fold risk
compared with children aged ,10 years old. Underlying causes
exhibiting a statistically significant age trend included deaths attrib-
uted to epilepsy and drowning. Epilepsy-related deaths peaked in
the second and third decades of life, accounting for almost
one-third of deaths in the 10–19 and 20–29 years age groups
(P, 0.001). In contrast, drowning exhibited a reverse trend with
age, accounting for 21% of deaths in children aged ,10 years
but only 3% in individuals !30 years old (P, 0.001) (Figure 4).
Discussion
According to the ONS data, the incidence of cardiac death in the
young in England and Wales is 1.8 per 100 000 per year, which cor-
responds to eight young lives per week. This figure is lower than
those documented in retrospective studies of sudden death in
the USA in young military recruits and young individuals in Minne-
sota, which relied on data such as death certificates and post-
mortem reports7,8 and more in keeping with prospective studies
in Italy where the reported incidence of sudden cardiac death in
young Italian athletes subjected to pre-participation cardiovascular
evaluation is 2.1 per 100 000 per year.9 Therefore, it is likely that
our figure derived from the ONS data is a significant underestimate
of the true incidence of cardiac death in the young, given the
nature of our study and the absence of systematic screening in
the UK.
Sudden arrhythmic death syndrome
The incidence of Class A1 deaths that best correlate with SADS
was 0.24 per 100 000 per year, with no significant gender or age
predilection. This is significantly higher than the previous incidence
of 0.10 per 100 000 per year obtained from the ONS statistics for
1997–1999 that used the ICD-9 classification, although an associ-
ated prospective national coroner survey would suggest that calcu-
lations based on ONS data continue to underestimate the true
incidence of SADS.4 The most plausible explanation for this discre-
pancy is that the ONS mortality statistics are derived largely from
documentation on death certificates which may under-report the
true incidence of cardiac arrhythmias. Indeed the classification of
deaths by ONS does not differentiate sudden from non-sudden
deaths clearly, although most of the pathologies reported as
causes of deaths, such as atherosclerotic heart disease and
cardiomyopathy, would be more likely to cause sudden rather
than non-sudden death in this age group. Malignant cardiac
arrhythmias secondary to ion channelopathies such as Brugada
syndrome and long-QT syndrome may manifest as epileptiform
seizures and collapse secondary to brain anoxia or drowning
resulting in misclassification of genuine cases of SADS as epi-
lepsy15,16 or unexplained drowning.17,18 The latter is particularly
relevant since there is a well established association between the
most common subtype of long-QT syndrome, LQT1, and
sudden death in swimmers.19,20 Conversely, post-mortem findings
such as coronary atherosclerosis without significant narrowing of
the arterial lumen or without macroscopic or microscopic evi-
dence suggestive of acute or chronic ischaemia, as well as mitral
valve prolapse and myocarditis,21 are quite common and may be
falsely attributed as the cause of death.
Mortality gender and age predilection
in the young
Consistent with prior literature reports, ischaemic or potentially
ischaemic causes contributed a greater proportion of deaths in
males and with increasing age, in particular after the age of
30 years. Conversely, potentially inherited cardiomyopathies such
as hypertrophic and dilated cardiomyopathies did not exhibit
any gender predilection but there was a significant age trend,
Figure 3 Proportional (%) distribution of underlying cause of
death by gender. IHD, ischaemic heart disease; SADS, sudden
arrhythmic death syndrome.
Figure 4 Proportional (%) distribution of underlying cause of
death by age. IHD, ischaemic heart disease; SADS, sudden
arrhythmic death syndrome.






contributing a greater proportion of deaths in the 10–19 age
group with a gradual decrease thereafter.
Epilepsy appeared to exhibit a female predilection, accounting
for a greater proportion of deaths during adolescence. These
results should however be viewed with caution given the limited
data available and the multiple factors which may influence
epilepsy-related mortality, as established by a prior large, prospec-
tive study in the UK.22 Finally, in accord with previous reports,
drowning-associated deaths were more prevalent among males
and children aged ,10 years, with a reverse trend with increasing
age.23
Clinical implications
Considering the devastating impact of sudden and cardiac death in
the young and the potential number of life years lost our findings
suggest that the number of deaths identified (8 deaths/week) is suf-
ficiently high to command attention even without the inclusion of
potential misclassifications (Class B). If consideration is given to the
possibility that at least 20% of deaths attributed to epilepsy or
drowning may actually be caused by a primary myocardial electrical
disorder, then the estimate of sudden and cardiac death in the
young is at least 10 per week.
It is imperative that awareness of young cardiac deaths and in
particular SADS is raised among pathologists and coroners to
ensure that accurate conclusions are derived from autopsies. If
the autopsy identifies cardiomyopathy or a case of SADS, this
should trigger the referral of families of victims for comprehensive
cardiological screening and guide their assessment. This is impor-
tant because a significant proportion of conditions implicated in
young cardiac death and SADS, in particular, are inherited.
Indeed, over half of families with SADS deaths demonstrate evi-
dence of an ion-channel disorder or a cardiomyopathy.5,6
Reforms and further tightening of procedures to address these
issues have been proposed, and a national pathology registry has
been launched in the UK.24,25
Increased awareness among primary care physicians is also vital
to ensure recognition of cardiac conditions in young people with
the propensity to cause sudden cardiac death since these deaths
are often preceded by warning symptoms including syncope.
Appropriate assessment may therefore prevent a proportion of
these tragic deaths.6
Limitations
This epidemiological study exhibits some important limitations that
warrant mention. The cause of death was ascertained from the
ONS data and the authors did not examine death certificates or
post-mortem reports on an individual basis in order to identify
potential misclassifications. Although the ONS data do not
provide information regarding the number of deceased individuals
who underwent a post-mortem examination, it would be reason-
able to assume that the majority of the victims were subjected to a
post-mortem examination given their youth and the UK medico-
legal implications.
The investigators concede that this study relied solely on infor-
mation provided to the ONS from documentation on death certi-
ficates and post-mortem reports which may not always accurately
reflect the true cause of death given the ambiguities related to the
diagnosis of conditions associated with sudden cardiac death in the
young. This may explain the absence of conditions such as arrhyth-
mogenic right ventricular cardiomyopathy (ARVC) as a distinct
entity, whereas minor manifestation of certain common disorders
such as atherosclerosis may have been falsely attributed as the
cause of death. In addition, ARVC does not have its own ICD-10
code and is classified currently as I42.8—other cardiomyopathies.
The purpose of this study, however, was to provide an estimate of
the incidence of cardiac death and underlying cardiac causes in the
young in order to highlight the need to establish the scale and
nature of the problem.
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Objective: To characterise the demographics and
aetiology of sudden cardiac death (SCD) in athletes
referred to a tertiary cardiac pathology centre in the UK.
Design: Retrospective non-case controlled analysis.
Setting: Cardiac pathology centre at the National Heart
and Lung Institute and Royal Brompton Hospital.
Subjects: Between 1996 and 2008, the hearts of 118
athletes were referred for pathological assessment to
ascertain the precise aetiology of SCD.
Results: The majority of athletes (n= 113; 96%) were
male and most (107; 91%) were amateurs participating
predominantly in football, rugby and running. The mean
(SD) age of death was 28 (12) years (range 7–59); 75%
athletes were aged (35 years. Most deaths (81%)
occurred during or immediately after exercise. Antecedent
symptoms of cardiac disease were reported in 21 (18%)
subjects, and 20 (17%) had a family history of premature
cardiovascular disease and/or SCD. 25 (21%) athletes had
relevant past medical history which included a known
history of cardiac disease. Cardiomyopathy was the
commonest cause of death and accounted for 62% of all
the SCDs. A significantly high proportion of athletes (23%)
exhibited a morphologically normal heart. Atherosclerotic
coronary disease accounted for only 3% of cases and was
confined to athletes aged .35 years.
Conclusions: SCD in sport is largely due to clinically
silent cardiomyopathies or primary electrical disorders
(morphologically normal heart). Antecedent symptoms
and family history are absent in over 80% of cases, and
therefore clinical screening with health questionnaires will
fail to identify most athletes with potentially sinister
cardiac disorders.
The sudden death of an athlete is a rare event with
an incidence ranging between 1:50 0001 to
1:200 0002 a year. However, such events are highly
publicised and have a substantial emotional impact
on the community at large when one considers
that athletes are perceived as the healthiest
segment of society.
Over 80% of non-traumatic-exercise related
deaths are attributable to cardiac disorders.1–5 The
majority of sudden cardiac deaths (SCDs) in young
athletes (,35 years) are due to hereditary or
congenital cardiac anomalies; hypertrophic cardio-
myopathy (HCM) is reported to be the commonest
cause of death in young athletes world wide. In
contrast, the vast majority of SCDs in older
athletes are secondary to atherosclerotic coronary
artery disease.
Most datasets examining SCD in athletes are
derived from American3 5 and Italian6 7 studies. The
United Kingdom lacks a national registry for
systematically reporting sudden death in sports,
and therefore knowledge relating to antecedent
warning symptoms, the demographics of victims,
circumstances and prevalent causes of sudden
death in athletes in a sizeable cohort is lacking.
However, such information is fundamental to
facilitate any debate about local provisions for a
potential pre-participation cardiovascular screening
programme and subsequent exercise recommenda-
tions.8–10
The aim of this study was to identify the
characteristics and causes of death in a large cohort
of athletes referred to the Royal Brompton
Hospital, a specialist tertiary cardiac pathology
centre in the UK.
METHODS
Between January 1996 and July 2008, 118 cases of
sudden death in people participating in regular sport
activities were referred to the Cardiac Risk in the
Young (CRY) Centre for Cardiac Pathology at the
Royal Brompton Hospital for further evaluation, by
coroners and pathologists throughout the UK.
Definitions
The term ‘‘sudden death’’ was defined as sudden
unexpected death (within 1–12 h of apparent
wellbeing) from natural causes during or shortly
after (within 24 h) exercise. The individual was
considered an ‘‘athlete’’ if he or she participated in
at least 2 h/week of organised physical training
and competed in regular team or individual sport.
Subjects
Subjects were divided into two groups based upon
their age at death: (a)(35 years and (b).35 years.
Data on age, sex, circumstances of death, sporting
discipline, antecedent cardiac symptoms, past
medical history and a family history of cardiac
disease (when available) of the deceased subject
were obtained from the referring pathologist or
coroner.
Toxicology screen
All patients included in this study underwent a
toxicology screen as part of the coroner’s mandate
since all deaths were sudden and unexpected.
Pathological analysis
Pathological analysis of all hearts was performed
by the senior author (MNS) with the consent of
the coroner and family of the deceased. The heart
weight was recorded and measurements of the left
and right ventricular wall thickness and internal
cavity dimensions were made at mid-ventricular
level excluding papillary muscle and fat. Sections of
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myocardium were fixed in formalin, embedded in paraffin and
stained with haematoxylin and eosin as well as elastic Van
Gieson stain to highlight myocardial fibrosis.
The extramural coronary arteries were studied macroscopi-
cally in the intact heart by making multiple cross sections of the
vessels (3–5 mm apart). Table 1 gives the macroscopic and
histological criteria for specific cardiac diseases.
Results were reported in four broad categories: (a) cardio-
myopathies; (b) coronary artery pathology; (c) morphologically
normal heart (d) and other cardiac pathology.
Statistical analysis
Means and standard deviations (SD) were calculated for




Of the 118 cases of SCD, the majority were amateur sportsmen
(n=107, 91%) and included seven subjects who had partici-
pated in 2–23 marathons. The remaining 11 cases (9%) were
seven athletes (6%) at a professional or semiprofessional level
(soccer n=6, cycling n=1) and four (3%) who participated in
intensive physical training in the armed forces.
The subjects were predominately male (n=113; 96%).
One hundred and thirteen athletes (96%) were white and five
were black (African/Caribbean in origin). The mean (SD) age of
SCD in this series was 27.9 (12.5) years (range 7–59). Seventy-
five per cent of all deaths were in subjects aged (35 years
and almost one-third were in child or adolescent athletes
(,18 years). The greatest number of deaths (n=20) occurred
in the 16–20 year age group (fig 1). With the exception of one
case, all female athletes who died were in the younger age
group.
The vast majority of SCDs (81%) occurred during (66%) or
immediately after (15%) exercise. In relation to sporting
discipline, most deaths occurred in soccer (n=44; 37%; age
11–35 years), followed by running (n=24; 20%; age 8–59 years)
and rugby (n=11 cases; 9%, age 15–42 years) (table 2).
Antecedent symptoms, past medical history and family history of
cardiac disease
Of the 118 cases, 21 (18%), had experienced one of more
antecedent symptoms suggestive of underlying cardiac disease
(table 3).
In 20 subjects (17%) there was a family history of premature
cardiovascular disease (with the majority of cases comprising
ischaemic heart disease, 69%) and/or family history of SCD
((50 years old) in a first-degree relative.
Twenty-five (21%) of the subjects had relevant previous
medical history. Seven subjects had a history of cardiac disease,
nine were clinically suspected to have underlying cardiac
pathology, five had risk factors for coronary artery disease and
four had had at least one epileptic seizure (table 3). Ten athletes
(8%) also had a previous diagnosis of asthma. As far as the
authors can ascertain, none of the asymptomatic subjects had
been subject to pre-participation cardiovascular evaluation to
identify disorders capable of causing SCD.
Causes of sudden cardiac death
Abnormal cardiac pathology (macroscopic and/or microscopic)
was identified in 91 (77%) of all cases. The remaining subjects
had a morphologically normal heart (table 4 and fig 2).
Toxicology screen
All but two subjects had a normal toxicology screen. Both were
body builders and had blood traces of anabolic steroids.
Table 1 Macroscopic and microscopic criteria for determining cardiac pathology
Disorder Macroscopic appearance Microscopic appearance
Cardiomyopathy
Hypertrophic cardiomyopathy Left ventricular wall thickness >15 mm
and or heart weight >500 g
Myocyte hypertrophy, disarray and
interstitial fibrosis
Idiopathic left ventricular hypertrophy Left ventricular wall thickness >15 mm
and or heart weight >500 g
Myocyte hypertrophy with or without
fibrosis and no myocyte disarray
Arrhythmogenic right ventricular
hypertrophy
Right ventricular thinning with fatty
replacement and fibrosis
Fat and fibrosis throughout the wall of the
right ventricle and/or left ventricle
Idiopathic fibrosis Normal left ventricular thickness
(15 mm
Focal and diffuse interstitial and/or
replacement fibrosis in the ventricular wall
Coronary artery pathology
Atherosclerosis Atherosclerosis with narrowing .75% Acute/chronic infarction in the left ventricle
Anomalous coronary artery Anomalous origin of the coronary artery,
coronary artery atresia, stenosis
Fibrosis/acute/chronic infarction in the left
ventricle
Coronary artery spasm Circumferential subendocardial
haemorrhagic infarction with normal
coronaries
Acute infarction in the left ventricle
Coronary dissection Tear in the coronary artery media Infarction in territory of artery
Morphologically normal heart Normal Normal
Other cardiac pathology
Myocarditis Normal, dilated wall Inflammation with myocyte necrosis
Floppy mitral valve Mitral valve ballooning Myxoid change in the valve
Sickle cell crisis Normal Sickle cell in intramural coronary vessels
with microinfarcts in the myocardium
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Deaths attributed to a primary myocardial disorder (cardio-
myopathy) were identified in 73 (62%) of all athletes with an
SCD. Left ventricular hypertrophy (LVH) was the most
commonly identified abnormality on macroscopic examination
and was detected in 49 (42%) athletes raising the possibility of
HCM. However, only 13/49 (27%) athletes with LVH exhibited
associated myocyte disarray, the historically regarded histologi-
cal hallmark of HCM. The remaining cases of LVH (n=36;
31%) were associated with histological evidence of either
isolated myocyte hypertrophy (n=27) or myocyte hypertrophy
and fibrosis (n=9). The authors classified these cases under the
term ‘‘idiopathic LVH’’. One case of HCM and another of
idiopathic LVH was associated with the presence of anabolic
steroid traces on toxicology screen.
Athletes with HCM were predominantly in the younger age
group (mean (SD) age 24.6 (7.1); range 11–43) and all but one
case was male. Similarly, 71% of all victims with idiopathic LVH
were in the younger age group (mean (SD) age 32.7 (12.6) years;
range 9–59) and all were male. Of the five Afro-Caribbean
subjects, four had evidence of idiopathic LVH.
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
was the second most common diagnosis and was identified in
16 (14%) members of our cohort. There was evidence of
biventricular involvement in 50% of cases. In contrast with
cases of idiopathic LVH and HCM, deaths were equally
distributed between the older and younger age group (mean
(SD) age 35.9 (12.2) years; range 16–57).
Idiopathic fibrosis without LVH occurred in seven cases with
all but one in the younger age group (mean (SD) age 28.4 (8.5)
years; range 17–43). Finally, one case exhibited features of both
arrhythmogenic right ventricular cardiomyopathy and HCM.
There was insufficient tissue sampling to provide a definite
diagnosis and the case was classified as an undetermined
cardiomyopathy.
Coronary artery pathology
Coronary artery pathology was identified in 11 (9%) subjects.
The main pathology was a congenital anomaly of the coronary
arteries which was seen in six of the 11 subjects all of whom
were male and (35 years old (mean (SD) age 15.8 (6.2) years;
range 7–25). Both coronary arteries arose from the same
coronary ostium in four cases; two cases had the left coronary
artery arising from the right sinus and two cases had the right
Figure 1 Bar chart showing the number
of sudden deaths in athletes in relation to
age in 118 deaths in sportsmen referred
to a tertiary centre in the UK over a 12-
year period.
Table 2 Demographic characteristics of the cohort
Characteristics Values
Number of subjects 118
Male 113 (96)
Age (years), mean (SD), {range} 27.9 (12.5), {7–59}







Weight lifting 3 (3)
Golf 3 (3)
Other ( 2 subjects/discipline) 20 (17)
Results are shown as number (%) unless stated otherwise.
Table 3 Antecedent symptoms, family history and relevant cardiac
history of the 118 subjects*
Patient information No of cases
Age (years)
(35 .35
Family history 20 (17%) 15 5
Family history of heart disease 13 9 4
Family history of SCD 8 6 2
Symptoms 21 (18%) 16 5
Syncope/dizziness 10 9 1
Shortness of breath 7 5 2
Palpitations 6 6 0
Chest pain 4 3 1
Relevant past medical history 25 (21%) 16 9
Clinical suspicion of cardiac disease after
investigation{
9 6 3
Epilepsy/seizure 4 4 0
Heart murmur 3 3 0
Diabetes 3 1 2
Hypercholesterolaemia 4 0 4
Congenital heart disease 1 1 0
Ventricular septal defect 2 2 0
Previous cardiac arrest 2 1 1
Atrial fibrillation/pacemaker insertion 1 0 1
Viral myocarditis 1 1 0
*Symptoms/findings do not add up since some subjects had more than one symptom/
finding; {abnormal ECG (n= 4), abnormal echo (n= 2), possible arrhythmia (n= 3).
SCD, sudden cardiac death.
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coronary artery arising from the left sinus. Of the remaining
two cases, one had atresia and hypoplasia of the left coronary
artery and the other stenosis of the ostium and a shelf-like slit of
the left coronary artery. Coronary atherosclerosis was the cause
of death in only three athletes who were all aged .35 years
(mean (SD) age 49.7 (4.0) years; range 45–52). A single case of
coronary artery spasm was detected in a 17-year-old man, as
well as one case of spontaneous dissection of the left anterior
descending artery in a 38-year-old man.
Other cardiac pathology
Lymphocyte myocarditis was the predominant finding in three
cases. Two subjects had valvular disease which included floppy
mitral valve and associated myocardial fibrosis. There was a
single subject with corrected, complex congenital heart disease
of univentricular circulation and Fontan circulation who
exhibited biventricular hypertrophy with no other associated
anomalies. Finally, one subject had evidence of an acute sickle
cell crisis with sickling within the coronary arteries and
associated acute ischaemia.
Morphologically normal heart
In almost a quarter of our cohort (23%) the post mortem
disclosed no cardiac abnormality which could account for the
cause of death, despite detailed macroscopic and microscopic
examination. The majority of these cases (96%) were in the
younger age group where the mean (SD) age of 18 (6.1) years
(range 8–42) was significantly lower than that of those dying
with identifiable cardiac pathology (p,0.001). Interestingly,
three of the five swimmers who died had a morphologically
normal heart.
Female athletes
Of the five females athletes in the series, two had a
morphologically normal heart, one had HCM, one exhibited
idiopathic fibrosis and another, coronary atherosclerosis.
DISCUSSION
The cardiovascular benefits of regular physical activity are well
established11 and only a small proportion of athletes with
unsuspected cardiac pathology are at increased risk of exercise-
related SCD.1–7 The majority of data examining the aetiology of
deaths in athletes originates from the USA (1866 cases (whole
series), 690 cases are primary CVD only)5 and Italy (55 cases),7
although a number of small studies also exist in other European
countries, including Spain (61 cases),12 France (80 cases)13 and
Ireland (51 cases).14 Data in the UK are scarce and limited to a small
group of older sport participants.14–16 As far as we know, this study
of 118 SCDs in athletes is the largest reported series in the UK.
Sport and gender predilection
Consistent with large American5 17 and Italian6 7 series of SCD in
athletes, just over 80% of deaths occurred during or immediately
after exercise, indicating that the interplay of physical, metabolic
and endocrine stresses of exercise on the heart is an important
trigger for fatal ventricular arrhythmias. Soccer and running were
the sports most commonly associated with SCD and this is in
agreement with most other studies.1–7 10 This sport bias most
certainly represents the high participation rates in these sporting
disciplines in most Western European countries. In concurrence
with previous studies, the great majority (96%) of subjects with
SCD subjects in our cohort were male.1–7 12–17 This may be
attributed to the lower participation rate of women in sport
generally and specifically in sports popular with male subjects,
such as soccer, which is the predominant sport in our study.
Cardiomyopathy
Consistent with previous studies in the USA2 3 5 17 and Italy,1 6 7
our results indicate that cardiomyopathies are the most
prevalent underlying pathology in SCD related to athletic
activity. In contrast, however, in this series LVH without
myocyte disarray, was the predominant finding (31%), com-
pared with HCM and ARVC in the USA and Italy, respectively.
Idiopathic LVH is becoming increasingly recognised and
although it has been reported in previous studies, this is the
first series in which it predominates. It is unclear at this stage
whether it represents an acquired pathological variant of the
physiological LVH exhibited as part of the ‘‘athlete’s heart’’ in
certain genetically predisposed backgrounds.18 The finding of
idiopathic LVH in four out of five Afro-Caribbean cases of SCD
may be relevant in this regard since a recent study in highly
trained black athletes has shown that 3% exhibit substantial
Table 4 Cause of sudden cardiac death according to histopathological
findings
Diagnoses (35 .35 Total
Cardiomyopathy 49 24 73
Idiopathic left ventricular hypertrophy 19 8 27
Idiopathic left ventricular hypertrophy with
fibrosis
3 6 9
Arrhythmogenic right ventricular cardiomyopathy 9 7 16
Hypertrophic cardiomyopathy 11 2 13
Idiopathic fibrosis 6 1 7
Undetermined cardiomyopathy 1 0 1
Morphologically normal heart 26 1 27
Coronary artery pathology 7 4 11
Anomalous coronary artery 6 0 6
Atherosclerosis 0 3 3
Coronary ‘‘spasm’’ 1 0 1
Coronary dissection 0 1 1
Other cardiac pathology 7 0 7
Myocarditis 3 0 3
Floppy mitral valve 2 0 2
Complex congenital heart disease 1 0 1
Sickle cell crisis 1 0 1
Figure 2 Pie chart showing the causes of sudden cardiac death in 118
sports deaths referred to a tertiary cardiac centre in the UK over 12
years. ARVC, arrhythmogenic right ventricular cardiomyopathy; CM,
cardiomyopathy; HCM, hypertrophic cardiomyopathy; IF, idiopathic
fibrosis; ILVH, idiopathic left ventricular hypertrophy. Percentages do not
add up to 100% because of rounding.
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LVH (>15 mm) and it is plausible that in such athletes, marked
LVH predisposes to exercise-related fatal ventricular arrhyth-
mias.19 LVH has also been associated with the use of anabolic
steroids.20 In our study traces of anabolic steroids were identified
at post mortem in two body builders; one was diagnosed with
idiopathic LVH and the other with HCM.
Idiopathic myocardial fibrosis with or without LVH, featured
in 14% of this cohort in contrast to significantly lower rates in
previous studies (2%–3%).12–14 The aetiology and importance of
cardiac fibrosis remains unclear; however, transient myocardial
damage has been detected in athletes in the post-race setting
and has been associated with transient diastolic and systolic
dysfunction.21 Possibly, in some athletes prolonged arduous
physical activity may result in myocardial necrosis and
subsequent fibrosis. This pathology may represent an acquired,
exercise-related cardiomyopathy and/or genetic predisposition
leading to a fatal arrhythmia. This concern was raised in a
recent case report from our group, a marathon runner who died
during a race with marked LVH and myocardial fibrosis.22 It is
also possible that at least some of these cases may be due to the
recently recognised familial arrhythmogenic left ventricular
cardiomyopathy.23
ARVC was the second most common cardiomyopathy and
accounted for 14% of all sudden deaths in our series. Our figures
were significantly higher than those reported in the US
series2 3 5 17 and not dissimilar from the reports from the
Veneto region of Italy1 6 7 24 and other European coun-
tries.12 13 25–28 These observations suggest that there may be a
higher genetic cluster of ARVC in Europe or, owing to the
Venetian experience, a greater awareness of this disorder
amongst pathologists in Europe.
Of note, we did not observe deaths from dilated cardiomyo-
pathy in our cohort, which contrasts with series from other
countries where the range was 2–11%.1 3 12 13
Coronary artery pathology
Coronary artery pathology was less prevalent in this study than
in the US and Italian experience. Sudden cardiac death
secondary to anomalous coronary arteries was confined to the
younger age group (median 17 years) in this series, a trend
supported by previous reports.2 3 5–7 12 13 17 Atherosclerotic cor-
onary artery disease was seen in a much smaller number of
patients and was confined to the older (.35 years) age group as
observed in previous sports deaths series.14–16
Morphologically normal heart
In this study there was a high prevalence of SCDs in subjects
with a morphologically normal heart (23%) despite detailed
macroscopic and histological examination. Previous studies have
reported significantly lower rates, as low as 1%,1 3 5 17 with only
a Spanish series reporting a figure comparable to our study
(16.3%).12 The identification of a morphologically normal heart
is of great importance since studies in the USA and the UK
suggest that more than 50% of such SCDs are caused by
malignant arrhythmias secondary to the presence of inherited
ion channel disorders usually affecting the potassium, sodium
and calcium ion channels of the myocardial cells.29 30 A previous
study undertaken at our unit highlights the prominent role of
electrical abnormalities in the normal heart in SCD, particularly
in younger subjects.31
Although selection bias has certainly contributed to the high
prevalence of SCD with a morphologically normal heart, this
study highlights the importance of establishing such a diagnosis
since ion channelopathies can be identified in other relatives
with non-invasive cardiac investigation, and appropriate treat-
ment instigated to avoid further tragedies.32 Of interest, three
children (aged 7–15 years) with morphologically normal hearts
died during swimming. This sport has been particularly
associated with deaths in the long Q–T syndrome33 34 and
catecholaminergic polymorphic ventricular tachycardia.35
Clinical implications related to pre-participation screening
Sudden death is often the first clinical manifestation of
underlying heart disease in young athletes. The Italian model
of pre-participation cardiovascular screening in young athletes,
using 12-lead ECG as a screening tool, is effective in reducing
SCD by identifying athletes with underlying cardiomyopathy
and ion channelopathies.6 7 This study indicates that based on
the high prevalence of cardiomyopathies and the relatively low
occurrence of coronary artery pathology in our subjects, pre-
participation cardiovascular screening using a 12-lead ECG
would probably have detected the underlying cardiac abnorm-
ality in a significant number of SCD victims. This argument is
further reinforced by the high prevalence of SCDs in people
with a morphologically normal heart, of which a significant
proportion may be attributed to inherited ion channelopathies
and which potentially might be detected by the 12-lead ECG.
The absence of antecedent cardiac symptoms and/or a family
history of cardiac disease and/or SCD in almost 80% of cases of
SCD confirms the prior observation that most cardiovascular
disorders responsible for SCD in the athlete are clinically silent
and unlikely to be discovered from spontaneous symptoms.
Cardiovascular screening including ECG testing will be asso-
ciated with a significantly higher diagnostic yield than reliance
on history alone.28 36–38
We recognise that almost one-third of the cases in this series
exhibited idiopathic LVH and it may argued that these cases
may not have been identified with ECG. However, it is unclear
at this stage whether idiopathic LVH represents a spectrum of
the HCM phenotype, an exaggeration of the physiological
response18 resulting in pathological LVH or whether it is indeed
an innocent bystander (genuine physiological LVH) in a person
who may have succumbed to a fatal ventricular disorder owing
to an undetectable ion channel disorder or congenital accessory
pathway. However, it is well established that over 90% of
people with HCM have an abnormal ECG.39 The experience of
two of the authors (SS and GW) of screening over 3000 highly
trained British athletes aged 14–35 years identified three athletes
who might have been considered to have HCM; all three
exhibited grossly abnormal ECGs.40 Although ion channel
disorders cannot be identified and accessory pathways may be
difficult to demonstrate at autopsy, ante mortem 12-lead ECG
has a high yield in the identification of ion channel disorders32
and accessory pathways. Based on these facts we suspect that a
significant proportion of athletes with idiopathic LVH would
have been identified on a routine ECG and in an expert setting
would have been subject to further investigations aimed at
confirming the pathological diagnosis and the assessment of risk
of SCD.
The predominance of deaths due to idiopathic LVH and
idiopathic myocardial fibrosis does raises the possibility that
some deaths in sport may be secondary to acquired myocardial
disorders resulting from the long-term effects of intensive
exercise,18 warranting several cardiac assessments throughout
the athlete’s career.
The Italian screening programme in athletes has been
successful in identifying and preventing deaths predominantly
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from the cardiomyopathies through subsequent disqualification
of the affected subject from sporting activities of moderate to
high intensity to minimise the risk of SCD. In this regard it is
prudent to highlight that in this study almost one-fifth of all
SCDs in athletes occurred at rest, suggesting that the
identification of cardiovascular diseases and subsequent dis-
qualification from sport will not prevent deaths in all athletes
harbouring potentially fatal cardiac disorders.
Limitations
We concede that conclusions drawn from this study do not
necessarily apply to the whole of the UK because of a significant
selection bias. The CRY Centre for Cardiac Pathology at the
Royal Brompton Hospital is an internationally recognised
cardiac pathology centre in the UK, where the hearts of many
young athletes are commonly referred, especially when the
findings are ambiguous and no clear cause of death can be
established by the local pathologist. It is therefore highly
probable that cardiac anomalies such as coronary artery
atherosclerosis, which can be easily identified, and cardiomyo-
pathies such as HCM, which have been well characterised, are
under-represented in this cohort. Similarly the prevalence of less
well-defined entities such as idiopathic left ventricular hyper-
trophy and a morphologically normal heart are likely to
represent an overestimate. A national database on SCD in
young athletes needs to be established in order to obtain more
accurate information in the future.
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Aims Post-mortemexaminationof the heart in young sudden cardiac death (SCD) is vital as the underlying aetiology is often an
inherited cardiac diseasewith implications for surviving relatives.Our aim is to demonstrate the improvement in diagnos-
tic quality offered by a specialist cardiac pathology service established to investigate SCD with fast-track reporting on
hearts sent by pathologists in cases of SCD.
Methods
and results
A tertiary centre prospective observational study was conducted. Detailed histopathological examination was per-
formed in a tertiary centre specialized in the investigation of cardiac pathology in SCD. Hearts from 720 consecutive
cases of SCD referred by coroners and pathologists from 2007 to 2009 were included. A comparison was drawn
with diagnoses from referring pathologists. Most SCDs occurred in males (66%), with the median age being 32 years.
The majority (57%) of deaths occurred at home. The main diagnoses were a morphologically normal heart (n ¼ 321;
45%), cardiomyopathy (n ¼ 207, 29%), and coronary artery pathology (n ¼ 71; 10%). In 158 out of a sample of 200 con-
secutivecases, a cardiac examinationwasalsoperformedby the referringpathologistwith adisparity in diagnosis in 41%of
the cases (k ¼ 0.48). Referring pathologistsweremore inclined to diagnose cardiomyopathy than normalitywith only 50
out of 80 (63%) normal hearts being described correctly.
Conclusion Expert cardiac pathology improves the accuracy of coronial post-mortem diagnoses in young SCD. This is important as
the majority of cases may be due to inherited cardiac diseases and the autopsy guides the appropriate cardiological
evaluation of blood relatives for their risk of sudden death.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Autopsy † Cardiomyopathy † Morphologically normal heart † Sudden arrhythmic death syndrome † Sudden
cardiac death † Young
Introduction
Inherited cardiac diseases are common causes of young sudden
cardiac death (SCD) and the family must not only contend with the
grief of their loss but also with the possibility that SCD may strike
the family again.1 The UK reports at least 10 cases of SCD occurring
perweekor1.8per100 000persons-year,with several casesmisclas-
sifiedunderdrowningorepilepsy.2 In theUK, national guidelines have
outlined the need for specialist cardiological evaluation for families
who have suffered an unexplained SCD (sudden arrhythmic death
syndrome, SADS) and expert post-mortem examination is a
critical first diagnostic steprequired toguideclinical evaluationof sur-
viving relatives.3 This aims to identify individuals at the risk of SCD, in
whommedical intervention is likely to prevent further tragedies.1,4 –6
Best practice guidelines set by the Royal College of Pathologists
and the Association for European Cardiovascular Pathology recom-
mend referral of whole hearts to specialist centres with high volume
and recognized expertise.7–9 In the UK, all sudden unexpected
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deaths have an autopsy carried out by a pathologist, whereas in the
restof Europethere iswidespreadvariationas to the rateof autopsies
for SCD even within the same country.10 Most British pathologists
have limited exposure to casesof youngSCDaswell as fewresources
and time constraints to perform the autopsy.11,12 Moreover, the
introduction of the Human Tissue Act in 2004 has limited preserva-
tion of tissue at autopsy.13 All these factors translate to either the
absence or the limited histopathological examination in the cases
of SCD, translating to an autopsy of reduced and/or variable
quality12,14,15 and may lead to erroneous diagnoses.2,16 A recent
report, which compared autopsy evaluation of SCD in the young
before and after best practice guidelines were introduced, deter-
mined that the histological analysis of the right ventricular (RV) and
left ventricular (LV) tissue was still unsatisfactory with ,50% of
cases providing a histological description of these sites.17
The charityCardiacRisk in theYoung (CRY) launched aCentre for
Cardiac Pathology, CRY CCP, established in the National Lung and
Heart Institute (Imperial College) and Royal Brompton Hospital
(RBH) in March 2007 to address the need for detailed histopatho-
logical evaluation of cases of SCD from potentially inherited condi-
tions by an expert cardiac pathologist at no cost to the family,
coroner, or health service. We report the diagnostic results of this
innovative service.
Methods
Population inclusion and exclusion criteria
This study was completed with ethical approval from the Brompton,
Harefield and National Heart and Lung Institute: Ref 07/Q040. A total
of 753 cases, referred between March 2007 and December 2009 for
expert cardiac pathological assessment to the CRY CCP service, were
considered for this prospective observational study. Inclusion criteria
were as follows: referral by a coronial pathologist of a witnessed instant-
aneous death; or a suspected sudden deathwhen the individual was seen
alive andwell up to24 hprior todeath; andwherenon-cardiac causeshad
been excluded at initial autopsy. All ages were included to demonstrate
the wide age range of referrals received at the centre.
Caseswereexcluded fromthestudy if thedeathoccurred in thecontext
of deteriorating heart failure (n ¼ 26), was non-sudden (n ¼ 4), or if sub-
sequent toxicologyprovided an explanation for the death (n ¼ 3).Dataon
age, sex, and location/circumstances of death of the deceased were
obtained from the referring pathologist or coroner. Subjects were
divided into two groups based upon their age at death: (i) ≤35 years and
(ii) .35 years.
Specimen referral process
A specific protocol was established for handling an SCD referral and is
summarized in Figure 1.
Referrals
The total numbers of SCD referrals were calculated before and after the
launch of the CRY CCP in March 2007. To examine trends over time,
SCD referrals were grouped into two time bands: 1999–2006 and
2007–09.
Heart specimen handling
Sudden cardiac death victims were examined by local pathologists in 45
counties within the UK. Following the exclusion of extra-cardiac causes
for the death, the hearts were referred to CRYCCP with the consent of
the coroner and the family of the deceased. Establishedmacroscopic and
histological criteria for the diagnosis of cardiac pathology were used and
are summarized in Supplementary material online, Table S17–9 For all
cases, observations and dimensions were consistently recorded. Ten
to twenty tissue sections were routinely taken according to agreed
national9 and international criteria7 and included: the RV outflow tract;
a right lateral cut containing right atrium, posterior leaflet of the tricuspid
valve, and lateral RV; a left lateral cut containing left atrium, mitral valve
and lateral LV; circumferential RV and LV samples; the anterior and pos-
terior septum; the three major coronary arteries; the ascending aorta;
and the conduction system. Extra tissue sections were taken to
confirm pathology when this was detected macroscopically and/or
microscopically. Sections were fixed in formalin, embedded in paraffin,
and stained with haematoxylin and eosin stain or elastic Van Gieson to
highlight myocardial fibrosis.
The results were reported in categories: (i) morphologically normal
heart, (ii) cardiomyopathies, (iii) coronary artery pathology, (iv) complex
congenital heart disease (CHD), (v) inflammatory disease, (vi) valve
disease, (vii) aortic disease, (viii) tumour, and (ix) other cardiac pathology.
Comparison with referring pathologist
opinion
A sample of 200 consecutive cases of SCD referred from March 2007
onwards were examined to find out whether the referring pathologists
had performed pathological examination of the heart and provided a
potential cardiac cause of SCD. Cardiac diagnoses were compared
between the referring pathologist and M.N.S. using the kappa (k)
coefficient.
Statistical methods
Data were analysed using the statistical software Stata version 10.1
(Statacorp). Categorical data were presented as percentages and
differences between groups, including changes, over time were assessed
with the use of thex2 or Fisher’s exact test. The kappa (k) coefficientwas
used as a measure of agreement. Numerical data were presented as
means+ SD or as median [interquartile range (IQR)]. A value P, 0.05
was considered statistically significant.
What’s new?
† The pathological investigation of sudden cardiac death (SCD)
poses significant diagnostic challenges, particularly in the
young where inherited cardiac diseases predominate.
† There is a considerable variability in the interpretation of
autopsy findings between general and specialist cardiac
pathologists, which can lead to alternative diagnoses in 40%
of the cases.
† General pathologists are likely tooverestimate the significance
of autopsy findings and attribute deaths to cardiomyopathy at
the expense of diagnosing a morphologically normal heart.
† Isolated left ventricular hypertrophy is present in a consider-
able proportion of SCDs and its significance remains
unclear, warranting further research.
† Investigation of SCD by an experienced cardiac pathologist is
essential when an inherited cause is suspected, to ensure diag-
nostic accuracy, given the potential implications for surviving
relatives.
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A total of 720 cases of SCDwere included in the period fromMarch
2007 to December 2009. There was a progressive increase in the
number of SCD referrals over time (Figure 2), with a statistically
significant upward trend when comparing the periods before and
after the CRY CCP launch (P ¼ 0.014).
Demographics
The cohort was predominantly male (n ¼ 475, 66%) and young.
The median age was 32 years, age range ,1–98 years, and 58%
were ≤35 years of age (Figure 3).
Location and circumstance of death
Themajority of deaths occurred at home (57%) (see Supplementary
material online, Table S2) of whommost died at rest (n ¼ 244, 34%),
including those found dead in bed (n ¼ 197, 27%). Sudden cardiac
death occurred during or immediately after exertion in 14% of the
total cohort, most of whom were young with a median age of
24 years. Sudden cardiac death in the community occurred in 144
(20%) cases, with 66 of the144 (46%) occurring during exertion,
mostly on sport pitches and in leisure centres. Subjects with a
Figure2 Barchart depicting a rising referral patternof SCDcases
toCRYCCPandRBHover aperiodof 10years.Arrow indicates the
launch of CRY CCP service.
Figure 1 Flow chart showing the cardiac referral procedure at CRY CCP.
*According to national guidelines for transporting biological material.
**Free service.
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normal heartweremore likely to die at restwhereas a higher propor-
tion of deaths in individuals with a cardiomyopathy were related to
exertion (P ¼ 0.0121) (see Supplementarymaterial online, Table S3).
Causes of sudden cardiac death
The main causes of SCD and their representation in the cohort
are presented in Tables 1, 2, and Supplementary material online,
Figure S1. The most common finding was a morphologically normal
heart implying SADS (n ¼ 321, 45%), which was also the leading
cause in those aged ≤35 years (228 of 422, 54%). Although males
predominated (197 of 321, 61%), female SCD victims were propor-
tionately more likely to have a normal heart (females; 51% vs. males;
41%, P ¼ 0.019). The groupwith amorphologically normal heartwas
also significantly younger compared with cases with structurally
abnormal hearts (P, 0.0001): median age as 28 years (IQR 20, 38)
compared with 36 years (IQR 26, 47).
Just under one-third of the cohort (n ¼ 207) had cardiomyopathy.
Males were proportionately more commonly affected by cardiomy-
opathy than females. Themost common cardiomyopathies included:
idiopathic left ventricular hypertrophy (ILVH) (26%), of which 42%
were associated with fibrosis; hypertrophic cardiomyopathy
(HCM) (20%); arrhythmogenic right ventricular cardiomyopathy
(ARVC) (14%); and obesity cardiomyopathy (14%).
Coronary artery pathologywas the thirdmain cause of death iden-
tified in 10% of all subjects. The main aetiology was atheroma (56 of
71, 79%, mean age 49.8+18.1 years) of whom 13 were ≤35 years
including an 11-year-old with known familial hypercholesterolaemia.
Non-atheromatous causes occurred in younger individuals (15 of 71,
21%,mean age 36.2+13.5 years) and includedmyocardial infarction
with normal coronary arteries (n ¼ 7); anomalous origin of the cor-
onary artery (n ¼ 5); right coronary artery from left coronary sinus
(n ¼ 3); and left coronary artery and left anterior descending
artery (LAD) from the pulmonary trunk (n ¼ 2); coronary artery
bridging of the LAD (n ¼ 1); and spontaneous coronary dissection
found only in two females.
Myocardial inflammation was noted in 4% of the patients. The
inflammatory typeswere: lymphocytic (n ¼ 9), toxic (n ¼ 8), eosino-
phillic and lymphocytic (n ¼ 5), granulomatous cardiac sarcoid
(n ¼ 4), neutrophillic (n ¼ 3), eosinophillic (n ¼ 2), and acute
rheumatic fever (n ¼ 1).
Valvular pathology totalled 24 cases (3%) with a predominance of
mitral valve prolapse (14of 24, 58%), which was associated with LV
fibrosis in 11 cases, followed by bicuspid aortic valve (n ¼ 7).
There were 23 cases of SCD with CHD, of which 17 (74%) had
surgical correction for their conditions in early life. Mild to extensive
fibrosis of the LV and/or RV was detected in the majority of CHD
cases (14 of 23, 61%). Aortic dissection or rupture accounted for
13 (2%) sudden deaths that were mostly in the young males.
With the exception of two atrioventricular (AV) nodal tumours,
examination of the conduction system did not establish accessory
pathways, fibrosis, or inflammation within the AV nodal tissue.
Overall, there were 587 of 720 cases (80%): 321 normal hearts,
207 cardiomyopathy, 23 complex CHD, 24 valve disease, and 12
aortic dissections, where death could be attributed to a potentially
genetic disorder and therefore may require evaluation of the family.
Specialist cardiac pathology compared
with coronial pathology
From a sample of 200 consecutive cases examined by M.N.S., in 158
(79%), a provisional diagnosis had been made by the referring path-
ologist. This matched the diagnosis of M.N.S. in only 94 of 158
Figure 3 The demographics are shown in 720 referrals of SCD according to age and gender.
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(59%) of the cases (Table 3). The k coefficient as a statistical measure
of concordance was moderately significant at 0.48. Referring pathol-
ogists were more inclined to diagnose pathology rather than desig-
nate the heart as morphologically normal with only 50 out of 80
(63%) normal hearts being described as such. Of the 30 normal
hearts diagnosed with pathology by the referring pathologist, 20
were thought to have signs of cardiomyopathy, the majority being
ARVC. In contrast, seven of the hearts described as normal by the re-
ferring pathologist, were in fact found to have signs of cardiac disease.
Indeed, the diagnosis of ARVC was overestimated (21 vs. 5), with
agreement in only 2 cases. The main observation misattributed to
ARVC was isolated fatty infiltration of the RV (n ¼ 10). Similarly,
HCM was over-diagnosed in 10 cases with over-interpretation of
myocyte disarray by the referring pathologist often due to the sam-
pling of the anteroseptal and posteroseptal walls wheremyocyte dis-
array is a normal finding. Remaining cases were in fact ARVC (n ¼ 2),
non-compaction cardiomyopathy (n ¼ 1), hypertensive heart
disease (n ¼ 1), and normal heart (n ¼ 1). Myocarditis (5 of 9,
56%) was also over-reported by the referring pathologist. In the ma-
jority of cases, inflammation was focal with no myocyte necrosis.
Histological images of these common confounders are shown in
Supplementary material online, Figure S2. Consensus was greatest,
however, in the diagnosis of dilated cardiomyopathy (6 of 8, 75%).
In two out of five (40%) cases of valvular disease, over-interpretation
of floppy mitral was noted, especially in older patients where slight
ballooning of the mitral leaflet edges is a normal finding. Finally, cor-
onary artery atheromawas considered a significant cause of death in
three cases but was determined to be non-significant by M.N.S. due
to over-interpretation of collapsed coronary arteries at autopsy.
Discussion
This study reports the results of a unique specialist cardiac pathology
service dedicated to the pathological investigation of predominantly
young SCD. Eighty per cent of deaths had pathological evidence to
support potentially inherited cardiac diseases including Marfan’s
syndrome, cardiomyopathy, and a morphologically normally heart
(SADS). Evaluation of first-degree relatives of victims with SADS
identifies inherited heart diseases in up to half of the families.1,4,5,18
It is therefore vital that SADS deaths and other deaths due to
potentially inherited heart diseases are recognized accurately at
post-mortem to trigger this process. Cardiac familial investigation
is, however, a time-consuming and expensive process that can be
distressing to relatives. For these reasons, clinicians need accurate
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Table 1 Cardiac causes of SCD stratified by age
≤35 years >35
Cardiac cause of death n % Median age (IQR) Age range, years n % n % P valuea
Normal heart 321 45 28 (20, 38) ,1–82 228 54 93 31 ,0.0001
Cardiomyopathy 207 29 36 (26, 47) ,1–98 97 23 110 36 ,0.0001
Idiopathic left ventricular hypertrophy 54 8 25 (34, 39) 4–69 30 7 24 8 –
Obesity CM 29 4 30 (40, 47) 9–64 10 2 19 6 –
Hypertrophic cardiomyopathy 42 6 28 (37, 52) 7–98 19 5 23 8 –
Arrythmogenic right ventricular CM 29 4 30 (37, 46) 10–56 12 3 17 6 –
Idiopathic fibrosis 17 2 34 (26, 42) ,1–51 9 2 8 3 –
Dilated cardiomyopathy 17 2 38 (21, 49) 15–81 8 2 9 3 –
Other CM 9 1 48 (11, 55) ,1–71 4 1 5 2 –
CM NOS 10 1 35 (27, 46) 14–64 5 1 5 2 –
Coronary artery pathology 71 10 45 (34, 63) 11–82 21 5 50 17 ,0.0001
Atheroma 56 8 46 (37, 66) 11–82 13 3 43 14 –
Non-atheromatous 15 2 35 (23, 45) 16–63 8 2 7 2 –
Inflammation 32 4 21 (14, 36) ,1–67 24 5 8 3 –
Complex congenital heart disease 23 3 23 (16, 30) ,1–44 19 5 4 1 –
Valvular disease 24 3 33 (23, 45) 12–79 14 3 10 3 –
Aortic disease 13 2 34 (34, 43) 13–59 8 2 5 2 –
Tumour 5 1 25 (22, 40) 7–43 3 1 2 1 –
Hypertensive heart disease 12 2 48 (38, 61) 35–85 1 0 11 4 –
Other cardiac pathologyb 12 2 23 (18, 85) ,1–98 6 1 6 2 –
Total 720 100 32 (22, 43) ,1–98 422 100 298 100 –
CM, cardiomyopathy; NOS, not otherwise specified.
Decimal values were rounded to the nearest whole number for ease of interpretation.
Values are expressed as percentage (number/total number) or median (range).
aStatistical analysis of cardiac causes of sudden death by age groups ≤35 and .35 years. Statistical analysis was not performed in groups with a small number of cases.
bOther miscellaneous causes were: non-toxic alcohol/drug-relatedmyocardial damage (n ¼ 4), amyloid (n ¼ 2), transplant rejection due to coronary allograft vasculopathy (n ¼ 1),
post-chemotherapy fatty replacement of the LV (n ¼ 1), cardiac rupture linked to a fatty RV (n ¼ 1), subendocardial fibroelastosis (n ¼ 2), and arrhythmia (supraventricular
tachycardia) related ischaemic damage (n ¼ 1).
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diagnostic pathology and the confidence that the autopsy was
sufficiently thorough to exclude non-genetic causes.
It is, however, as important to ascertain the absenceof disease, as it
is to find it. Our study demonstrates that a morphologically normal
heart was in fact under-diagnosed and cardiomyopathy was over-
diagnosed by general pathologists. This explained most of the incon-
gruence (59%) indiagnoses givenby the referringpathologists and the
specialist cardiacpathologist. Thediscrepancyalso supports theneed
for an expert cardiac pathologist to support general pathologists in
the evaluation of sudden death, particularly in the young. It empha-
sizes the need for recognition of what is normal and abnormal,
both macroscopically and microscopically. The spectrum of normal
variation can be misinterpreted as pathological, such as fatty infiltra-
tionof theRVand slight ballooningof themitral valve, both associated
with the female gender and older age.19,20
The importance of a specialist cardiac
pathology service
Erroneous autopsy interpretation may mislead clinicians and cause
missed diagnostic opportunities that could result in further tragedies
within the same family. This is particularly pertinent to primary care
physicians and cardiologists who are required to interpret a post-
mortemreport, oftenwithout any guidance, aswell as initiate referral
of family members and plan cardiological evaluation. Our study thus
highlights the importance of an experienced cardiac pathology
service dedicated to providing a thorough cardiac autopsy and
ensuring a higher probability of accurate interpretation.
Pathological findings and their
implications
In the under 35 age group, 54% were normal heart/SADS cases.
At autopsy, it is a diagnosis of exclusionwhere theheart is structurally
normal and toxicology is negative. This is a higher proportion than
other recent series, where proportions of structurally normal
hearts in similar-aged groups of sudden death victims range from
26 to 43%.21–24 This may reflect referral bias (see limitations), but
nonetheless reinforces the importance of normal heart/SADS and
its genetic implications.1,4
Among the cardiomyopathies, ILVH without the evidence of dis-
array was the most common structural abnormality in our cohort.
Idiopathic LVH is an increasingly recognized entity in cases of SCD
in athletic25 and non-athletic individuals.26 Although its exact signifi-
cance remains unclear, a recent study from our group suggested a
numberof plausible hypotheses including innocent bystander, patho-
logical variant of physiological LVH in genetically predisposed indivi-
duals, part of the HCM spectrum, and a trigger of arrhythmia in the
context of an inherited arrhythmogenic syndrome.26 Other pro-
cesses can mimic inherited cardiomyopathies. For example, ARVC
was over-diagnosed by coroners’ pathologists based upon RV fatty
infiltration alone, a common finding in an increasingly obese popula-
tion and in subjects with a history of alcohol misuse or inherited
myopathies. Variable amounts of intramyocardial fat in the RV have
also been documented in individuals dying of non-cardiac causes.20
The presence of fibrosis in association with fat is necessary to
diagnose ARVC, reinforcing the need for detailed histological
examination including the taking of further blocks by an experienced
cardiac pathologist.27
Gender and risk of sudden cardiac death
Male gender accounted for two-thirds of SCDs in our cohort. This
observation is consistent with existing literature which unanimously
reports a male predominance in SCD, in both athletic and sedentary
individuals.22,28,29 This also correlates with the higher incidence of
male SCDs observed in cardiomyopathies in general and in arrhyth-
mia syndromes such as long QT 1 (LQT1) (prepubescent males),
catecholaminergic polymorphic ventricular tachycardia (CPVT),
and Brugada syndrome.29–32 Female gender, on the other hand,
has only been associatedwith a higher risk in longQT syndrome, par-
ticularly drug-induced torsade-de-pointes LQT2 in young female
adults.32
Causes of sudden cardiac death
by circumstance of death
Normal hearts occurred twice as often as cardiomyopathy in SCD
under rest with a comparative tendency for cardiomyopathy to be
more associated with SCD under exertion. This is in line with
other studies. Individuals that die during sleep commonly have a
. . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Cardiac causes of sudden death by gender
Female Male
Cardiac cause of death n % n % P valuea
Normal heart 124 51 197 41 0.019
Cardiomyopathy 48 20 159 33 ,0.0001
Idiopathic left ventricular
hypertrophy
6 2 48 10 –
Obesity CM 12 5 17 4 –
Hypertrophic
cardiomyopathy
8 3 34 7 –
Arrythmogenic right
ventricular CM
2 1 27 6 –
Idiopathic fibrosis 11 4 6 1 –
Dilated cardiomyopathy 5 2 12 3 –
Other CM 3 1 6 1 –
CM NOS 1 0 9 2 –
Coronary artery pathology 23 9 48 10 0.759
Atheroma 16 7 40 8 –
Non-atheromatous 7 3 8 2 –
Inflammation 10 4 22 5 –
Complex congenital heart
disease
9 4 14 3 –
Valvular disease 12 5 12 3 –
Aortic disease 3 1 10 2 –
Tumour 3 1 2 0 –
Hypertensive heart disease 7 3 5 1 –
Other cardiac pathology 6 2 6 1 –
Total 245 100 475 100 –
CM, cardiomyopathy; NOS, not otherwise specified.
Values are expressed as percentage (number/total number).
aStatistical analysis of cardiac causes of sudden death by gender. Statistical analysis
was not performed in groups with a small number of cases.
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normal heart and are likely to be affected by circadian rhythm and
autonomic nervous system factors.33 Sudden cardiac death in ath-
letes during or shortly after exertion ismostly attributed to an under-
lying cardiomyopathy, where adrenergic surges are thought to be
important.28 Arrhythmia syndromes such as LQT1 and CPVT that
are likely to underlie morphologically normal heart SCD are also
associated with sudden death on exertion.32 Others such as LQT3
and Brugada syndrome are associated with death during sleep or at
rest. This is supported by the study of Behr et al.,1 where most of
the SADS victims died at rest/during sleep.32
Limitations
TheCRYCCPoffers anationally recognized service and ismore likely
to attract challenging cases or caseswhere amorphologically normal
heart is suspected. It does not, however, receive all SCD referrals in
the country. For these reasons, conclusions drawn from this study,
with particular reference to the prevalence of different causes of
SCD, may not reflect the whole of the UK because of selection
bias. The aim of this study was, however, to investigate the import-
ance of expert opinion in the diagnosis of SCD. It is plausible that
some referring pathologists intended to send the heart for specialist
review from the outset and performed only limited histopathological
evaluation. Discrepancies between the autopsy conclusions of our
specialist centre and that of local pathologists may have been
overestimated.
The over-diagnosis of ARVCby referring pathologistsmay, in part,
be explained by the use of older contemporaneous task force criteria
that proposed fatty replacement alone as indicative of ARVCdisease.
New guidelines emphasize that histology must confirm the presence
of fibrosis, alone or in combination with fatty infiltration.34 Our
centre adhered to the new criteria throughout the study, long
before their official acknowledgement.7
TheCRYCCPservice is baseduponanalysis undertakenbya single
pathologist, albeit an acknowledged international expert. Having an
additional pathologist to corroborate the cardiac pathological inter-
pretation would be desirable, but single centres cannot justify more
than one pathologist doing cardiacwork full-time. There are also few
cardiac pathology specialists in the UK, posing a limitation on double
reporting. This issue is being addressed by the UKCardiac Pathology
Network35 by establishing cardiac pathology pathways in the country
to support and train general pathologists.
The use of imaging has been proposed to replace the conventional
autopsy and was not included in our study. It is clear, however, from
our experience that these are currently unsuitable for the accurate
diagnosis of cardiac causes of death.36
Finally, we acknowledge the lack of post-mortem genetic testing,
‘molecular autopsy’, to support the diagnosis of possible genetic
conditions.1 Although genetic testing can be a useful tool, accurate
conventional pathological findings remain the cornerstone of the
diagnosis of conditions predisposing to SCD and subsequent
guidance of familial evaluation and genetic analysis.
Conclusions
This study demonstrates the value of specialist cardiac pathological
analysis in SCD, particularly in the young, and highlights that patho-
logical diagnoses consistent with underlying cardiac genetic disease
may account for a majority of cases. Accurate and reliable diagnoses
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Inter-agreement in pathologists’ individual diagnoses in 158 cases















ARVC 2 2 1 0 0 0 0 0 0 0 5
HCM 0 7 1 0 0 0 0 0 1 2 11
LVH 1 5 9 0 0 0 0 0 1 0 16
DCM 0 0 0 6 0 0 0 0 0 2 8
CM NOS 0 0 0 0 4 0 0 0 0 0 4
Other CM 3 1 1 0 0 6 1 0 2 1 15
Inflammation 0 0 1 0 0 0 4 0 0 0 5
Valvular
disease
0 0 0 0 0 0 0 3 1 1 5
Normal 13 1 2 0 1 3 4 2 50 4 80
Other
pathology
2 1 0 0 0 1 0 0 2 3 9
Total 21 17 15 6 5 10 9 5 57 13 158
ARVC, arrhythmogenic right ventricular cardiomyopathy; CMNOS, cardiomyopathy not otherwise specified; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy;
other CM, other cardiomyopathy.
Shaded boxes indicate those cases where there was agreement.
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are therefore invaluable for coroners’ pathologists, primary care,
cardiologists, and ultimately the deceased’s families. The large and
increasing number of referrals to the CRY CCP reflects a demand
for fast-track expert cardiac diagnostic service for SCD in the UK.
We propose that this should be considered an ideal model for
future service provision in the UK and abroad.
Supplementary material
Supplementary material is available at Europace online.
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Low Prevalence of Risk Markers in Cases of Sudden
Death Due to Brugada Syndrome
Relevance to Risk Stratification in Brugada Syndrome
Hariharan Raju, MBCHB,* Michael Papadakis, MBBS,* Malini Govindan, B MED,*
Rachel Bastiaenen, MBBS,* Navin Chandra, MBBS,* Ann O’Sullivan, BSC,† Georgina Baines, BSC,‡
Sanjay Sharma, MBCHB, MD,* Elijah R. Behr, MBBS, MD*
London and Oxford, United Kingdom
Objectives The objective of this study was to determine the prevalence of conventional risk factors in sudden arrhythmic
death syndrome (SADS) probands with Brugada syndrome (BrS).
Background Patients with BrS and previous aborted sudden cardiac death (SCD) are at high risk of recurrent events. Other
universally accepted clinical features associated with higher risk include unheralded syncope and the presence
of a spontaneous type 1 electrocardiogram (ECG).
Methods We analyzed reported symptoms and reviewed ECGs from SADS probands with familial diagnoses of BrS, estab-
lished by cardiological evaluation, including ECG, 2-dimensional echocardiography, Holter monitoring, exercise
tolerance testing, and ajmaline provocation. These cases underwent familial evaluation between 2003 and
2010.
Results A total of 49 consecutive families with a confirmed SADS death and a diagnosis of BrS were evaluated, compris-
ing assessment of 202 family members in total. One family had 2 members with SADS, resulting in a total of 50
probands included. Mean age of death of probands was 29.1 ! 10.6 years, with 41 males (82%) (p " 0.05).
Antemortem ECGs were available for 5 SADS probands, 1 of which demonstrated a spontaneous type 1 pattern.
In 45 probands, symptoms before death were reported reliably by family members. Of these, 9 (20%) had expe-
rienced at least 1 syncopal episode before the fatal event. Importantly, 68% of probands would not have fulfilled
any current criteria for consideration of implantable cardioverter-defibrillator.
Conclusions The “low-risk” asymptomatic BrS group comprises the majority of SCD in this cohort. Current risk stratification
would appear to be inadequate, and new markers of risk are vital. (J Am Coll Cardiol 2011;57:2340–5)
© 2011 by the American College of Cardiology Foundation
Brugada syndrome (BrS) is a primary electrical disease that
predisposes those affected to life-threatening ventricular
arrhythmias, which are predominantly nocturnal (1). De-
spite its recent introduction as a clinical entity (2), BrS has
an established genetic etiology related predominantly to
cardiac sodium channel dysfunction in 20% of cases and
demonstrates an autosomal dominant inheritance pattern
(3). Nevertheless, BrS remains characterized by stereotypi-
cal electrocardiographic (ECG) findings in affected patients
(1), in combination with clinical or familial history. How-
ever, in some patients, ECG changes can fluctuate between
normal and the Brugada pattern (4); hence, provocation
testing with a class I antidysrhythmic, such as ajmaline, is
used to unmask the BrS phenotype in suspected cases (5–8).
Patients with BrS who have survived a ventricular fibrilla-
tion arrest are recommended to receive an implantable
cardioverter-defibrillator (ICD) in light of the significant
risk of recurrent events (1,9). The other recognized high-
risk group recommended for an ICD consists of patients
with symptoms secondary to a presumed self-terminating
malignant arrhythmia in the presence of a type 1 Brugada
ECG (10,11). A number of studies have evaluated the
additional value of specialist ECG and invasive assessments
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in risk stratification, although conclusions regarding their
impact have been inconsistent (9–13). We report on a
retrospectively analyzed cohort of individuals who experi-
enced unexplained sudden death, with a diagnosis of BrS
established following familial evaluation (14,15), with re-
gard to the prevalence of these high-risk characteristics.
Methods
Study cohort. This study represents unselected, consecu-
tive, familial diagnoses of BrS from 3 tertiary referral centers
in the United Kingdom, in the context of unexplained
familial sudden cardiac death (SCD). Data from clinical
evaluations of the blood relatives of individuals who expe-
rienced sudden arrhythmic death syndrome (SADS) re-
ferred between 2003 and 2010 to specialist inherited cardiac
disease clinics at Lewisham University, King’s College, and
St. George’s Hospitals (London) were retrospectively re-
viewed. All SADS probands with at least 1 blood relative
diagnosed with BrS were included.
Cardiological evaluation. An evaluation protocol for fam-
ilies with a member with SADS has been established (Fig. 1),
with particular emphasis on evaluation for evidence of
familial BrS. All family members were investigated with
clinical history and noninvasive
evaluation by ECG, transtho-
racic echocardiography (includ-
ing close evaluation of the right
ventricle), Holter ambulatory
monitoring, and stress testing,
with additional magnetic reso-
nance imaging to exclude struc-
tural heart disease.
Genetic testing. Following ap-
propriate genetic counseling, we
offered sodium channel, voltage-
gated, type V, alpha subunit
(SCN5A) mutation analysis to
family members with a clinical
diagnosis of BrS.
Ajmaline provocation test. Ajmaline provocation was per-
formed with 1 mg/kg intravenous ajmaline administered
over 5 min, with real-time ECG monitoring and ECGs
recorded for analysis at 10- to 30-s intervals for 15 min from
the start of ajmaline administration or until return of the
ECG to baseline. Before March 2006, standard 12-lead
ECG monitoring was used during ajmaline provocation.
Abbreviations
and Acronyms




SADS ! sudden arrhythmic
death syndrome
SCD ! sudden cardiac
death
SCN5A ! sodium channel,
voltage-gated, type V,
alpha subunit
Figure 1 Investigational Cascade for SADS Probands and Their Families
A summary of the investigation undertaken following referral of a family of an individual who experienced sudden arrhythmic death syndrome (SADS) and criteria for
establishing a familial diagnosis of Brugada syndrome (BrS). ECG ! electrocardiogram; ETT ! exercise tolerance test; MRI ! magnetic resonance imaging.
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Subsequently, further “high” right ventricular leads were
added to improve diagnostic yield by using a 15-lead ECG
recording machine. Initially, this technique used V1, V2, and
V3 cranially displaced by 1 intercostal space (16) in addition
to the standard 12 conventional leads. In September 2009,
the standard V3 position was sacrificed in favor of including
V1 and V2 cranially displaced in both the second and third
intercostal spaces, in addition to conventional V1 and V2,
thereby maintaining 6 right ventricular leads for diagnostic
purposes. Diagnosis of a Brugada type 1 ECG pattern,
either during peak ajmaline effect or at baseline, was
established by ECG review by 2 investigators (H.R. and
M.P.). Any individual’s diagnosis of BrS was established as
described in the Definitions section.
Characteristics of SADS probands. Prior familial SCD
and presence of symptomatic events in each proband were
determined by interviews with all evaluated family members
by at least 1 of the investigators (H.R., M.P., S.S., and
E.R.B.) and review of medical examiner and coroner re-
ports. Structured clinical questions regarding the presence of
prior transient loss of consciousness, seizures, or faints were
retrospectively coded as probable syncopal events for the
study analysis. All decisions regarding relevance of symp-
toms described were made by 2 investigators (H.R. and
M.P.), with disputed results adjudicated by a senior inves-
tigator (E.R.B. or S.S.).
The presence of an antemortem ECG for all probands
was sought by detailed questioning of evaluated family
members. This included review of history of attendance at
health screening events, any hospital attendance, or presence
of any prior cardiovascular symptoms (palpitations or chest
pain) that may have prompted an ECG. When any family
members suggested the SADS proband may have attended
for medical assessment prior to his or her death, the
existence of an antemortem ECG was questioned by written
communication to any medical professional involved in the
proband’s investigation. As with familial ECGs, all ECGs
of probands taken before death were reviewed by 2 investi-
gators for evidence of a spontaneous Brugada pattern.
Definitions. SADS is an umbrella term for unexpected and
unexplained sudden death. It is characterized by the follow-
ing conditions: sudden death; age 1 to 64 years; last seen
alive and well within 12 h of being found dead; no prior
recorded cardiac disease; and normal coroner’s post-
mortem, negative toxicology results, and normal expert
cardiac pathologist’s examination, when available (17). A
proband represents any individual who experienced a SADS
death.
A type 1 Brugada ECG pattern is defined as !2-mm
coved-type ST elevation with or without right bundle
branch block pattern in at least 2 right precordial or “high”
right precordial (i.e., in the second or third intercostal space)
leads (18–21).
Familial diagnosis of BrS was established by the identi-
fication of spontaneous or ajmaline-provoked Brugada type
1 ECG pattern in any one family member of a SADS
proband. The cause of death in the proband was presumed
to be BrS-related in all cases described, following a familial
diagnosis of BrS. When the familial SADS proband died at
age 45 years or older, the presence of other syndromic
diagnostic criteria, such as more than 1 family member with
typical Brugada ECG phenotype or syncopal symptoms,
was determined by additional structured questioning and
review of familial cardiological evaluation results.
Results
At least 1 member of a family group was diagnosed with
BrS in 49 families affected by a SADS death, suggesting
that BrS is the likely etiology for any associated proband’s
sudden death. A total of 50 probands were included, with 1
family having 2 individuals with confirmed SADS. In 2
families reviewed, the proband was older than 45 years. One
of these 2 families had stereotypical Brugada ECG changes
in more than 1 blood relative, thereby fulfilling the consen-
sus statement diagnostic criteria (1).
Demographics. Details of associated familial evaluation
are provided in Table 1. In total, 202 blood relatives of
probands were cardiologically evaluated and contributed to
the reported proband histories. Demographic characteristics
and reported symptoms in the included probands are sum-
marized in Table 2. The mean age of death of probands was
29.1 ! 10.6 years (range 4 to 56 years). A predominance of
male BrS deaths was noted (41 male [82%] vs. 9 female
[18%]; p" 0.05). Circumstances of death were obtained for
46 probands. Of these, 18 deaths (39%) occurred during
sleep, with a further 19 (41%) at rest during the daytime;
only 5 (11%) occurred during or immediately after signifi-
cant exertion.
Genetic testing. Details of families for whom SCN5A
mutation analysis was undertaken (n # 28) are given in
Table 2. Of the 5 families with unequivocal mutations, 3
have mutations that have previously been reported as disease
causing (2 families with E1784K and 1 family with I1377V
mutations) and 2 have highly probable novel mutations
(D349H and H558fs). Overall, unequivocal mutations have
been found in 18% of families for whom SCN5A mutation
analysis was undertaken.
Risk profile of probands. Antemortem ECGs were avail-
able for 5 probands (Fig. 2), 1 of which demonstrated a
spontaneous type 1 pattern (Fig. 2A) and was taken during
presentation with gastrointestinal symptoms in a previously
asymptomatic individual. A further proband had evidence of




Mean no. evaluated per family ! SD 4.0! 2.4
Total diagnosed with BrS 83
Mean no. diagnosed with BrS per family ! SD 1.7! 1.1
BrS # Brugada syndrome; SADS # sudden arrhythmic death syndrome.
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a prior resting type 3 Brugada pattern in just 1 right
ventricular lead (Fig. 2B). Both of these ECGs were taken
more than 1 year before each proband’s terminal event.
None of the probands had undergone prior provocation
testing for investigation of inducible Brugada ECG pattern
or invasive electrophysiological assessment; none had a
pre-established personal or familial diagnosis of BrS or
other inherited cardiac disease. Probands’ symptoms before
death were reported reliably by family members in 45 cases,
with the remainder uncertain of any prior medical history or
symptoms. Only 9 of these 45 probands (20%) were
reported to have experienced at least 1 syncopal episode
before the fatal event. Seven probands (14%) had a prior
family history of premature SCD, 1 of whom also had a
personal history of syncope. Fifteen probands (30%) had
either a prior family history of SCD or personal reported
history of syncope. Among those who were previously
symptomatic, 5 probands were male, whereas 4 were female.
Discussion
We report on 50 individuals who experienced sudden death
related to BrS, who were diagnosed retrospectively follow-
ing careful cardiological evaluation of family members. In
keeping with previous reports, there was a male preponder-
ance among probands, a significant minority with identified
disease-causing familial SCN5A mutations, and deaths
occurring predominantly at rest or during sleep (3,12,22).
Markers of risk in BrS. Current data regarding prospective
risk stratification in patients with BrS have predominantly
been determined on the basis of short- and medium-term
prospective cohort observation of those identified in life.
The FINGER (France, Italy, the Netherlands, Germany)
study remains the largest cohort studied thus far, with 1,029
consecutive patients and indicates that a prior cardiac arrest,
spontaneous type 1 ECG, and syncope were the only
independent indicators of arrhythmic risk in patients with
Brugada ECG (13).
In our cohort of SADS probands with BrS, only 18%
(9 of 50) had a confirmed prior identified syncopal event, as
determined by reported symptoms and medical history from
relatives. This suggests that the majority of sudden deaths in
Figure 2 Antemortem ECGs in 5 SADS Probands
With Brugada Syndrome
(A) The sole spontaneous type 1 antemortem ECG seen in our cohort of SADS
probands with BrS. (B) An antemortem borderline type 3 Brugada phenotype
seen in V2 only. (C) A nondiagnostic antemortem adult ECG. (D) An antemor-
tem ECG taken at age 8 years, with no spontaneous Brugada phenotype. (E)
An antemortem ECG taken at age 4 years, with no spontaneous Brugada phe-
notype. Abbreviations as in Figure 1.
Clinical Characteristics of SADS ProbandsW th Familial Diagnosi BrSTable 2 Clinical Characteristics of SADS ProbandsWith Familial Diagnosis of BrS
Clinical Presentation Syncope Asymptomatic Unknown
No. of probands 9 36 5
Male/female 5/4 31/5 5/0
Age, yrs 29! 16 29! 10 31! 6
Type 1 BrS pattern/no. of ECGs
available
0/2 1/3 0/0
Family history of prior SCD 1 (11) 6 (17) 0 (0)
Died in sleep or rest 8 (89) 28 (78) 1 (20)
Definite mutation/SCN5A analysis 1/5 4/22 1/1
Values are n, mean ! SD, or n (%).
ECG " electrocardiogram; SCD " sudden cardiac death; SCN5A " sodium channel, voltage-
gated, type V, alpha subunit; other abbreviations as in Table 1.
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BrS occurred in asymptomatic individuals. The absence of
symptoms, however, does not necessarily ensure absence of
significant prior arrhythmia. Cohort observation of ICD
interrogations in 19 patients with BrS with prior aborted
sudden death revealed 64 episodes detected as ventricular
fibrillation, 26 of which were asymptomatic by virtue of
them being nocturnal and self-limiting, requiring no device
discharge (1). This evidently limits the sensitivity of
reported symptoms as a marker of prior ventricular
arrhythmias. Furthermore, the specificity of syncope for
ventricular arrhythmias among patients with BrS may be
limited by the observation that there is a preponderance
of other etiologies of syncope, including reports of
significant vasovagal responses with head-up tilt testing
among patients with BrS (23).
Although ECGs were available for a minority of pro-
bands, only 1 demonstrated a spontaneous type 1 pattern,
calling into question the utility of its absence as a marker of
low risk.
Of the total cohort, only 18% were identified as fulfilling
2005 consensus (1) criteria for ICD implantation on the
basis of prior syncope. A further 14% may have warranted
risk stratification with electrophysiological study according
to consensus criteria because of the presence of a type 1
ECG before death (1 of 50) or a family history of prior SCD
(6 of 50). Hence, current markers of risk for cardiac events
and sudden death would have been insensitive, with 68% of
our cohort categorized as low risk. Therefore, these markers
may not have predicted the BrS deaths, even if a diagnosis
of BrS had already been established. In particular, the
majority of our cohort was asymptomatic before unheralded
sudden death. Current data suggest that these asymptomatic
individuals’ risk would have been low, !1% per year (13),
even if a spontaneous type 1 ECG pattern was seen. Given
that current treatment is limited to ICD implantation, with
its inherent complications in young patients, risk stratifica-
tion in asymptomatic patients clearly requires improvement.
Case inclusion. The diagnosis of BrS was based primarily
on the demonstration of a positive ajmaline provocation test
using high right ventricular leads. Subsequent genetic eval-
uation of our cohort identified disease-causing SCN5A
mutations in 18% of our included families. This figure is not
dissimilar to that reported in previous genetic series in
patients with BrS and supports our diagnostic assumption
that in the context of a death from SADS, a positive
ajmaline provocation test using high right ventricular leads
is a genuine reflection of an underlying sodium ion channel
disorder (3). The utility of high right ventricular leads has
been confirmed in a few small series, predominantly in
Southeast Asian patients (21,24,25). The 2005 Heart
Rhythm Society and European Heart Rhythm Association
consensus document recommends that this group be treated
no differently than those with ECG changes in standard
leads (1).
Study limitations. Despite being the largest cohort of its
kind reported, this study remains limited by the relatively
small number of SADS probands with BrS included. Only
5 probands had a documented prior ECG in this study.
Hence, it is difficult to make judgments on the presence or
absence of a spontaneous type 1 Brugada ECG in the
absence of prior investigation. This is an important consid-
eration, given its apparent importance in risk stratification
(1), although syncope is a much more significant risk factor
(13). Unsurprisingly, in light of their predominantly asymp-
tomatic status, none of the SADS probands had undergone
comprehensive cardiological evaluation before the terminal
event. It is also possible that probands may not have relayed
any prior symptoms to family members and medical
practitioners.
Conclusions
This cohort suggests that the majority of individuals expe-
riencing BrS sudden death are asymptomatic before their
terminal event. Antemortem ECGs, when available, do not
demonstrate a spontaneous type 1 ECG pattern. This
suggests that current risk factors in BrS are insufficient to
foretell unheralded sudden death events in those affected.
This questions the utility of current risk stratification
criteria.
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The majority of sudden cardiac deaths (SCDs) are attrib-utable to atherosclerotic coronary artery disease and are 
manifest in the older population, whereas cardiomyopathies 
predominate in the young (<35 years).1 In a proportion of SCDs, 
a cardiac abnormality cannot be identified despite detailed his-
topathologic examination and toxicology screen; such cases are 
classified as sudden arrhythmic death syndrome (SADS).1 The 
recognition of SADS is imperative, because evaluation of blood 
relatives of the deceased identifies a hereditary arrhythmogenic 
syndrome in ≈50% of families, thereby providing a likely cause 
of death and identifying surviving relatives at risk from the 
same fate.2,3
Clinical Perspective on p 596
The interpretation of the results of postmortem evaluation of 
SCD cases is a complex task and uncertainty may exist about 
the causal relationship between the pathological findings and 
the sudden death.4 The significance of myxoid degeneration 
of the mitral valve with prolapse, stable atherosclerotic 
coronary plaque with limited (<50%) luminal stenosis and 
focal myocarditis, which are relatively prevalent in the general 
population, may be erroneously overestimated. Not infrequently, 
postmortem diagnoses of hypertrophic cardiomyopathy (HCM) 
and arrhythmogenic right ventricular cardiomyopathy are based 
solely on the presence of left ventricular hypertrophy (LVH) 
and fatty infiltration of the right ventricular wall, respectively, 
in the absence of pathognomonic histological changes. Left 
ventricular hypertrophy, however, is a recognized feature of 
© 2013 American Heart Association, Inc.




Background—The sudden death of young individuals is commonly attributed to inherited cardiac disorders, and familial 
evaluation is advocated. The identification of pathognomonic histopathologic findings, or the absence of cardiac pathology 
(sudden arrhythmic death syndrome [SADS]) at postmortem, directs familial evaluation targeting structural disorders 
or primary arrhythmogenic syndromes, respectively. In a proportion of autopsies, structural abnormalities of uncertain 
significance are reported. We explored the hypothesis that such sudden cardiac deaths represent SADS.
Methods and Results—Families (n=340) of index cases of sudden cardiac deaths who underwent postmortem evaluation 
were evaluated in specialist cardiogenetics clinics. Families in whom the deceased exhibited structural abnormalities of 
uncertain significance (n=41), such as ventricular hypertrophy, myocardial fibrosis, and minor coronary artery disease, 
were included in the study. Results were compared with 163 families with normal postmortem (SADS). Relatives 
underwent comprehensive cardiac evaluation. Twenty-one families (51%) with autopsy findings of uncertain significance 
received a diagnosis based on the identification of an inherited cardiac condition phenotype in ≥1 relatives: 14 Brugada 
syndrome; 4 long-QT syndrome; 1 catecholaminergic polymorphic ventricular tachycardia; and 2 cardiomyopathy. A 
similar proportion of families (47.2%) received a diagnosis in the SADS cohort (P=0.727). An arrhythmogenic syndrome 
was the predominant diagnosis in both cohorts (46% versus 45%; P=0.863).
Conclusions—Familial evaluation after sudden cardiac deaths with autopsy findings of uncertain significance identified 
a similar proportion of primary arrhythmogenic syndromes to a contemporary series of SADS. Our study highlights 
the need for accurate interpretation of autopsy findings to avoid erroneous diagnoses, with potentially devastating 
implications.  (Circ Arrhythm Electrophysiol. 2013;6:588-596.)
Key Words: cardiac arrhythmia ◼ cardiomyopathies ◼ death, sudden cardiac ◼ pathology ◼ ion channel
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physiological adaptation to exercise,5 and fatty infiltration of 
the right ventricle is commonly present in obese individuals.6 
The distinction between pathology and normal variants may, 
therefore, be challenging in the context of SCDs.
This study explored the hypothesis that a proportion of 
SCDs with autopsy findings of uncertain significance may 




The SCDs of several young individuals prompted the United Kingdom 
government to commission the 8th chapter of the National Service 
Framework for heart disease, aimed at facilitating early identification 
of individuals at risk of SCD. St George’s Hospital and University 
Hospital Lewisham (London, UK) have implemented dedicated in-
herited cardiac diseases clinics, serving relatives of individuals who 
experienced SCD, from throughout the United Kingdom. Family 
members undergo comprehensive cardiac evaluation aimed at iden-
tifying those at risk and preventing further tragedies.
Study Cohort
Between 2003 and 2009, 368 families of cases of premature SCDs 
(aged between 4 and 64 years) were evaluated in our inherited car-
diac diseases clinics. Criteria for inclusion in the study comprised 
the following: (1) unexpected death of an apparently healthy indi-
vidual; (2) death from natural causes; (3) last seen alive and well 
within 12 hours; (4) complete postmortem report; (5) the absence of 
an extracardiac cause of death; and (6) negative toxicology screen. 
Twenty-eight families were excluded from further analysis based on 
the absence of a complete postmortem report (n=4), positive toxicol-
ogy (n=14), and the presence of documented past medical history 
before death (n=10).
Postmortem reports of the 340 SCD cases were scrutinized by 2 
authors and divided into the following 3 groups: Group 1, autopsy 
findings highly suggestive of structural cardiac pathology account-
ing for the SCD (n=136); Group 2, no identifiable structural cardiac 
pathology, consistent with an SADS death (n=163); and Group 3, 
autopsy findings with structural abnormalities of uncertain causal ef-
fect (n=41). In cases of disagreement a third, senior author was con-
sulted. The main study cohort consisted of 41 families, comprising 
157 blood relatives, where the postmortem report was classified into 
group 3. The 163 families in group 2 (SADS cohort) were used as 
controls for comparison (Figure 1).
Autopsy Evaluation
All cases of SCDs included in the study had undergone a full coro-
ners’ pathologist postmortem, and in 39% of cases a specialist cardiac 
pathologist had performed additional assessment. The diagnostic cri-
teria for specific structural cardiac diseases and examples of autopsy 
findings of uncertain significance are outlined in Table 1.
Familial Cardiological Evaluation
All relatives underwent comprehensive cardiac evaluation according 
to a previously published protocol.5 Baseline ECG, echocardiogra-
phy, holter monitoring, and exercise tolerance testing were performed 
routinely. Ajmaline provocation testing to identify the type-1 Brugada 
phenotype was performed in the event of normal ECG recordings and 
echocardiograms or in the presence of type-2 or type-3 Brugada ECG 
patterns. Ajmaline testing was performed by placing leads V1 and 
V2 in the conventional 4th intercostal space as well as the higher 3rd 
and 2nd intercostal spaces.7 Ajmaline testing was not performed in 
relatives ≤16 years of age (n=28) who did not have sinister cardiac 
symptoms or in patients (n=7) who refused consent.
Cardiac MRI (CMR) with gadolinium was performed in all rela-
tives with ECG or echocardiographic features suggestive of cardio-
myopathy. All relatives diagnosed with an arrhythmogenic syndrome 
where the deceased’s postmortem findings could be interpreted to 
SCD victims whose families were referred for cardiac evaluation
n=368























Figure 1. Flow chart of study cohort (solid arrows), including diagnostic yield. CPVT indicates catecholaminergic polymorphic ventricular 
tachycardia; SADS, sudden arrhythmic death syndrome; and SCD, sudden cardiac death.
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Table 1. Pathological Criteria for Defining Cardiac Pathology and Certainty of Causal Effect in  
Sudden Cardiac Death Autopsies
Post-mortem findings highly suggestive of causal effect Post-mortem findings of 
uncertain significance
Hypertrophic cardiomyopathy
Left ventricular hypertrophy 
and/or myocardial fibrosis in the 
absence of myocardial disarray
Macroscopic
Left ventricular wall thickness 
≥15 mm and/or heart weight 
≥500 g
Microscopic
Myocyte hypertrophy + 
disarray + interstitial fibrosis 
+/- abnormal intra-myocardial 
small vessels
Arrhythmogenic right ventricular cardiomyopathy
Fatty infiltration of the right 
ventricular wall in the absence of 
fibrosis
Macroscopic
Right ventricular thinning + 
fatty replacement + fibrosis
Microscopic
Fat + fibrosis of the wall of the   
right and/or left ventricle
Dilated cardiomyopathy
Mild ventricular dilatation in the 
absence of significant fibrosis or 
myocardial inflammation
Macroscopic
Heavy heart with dilated 
ventricles and absence of 
coronary artery disease
Microscopic
Absence of inflammatory 
myocardial disease
Coronary atherosclerosis
Atherosclerosis with estimated    
≤50% luminal narrowing of the 
coronary arteries or 2mm probe 
patent in the absence of acute or 
chronic infarction
Macroscopic
Atherosclerosis with estimated 
luminal narrowing  >75%
Microscopic
Acute or chronic infarction in 
the left ventricle
Myocarditis
Scattered lymphocytic       
inflammatory foci with no 
fibrosis     or myocyte necrosis
Macroscopic
Normal or dilated ventricles
Microscopic
Inflammation with myocyte 
necrosis
Mitral valve papillary muscle or chordae tendineae rupture with 
marked ballooning of both leaflets above the atrioventricular        
junction
Floppy mitral valve with mild 
ballooning between chordae in 
one or both leaflets
Aortic stenosis with left ventricular hypertrophy Isolated bicuspid aortic valve
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represent a cardiomyopathy (LVH, myocardial fibrosis, ventricular 
dilatation, and fatty infiltration of the myocardium) also underwent 
CMR. Further investigations were based on clinical need.
Genetic Testing
Mutation analysis was offered to all relatives with phenotypic ab-
normalities suggestive of inherited arrhythmogenic syndromes or 
cardiomyopathies, after appropriate counseling.8 After consent, tar-
geted mutation analysis was performed in 1 phenotypically affected 
member of each family, dependent on the suspected clinical condi-
tion: KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in long-QT 
syndrome (LQTS); SCN5A in Brugada syndrome (BrS); selected 
exons (7–9, 13–16, 43–50, 82–84, and 87–105) of ryanodine re-
ceptor 2 gene (RYR2) in catecholaminergic polymorphic ventricu-
lar tachycardia (CPVT). Exons and flanking intronic regions were 
amplified from genomic DNA, and bidirectionally sequenced to 
identify coding variants. Variants were labeled as pathogenic if they 
were previously reported to be associated with disease susceptibil-
ity9,10; in-frame or frameshift-causing insertions or deletions; af-
fecting splice sites; missense mutations likely to be pathogenic, as 
identified by 2 in silico models (affect protein function by a toler-
ance index score of <0.05 in sorting intolerant from tolerant [SIFT] 
and classified probably damaging by polymorphism phenotyping 
[PolyPhen]).11,12 If a pathogenic mutation was identified in a phe-
notypically affected member, other family members were offered 
cascade screening. Segregation analysis was used to confirm muta-
tion pathogenicity.
Pathogenesis of SCD
An inherited condition was deemed the most likely cause of SCD if ≥1 
blood relatives of the deceased exhibited phenotypic evidence of the 
disease. Standard criteria for the diagnosis of LQTS were used.13 The 
second consensus criteria for the diagnosis of BrS were used.14 Only the 
presence of the type-1 Brugada pattern (coved ST-segment elevation 
≥2 mm followed by a negative T-wave) in >1 right precordial leads, in-
cluding higher intercostal leads,7 was considered diagnostic. Standard 
criteria were applied for the diagnosis of CPVT.15 Cardiomyopathies 
were diagnosed based on published diagnostic criteria.16
Statistical Analysis
Data analysis was undertaken using R version 2.15.2 (R Development 
Core Team). Data are expressed in mean±SD. Comparison of popula-
tion proportions used Fisher exact test with Donner’s adjustment as 
necessary to account for clustered data.
Results
Characteristics of Cases of SCDs and Blood 
Relatives
The characteristics of the cases of SCDs are depicted in Table 2. 
Of the 157 blood relatives evaluated, 48% were male, with a 
mean age of 33.7±17.9 years (range, 9–70 years). Almost a 
quarter (23%) of the evaluated relatives reported cardiac symp-
toms with 10% having experienced ≥1 episode of syncope in 
the past.
Autopsy Findings and Results of Familial 
Evaluation
The postmortem findings of uncertain pathological signif-
icance in the 41 cases are illustrated in Figure 2. After familial 
evaluation, 21 (51%) out of the 41 SCD cases were considered 
to have died from a definite or probable inherited cardiac 
disorder (Figure 1). Of the 157 relatives who underwent 
cardiac evaluation, 36 (23%) were diagnosed with a cardiac 
condition, which had not been previously identified.
Diagnosis of Arrhythmogenic Syndromes
A hereditary arrhythmogenic syndrome was diagnosed in 
19 of 21 families in whom an underlying inherited cardiac 
condition was identified. Brugada syndrome (n=14) was the 
predominant diagnosis, followed by LQTS (n=4) and a single 
case of CPVT.
After familial evaluation, an arrhythmogenic syndrome 
was detected in 42% (11/26) of cases where the autopsy find-
ings were suggestive of a possible cardiomyopathy (LVH, 
myocardial fibrosis, ventricular dilatation, myocardial fatty 
infiltration; Figure 2). In these cases, all relatives with an 
arrhythmogenic syndrome phenotype underwent CMR scans, 
in addition to standard evaluation, to exclude coexistent myo-
cardial disease. All CMR scans were reported as normal. Of 
interest, in the 19 SCD cases where LVH or myocardial fibro-
sis was reported at postmortem, (isolated LVH: n=10; myo-
cardial fibrosis alone: n=6, or in conjunction with LVH: n=3) 
evaluation of family relatives identified an arrhythmogenic 
syndrome in ≈50% of families (5 out of 10 cases with isolated 
LVH and 4 out of 9 cases with myocardial fibrosis). A cardio-
myopathy was diagnosed in only 1 case in either group. In 
the remaining 8 (42%) cases, we were unable to identify any 
features of inherited cardiac pathology.
Brugada syndrome was also diagnosed in 1 of the 3 families 
whose proband exhibited isolated fatty infiltration of the right 
ventricle (Figure 3.4). One of the families where the patholo-
gist reported marked right ventricular dilatation was subse-
quently diagnosed with CPVT, based on the identification of 
typical bidirectional ventricular tachycardia on exercise test-
ing in 2 relatives.
Moreover, 2 out of the 6 families whose probands exhib-
ited atheromatous disease at postmortem were diagnosed 
with BrS. Both probands were young, aged 28 and 34 years, 
respectively, and exhibited up to 50% coronary artery lesions 
in the left anterior descending and right coronary arteries 
(Figure 3.1). In 1 of the 2 families where an inflammatory 
infiltrate commonly attributed to myocarditis was present, 
BrS was diagnosed during Ajmaline provocation testing in 
the deceased’s father. In similar fashion, 1 of the 3 families 
whose proband exhibited pathological features of mitral valve 
prolapse was subsequently diagnosed with BrS based on the 
presence of type-1 Brugada ECG in 2 relatives.
Diagnosis of Cardiomyopathy
Only 2 families were diagnosed with an inherited cardio-
myopathy; 1 dilated cardiomyopathy and 1 HCM. The 
first case was of a 17-year-old boy who died in his sleep. 
The postmortem revealed circumferential subendocardial 
hemorrhage with extensive myocardial fibrosis of the left 
ventricle. Evaluation of his relatives revealed a dilated, 
globally hypokinetic left ventricle in his mother and 1 of 
his sisters. The second case was of a 20-year-old male who 
died at rest. The postmortem revealed a heavy heart (>500 g) 
with LVH but no evidence of myocardial fibrosis or myocyte 
disarray. There was no history of hypertension or regular 
exercise. Familial evaluation revealed asymmetrical septal 
hypertrophy in the context of a nondilated left ventricular 
cavity in his father, raising suspicion of HCM. Unfortunately, 
the father declined further investigations.
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Mutation Analysis
We had the opportunity to undertake mutation analysis in 
relatives with phenotypes suggestive of inherited cardiac 
conditions in 17 out of the potential 21 families. In 2 families 
(1:HCM, 1:BrS), individuals declined genetic testing after 
counseling. In 2 LQTS families, genetic testing was performed 
by their local geneticist. Because of the absence of coexisting 
atrioventricular block, mutation analysis was not performed in 
the dilated cardiomyopathy family.8 Of the 13 families with BrS 
who underwent genetic testing, 3 carried pathogenic SCN5A 
mutations (R376H, H558fs, A1680T). Pathogenic mutations 
were also identified in the 2 LQTS families tested (E1784K 
and G840R in SCN5A) and in the CPVT family (A4556T in 
RYR2). Four of the identified mutations are previously reported 
as disease-associated (SCN5A R376H, A1680T, E1784K, and 
RYR2 A4556T).9,10 One novel SCN5A mutation (H558fs) is a 
deletion, resulting in a frameshift, whereas the other (G840R) 
is a missense mutation with in-silico confirmation of disease 
causation.11,12 A detailed description of the 6 families with a 
positive genotype is tabulated in the Table in the online-only 
Data Supplement.
Immediate Management
All relatives affected received appropriate lifestyle modi-
fication and drug avoidance advice. Eleven patients were 
prescribed β-blockers and 2 angiotensin-converting enzyme 
inhibitors. Prophylactic cardioverter defibrillators were 
implanted in 5 patients: 3 BrS; 2 LQTS, and 2 LQTS patients 
received a pacemaker.
Comparison of Diagnostic Yield With the SADS 
Cohort
The SADS cohort consisted of 163 families, comprising 
463 relatives. The characteristics of the SADS victims are 
described in Table 2. The diagnostic yield in the SADS cohort 
Table 2. Characteristics of Victims of Sudden Cardiac Death With Autopsy Findings of Uncertain Significance. A Comparison Is Made 
With Victims With Normal Postmortem (SADS)
Uncertain Significance 
(n=41)
SADS Deaths  
(n=163) P Value
Mean age (range, y) 29.9±14.4 (4–59) 27.6±11.1 (1–56) 0.267
Sex: male 80% 67% 0.128
Ethnicity: white 93% 91% 1.000
Mode of death
 Asleep/at rest 61% 61% <0.001
 During/postexertion 37% 17%
 Unknown 2% 22%
Reported antecedent cardiac symptoms* 37% 27% 0.250
 Syncope 15% 15%
Previous family history of premature (<55 y) 25% 17% 0.369
sudden cardiac death
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Figure 2. Histogram depicting the diagnostic yield of familial evaluation in victims of sudden cardiac death. The x-axis represents the 
number of families, and the y-axis represents the pathology identified in the deceased during postmortem evaluation of the heart. The 
different colors within the columns represent the diagnosis established after cardiac evaluation of surviving relatives with absolute num-
bers of families stated within the relevant color. CPVT indicates catecholaminergic polymorphic ventricular tachycardia; and LVH, left 
ventricular hypertrophy.






Papadakis et al    Autopsy Findings of Uncertain Significance in SCD  593
was similar to that of individuals with autopsy findings of 
uncertain significance (47.2% versus 51%; P=0.727). In both 
cohorts, the predominant diagnosis was of a primary arrhyth-
mogenic syndrome (Figure 4). A similar proportion of the 
relatives who were evaluated in the SADS and the autopsy 
findings of uncertain significance cohorts were diagnosed 
with a cardiac condition (24.6% versus 22.9%; P=0.715).
Discussion
SCDs in young, previously healthy individuals instigates 
cardiac evaluation of first-degree relatives aimed at identifying 
potentially inherited cardiac pathology to minimize the risk of 
further tragedies.2,3 In a significant proportion of SCDs, the 
pathologist may observe findings that are relatively common 
in the general population, or findings that partially fulfill 
diagnostic criteria for structural cardiac disease, leaving 
uncertainty about causality and management of surviving 
relatives. In this study of 41 families with postmortem 
findings of uncertain significance, ≈50% were diagnosed with 
a hereditary arrhythmogenic syndrome, and the causes of SCD 
were similar to those observed in a true SADS cohort. This 
finding is of particular importance because by convention the 
absence of any cardiac pathology is considered a prerequisite 
for the definition of a death as SADS.1
Figure 3. Histopathologic slides 
of: 1, an individual who exhib-
ited coronary artery disease 
on autopsy and subsequent 
familial evaluation identified 
Brugada syndrome (BrS): 
A, macroscopic examination 
of the left anterior descending 
coronary artery in an otherwise 
normal heart shows eccentric 
atheroma. This can be opened 
with a 2-mm probe (black 
arrow), indicating that there 
would have been normal blood 
flow during life; B, staining with 
Trichrome stain (Elastin Van 
Gieson) confirmed eccentric 
atheroma. 2, An individual who 
exhibited isolated left ventricu-
lar hypertrophy on autopsy and 
subsequent familial evaluation 
identified long-QT syndrome: 
A, short axis slice showing a 
circumferentially thickened left 
ventricular wall measuring 2 
cm. The left ventricular cav-
ity diameter is also reduced; 
B, hematoxylin and eosin stain-
ing confirms idiopathic myocyte 
hypertrophy with enlarged 
box-shaped nuclei. No myo-
cyte disarray is noted. 3, An 
individual who exhibited myo-
cardial fibrosis on autopsy and 
subsequent familial evaluation 
identified BrS: ×2 (A) and ×10 
(B) magnification of picro-sirius 
red staining shows extensive 
myocardial replacement with 
collagen (stained red) in the left 
ventricular wall from epicardium 
into midmyocardium. There is 
also fine interstitial collagen 
surrounding individual myo-
cytes (yellow). Mild fatty infiltra-
tion is also noted within the 
collagen areas. 4, An individual 
who exhibited right ventricular 
fatty infiltration on autopsy and 
subsequent familial evaluation 
identified BrS: ×4 (A) and ×20 
(B) magnification of hematoxylin 
and eosin stain of the right ven-
tricular wall showing significant 
fatty infiltration in the outer third 
of the myocardium (stained 
red). There is no fibrous tissue.
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Implications of Autopsy Findings of Uncertain 
Significance
The causal effect of the autopsy findings is unclear. The 
authors offer 4 plausible hypotheses:
(a) Innocent Bystander
Bicuspid aortic valve and floppy mitral valve are present 
in 1% to 2% of the general population and may represent 
innocent bystanders. Likewise, coronary atherosclerosis 
without significant narrowing of the arterial lumen and 
without evidence of acute or chronic ischemia is common. 
Moreover, it is well documented that the degree of coronary 
artery stenosis can be overestimated by the pathologists as a 
result of postmortem collapse of the vessel wall.17 Finally, foci 
of lymphocytes are common in the normal heart, and a degree 
of myocardial inflammation may be the effect of prolonged 
resuscitation efforts rather than evidence of myocarditis 
resulting in SCDs.18
(b) Primary Cause of SCDs
Most of the conditions identified at autopsy in our cohort 
have been associated with ventricular arrhythmias and sud-
den death.5 Similarly, the absence of severe luminal narrow-
ing of the coronary arteries does not preclude ventricular 
arrhythmias attributable to myocardial ischemia, particularly 
as a result of coronary artery vasospasm,19 and isolated fatty 
infiltration involving the cardiac conduction system has been 
implicated in SCD of obese people.20
(c) Trigger in the Context of an Arrhythmogenic Syndrome
Consideration must also be given to the fact that structural 
cardiac disorders may serve as triggers for arrhythmias in the 
context of a coexistent inherited arrhythmogenic syndrome. 
One third of SCDs in our cohort with minor coronary disease 
were subsequently attributed to an arrhythmogenic syndrome. 
Current evidence suggest that the presence of coronary artery 
disease is an independent risk factor for LQTS-related symp-
tomatic events.21 It seems likely that transient ischemia alters 
the arrhythmic substrate by reducing the threshold for afterde-
polarizations or increasing transmural dispersion of repolar-
ization, both recognized mechanisms for arrhythmogenesis in 
ion-channel disease.22
(d) Spectrum of Arrhythmogenic Syndromes
There is mounting evidence that individuals with ion-channel 
defects may exhibit structural cardiac changes.22 Although the 
majority of BrS patients possess a structurally normal heart, 
a small proportion, seems to exhibit evidence of ventricular 
wall motion abnormalities, ventricular dilatation, and fibro-
sis.23,24 Such structural abnormalities may be subtle, requiring 
sophisticated diagnostic tools.25 Several theories have been 
postulated to correlate ion-channel dysfunction with structural 
abnormalities, ranging from impaired excitation–contraction 
coupling and energy production, to a hibernation-like state 
which over time may even lead to intracellular lipid accu-
mulation.22 Support for potential structural abnormalities in 
patients with BrS is also provided by the study of Nadema-
nee et al26 where the authors identified the anterior aspect of 
the RVOT epicardium as the substrate for the Brugada ECG 
pattern.
Additionally, there are reports in the literature of identi-
cal mutations presenting with either a cardiomyopathy or 
an arrhythmogenic syndrome phenotype, suggesting that 
structural and ion-channel defects may be part of a spectrum 
incorporating myocardial disease and primary arrhythmo-
genic syndromes. Mutations in the cardiac ryanodine recep-
tor gene, commonly implicated in CPVT, have been reported 
in individuals exhibiting an arrhythmogenic right ventricular 
cardiomyopathy phenotype.27 Mutations in the SCN5A gene, 
implicated in BrS, may present with arrhythmia, conduc-
tion disease, and atrial or ventricular dilatation.28 Heritable 
SCN5A defects have also been associated with early-onset 
dilated cardiomyopathy and atrial fibrillation.29
LVH and Myocardial Fibrosis
In our cohort, isolated LVH and myocardial fibrosis were the 
most prevalent findings. Idiopathic LVH is an increasingly rec-
ognized entity in cases of SCDs. It remains unclear whether 
it represents an innocent bystander, a pathological variant of 
physiological LVH in genetically predisposed individuals or 
part of the HCM spectrum.5 Although LVH is a well-recog-
nized feature of cardiovascular adaptation to exercise, in our 
study, only 4 out of the 10 individuals exhibiting isolated LVH 
exercised on a regular basis. Data from the Framingham study 
also indicate that LVH confers a 4-fold risk of sudden death.30 
In addition, experimental studies suggest that LVH alters 
ion-channel expression and function predisposing to reen-
try arrhythmias and ventricular fibrillation.31 Although in the 
majority of individuals such adaptations are unlikely to result 










Figure 4. Pie charts depicting the results 
of familial evaluation in the autopsy find-
ings of uncertain significance and the 
SADS cohorts. ARVC indicates arrhyth-
mogenic right ventricular cardiomyopathy; 
BrS, Brugada syndrome; CPVT, catechol-
aminergic polymorphic ventricular tachy-
cardia; DCM, dilated cardiomyopathy; 
HCM, hypertrophic cardiomyopathy; 
LQTS, long-QT syndrome; and SADS, 
sudden arrhythmic death syndrome.
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individual with an underlying arrhythmogenic syndrome may 
exacerbate electric instability and predispose to sudden death.
The amount of myocardial fibrosis and the collagen texture 
seem to play a role in vulnerability to arrhythmia.32 Moreover, 
myocardial fibrosis may represent incomplete expression of 
underlying cardiomyopathy. Myocardial fibrosis has also been 
reported in marathon runners and in cases of SCDs in athletic 
individuals, raising concerns whether prolonged arduous exer-
cise can lead to repeated myocardial injury, necrosis, and sub-
sequent fibrosis.8 Finally, animal models have demonstrated 
that SCN5A mutations cause progressive impairment of atrial 
and ventricular conduction associated with myocardial rear-
rangements and fibrosis.33
The Role of the Cardiac Pathologist
This study highlights the importance of accurate interpretation 
of the autopsy findings because false conclusions may mis-
guide familial evaluation or offer false reassurance to surviv-
ing relatives and dissuade physicians from initiating familial 
screening. Given the relative rarity of SCDs from inherited 
conditions and the challenges associated with their diagnosis, 
the authors propose that all cases of SCDs and, particularly, 
SCDs in young (≤35 years) individuals, where an inherited 
condition is suspected or diagnostic uncertainty remains as to 
the cause of death, should be referred for further evaluation to 
an expert cardiac pathologist.
Limitations
The predominant diagnosis in our cohort was of BrS, 
reflecting the victims’ demographics (80% males, mean 
age of 30 years), predominant mode of death (60% asleep/
at rest), and the routine use of Ajmaline provocation testing. 
It is plausible that some Ajmaline-based diagnoses may be 
erroneous. Although currently there are no large series of 
normal subjects undergoing Ajmaline test, existing literature 
in SCN5A positive families suggests that the specificity 
of the Ajmaline challenge exceeds 94%.34 Therefore, in the 
absence of an alternative gold standard, provocation testing 
with a sodium channel blocker remains an integral part of the 
evaluation of individuals with suspected BrS.
The authors also concede that given the relative novelty of 
the condition and the association of the Brugada phenotype 
with several structural cardiac abnormalities, it is possible that 
some of the relatives exhibiting the Brugada phenotype did 
not have a genuine arrhythmogenic syndrome. However, all 
individuals who were diagnosed with BrS underwent com-
prehensive evaluation, including a detailed echocardiogram, 
and a significant proportion were subjected to CMR, and none 
exhibited any evidence, suggesting structural cardiac anoma-
lies. Further support for the presence of BrS is underscored 
by the genetic yield (23%) of pathogenic SCN5A mutations, 
similar to existing literature.14
In the 6 families in whom a pathogenic mutation was identi-
fied in evaluated relatives, we were unable to perform post-
mortem analysis in the tissues of the victims for confirmation 
of the genotype because no tissue was available by the time the 
relatives were evaluated in our clinic. In the United Kingdom, 
the Human Tissue Act does not permit retention of tissue as 
part of a deceased patient’s record, and retention for research 
requires familial consent at the time of postmortem.35 As 
such, in the majority of cases, histological slides are prepared, 
reported, and imaged at the time of the postmortem examina-
tion, allowing early return of the tissue for burial or cremation.
Conclusion
The current study underscores the need for accurate interpre-
tation of autopsy findings in cases of SCDs to avoid erroneous 
diagnoses with potentially devastating implications for surviv-
ing relatives. Our data suggest that all SCDs with inconclu-
sive autopsy findings should be considered as potential SADS 
deaths, and comprehensive evaluation of family relatives for 
both inherited primary arrhythmogenic syndromes and struc-
tural cardiac abnormalities should be advocated.
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CLINICAL PERSPECTIVES
Sudden death in young individuals is commonly attributed to inherited cardiac diseases. Postmortem examination is a critical 
first diagnostic step to guide clinical evaluation of surviving relatives toward structural disorders or primary arrhythmogenic 
syndromes. In a significant proportion of sudden cardiac deaths, the pathologist may identify structural abnormalities, which 
are relatively prevalent in the general population or do not quite fulfill established diagnostic criteria; therefore, an element 
of uncertainty may exist about the causal relationship between the pathological findings and the sudden death. This is the 
first study to demonstrate that ≈50% of such deaths may be attributable to arrhythmogenic syndromes implicated in sud-
den arrhythmic death syndrome (SADS). This finding is of particular importance because conventional criteria require the 
absence of any cardiac pathology as a prerequisite for the definition of a death as SADS. In the current study, familial evalu-
ation after sudden cardiac death with autopsy findings of uncertain significance identified a similar proportion of primary 
arrhythmogenic syndromes to a large series of SADS. Our results highlight the need for accurate interpretation of autopsy 
findings by physicians involved in the decision-making process before the family reaching a cardiogenetics clinic, to avoid 
erroneous diagnoses, or worse still, false reassurances with potentially devastating implications for surviving relatives. Our 
data suggest that all sudden cardiac deaths with inconclusive autopsy findings should be considered as potential SADS 
deaths, and comprehensive evaluation of family relatives for both inherited primary arrhythmogenic syndromes and struc-
tural cardiac abnormalities should be advocated.
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Unmasking of the Brugada phenotype
during exercise testing and its
association with ventricular
arrhythmia on the recovery phase
Two largely asymptomatic men, a 36-year-old (patient A) and a
56-year-old (patient B), were evaluated following the sudden
death of a first-degree relative. Both resting 12-lead electro-
cardiograms exhibited minor ST-segment elevation in V1 and
0.2 mV saddle-shaped ST-segment elevation in V2. During an
exercise test, patient A developed 0.7 mV ST-segment elevation
with coved pattern and T-wave inversion in V2 and ST-segment
elevation and T-wave inversion in V3, at peak exertion (panel A).
The test was terminated. Patient B exercised to exhaustion
without significant ECG changes but exhibited multiple ventri-
cular extrasystoles in recovery that terminated spontaneously
(panel B(B)). Both patients exhibited ST-segment elevation in
leads V1–V3, highly characteristic of the Brugada syndrome (panel
A and panel B(A)) post exercise. Both remained asymptomatic. An
Ajmaline provocation test was positive supporting a diagnosis of
Brugada syndrome. Coronary angiography and cardiac magnetic
resonance imaging were normal. Both patients were offered an
internal cardioverter defibrillator.
Brugada syndrome predisposes to fatal arrhythmias and most
deaths occur at rest.1 Exercise is not considered a risk factor and
exercise testing is not routinely performed. Scarce reports in the
literature describe normalisation of the ST-segment elevation,with
increased sympathetic activity during exercise and unmasking of
the syndromewith increased parasympathetic tone in recovery.2 In
patient A, however, the Brugada phenotype developed during peak
exertion, refuting this simplistic theory as the sole explanation. In
patient B the ventricular ectopics in recovery raise concerns
regarding thesafetyof strenuousexertion inpredisposed individuals
andhighlight the importance of exercise testing in thediagnosis and
risk stratification of Brugada syndrome.
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Panel A (Patient A) ECG strips of the right precordial leads V1–V3. ST-
segment changes before, at peak and during the recovery phase of the
treadmill exercise stress test. ETT, exercise tolerance test.
Panel B (Patient B) (A) ECG strips of the right precordial leads V1–V3.
ST-segment changes before, at peak and during the recovery phase of
the treadmill exercise stress test. (B) Rhythm strip demonstrating multiple
ventricular extrasystoles of increasing frequency 40 s into recovery. The
ectopics terminated spontaneously within 10 s. ETT, exercise tolerance test.
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